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TRPM2 (1507 amino acids), a non-selective cation channel with substantial permeability 
for Ca2+, is	  responsive	  to	  oxidative	  stress,	  and	  is	  a	  mediator	  of	  cell	  death	  in	  several	  cell	  types. Ca2+-calmodulin has been shown to promote channel activation and inactivation, 
however the mechanisms are not fully understood. Identifying candidate CaM binding sites 
using in silico screening, I hypothesized that Ca2+-dependent inactivation (CDI) of TRPM2 
is mediated by an intracellular CaM binding domain unique from that of activation (406-
415AA). I systematically determined the minimum binding domains for three CaM 
candidate sites on TRPM2’s intracellular domains using truncated fragments and 
subsequent CaM-Sepharose pull-downs. TRPM2 with substitution mutations to candidate 
sites were transfected into HEK293 cells; currents were recorded using 2mM or 0.5mM 
Ca2+ extracellular fluid and adenosine diphosphate ribose	  (ADPR) in the patch pipette.  
Abolished and reduced currents respectively were observed as a result of amino acid 
substitution to CaM binding regions at 172-187AA and 1087-1101AA of TRPM2. The two 
identified CaM candidate sites may establish a potential molecular link to CDI of TRPM2.	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  293:	  	   human	  embryonic	  kidney	  cell	  line	  HPLC:	   	   high	  performance	  liquid	  chromatography	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hTRPM2:	   human-­‐	  melastatin-­‐related	  transient	  receptor	  potential	  2	  ICS:	  	   	   intracellular	  solution	  IQ-­‐like:	  	   calmodulin	  consensus	  binding	  site,	  IQXXXRGXXXR	  Iss/Ip:	  	   steady	  state/peak	  ratio	  (Inactivation)	  LTD:	  	   	   long-­‐term	  depression	  K+:	   	   potassium	  KCl:	   	   potassium	  chloride	  kHz:	   	   kilo	  Hertz	  KOD:	   	   Thermococcus	  kodakarensis	  M’Ω:	   	   mega	  Ohms	  MEM:	  	   	   Modified	  Eagle	  Medium	  Mg+:	   	   magnesium	  Mg-­‐ATP:	   magnesium	  adenosine	  5’-­‐triphosphate	  min:	   	   minute	  ml:	   	   milliliter	  mPTP:	  	   mitochondrial	  transition	  pore	  opening	  mM:	   	   millimolar	  mRNA:	   messenger	  ribonucleic	  acid	  mV:	   	   millivolt	  Na+:	   	   sodium	  nA:	   	   nanoamp	  ng:	   	   nanogram	  NotI:	   	   Restriction	  Enzyme	  from	  NotI	  gene	  of	  Nocardia	  otitidis-­‐caviarum	  N-­‐term:	   intracellular	  trail	  of	  TRPM2	  (1-­‐750AA)	  mm:	   	   millimeter	  nM:	   	   nanomolar	   	  mTRPM2:	   mouse-­‐melastatin-­‐related	  transient	  receptor	  potential	  2	  NMDA:	  	   N-­‐Methyl-­‐D-­‐aspartic	  acid	  NMDAR:	   N-­‐Methyl-­‐D-­‐aspartic	  acid	  receptor	  NP-­‐40:	  	   nonyl	  phenoxypolyethoxylethanol	  NUDIX:	  	   nucleoside	  diphosphate	  coupled	  to	  a	  varying	  moiety	  X	  (NUDT9-­‐H)	   	  OSM:	   	   osmolarity	  pa:	   	   picoamp	  PARG:	  	  	   polyADPR-­‐glycohydrolase	  PARP:	  	  	   polyADPR-­‐polymerase	  PCR:	   	   polymerase	  chain	  reaction	  PD:	  	   	   parkinson’s	  disease	  PTPL1:	   protein	  tyrosine	  phosphatase	  L1	  RNAi:	   	   ribonucleic	  acid	  interference	  ROS/RNS:	  	   reactive	  oxygen/nitrogen	  species	  RT-­‐PCR:	  	   real-­‐time	  polymerase	  chain	  reaction	  SIRT2:	  	   NAD-­‐dependent	  deacetylase	  sirtuin-­‐2	  SIRT3:	  	   NAD-­‐dependent	  deacetylase	  sirtuin-­‐3	  SNc:	  	   	   substantia	  nigra	  pars	  compacta	  SNP:	   	   single	  nucleotide	  polymorphism	  SSF-­‐TRPM2:	  	   TRPM2	  missing	  first	  214AA	  (striatum	  short-­‐form	  TRPM2)	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TEMED:	   tetramethylethylenediamine	  TNFα:	  	  	   tumor	  necrosis	  factor	  TRIS:	   	   tris(hydroxymethyl)aminomethane	  TRP:	  	   	   transient	  receptor	  potential	  TrpL:	  	   	   TRP-­‐like	  homolog	  TRPM2:	  	   melastatin-­‐related	  transient	  receptor	  potential	  2	  TRPM2-­‐ΔC:	  	   splice	  variant	  resulting	  from	  a	  missing	  exon	  27	  (1292-­‐1325AA)	  TRPM2-­‐ΔN:	  	   splice	  variant	  resulting	  from	  a	  missing	  exon	  11	  TRPM2-­‐ΔNΔC:	  splice	  variant	  missing	  both	  exon	  11	  and	  27	  TRPM2-­‐AS:	  	   TRPM2	  antisense	  transcript	  caused	  by	  a	  promoter	  in	  intron	  24	  TRPM2-­‐TE:	  	   TRPM2	  antisense	  transcript	  caused	  by	  a	  promoter	  in	  intron	  24	  TRPM2-­‐S:	  	   splice	  variant	  resulting	  from	  a	  stop	  codon	  between	  exons	  16	  and	  17	  	  UV:	   	   ultraviolet	  VGCC:	  	  	   voltage-­‐gated	  calcium	  channel	  WP-­‐ALS:	  	   western	  Pacific	  amyotrophic	  lateral	  sclerosis	  WT:	  	   	   wildtype	  	  	  
Unique	  Constructs	  
	  pTNT-­‐GST	  TRPM2	  truncations	  generated	  for	  CaM-­‐Sepharose	  pull	  down	  (figure	  2.1)	  
	   CT1:	   	   1047-­‐1163AA	  CT2:	   	   1163-­‐1278AA	  CT3:	   	   1278-­‐1395AA	  CT4:	   	   1395-­‐1507AA	  CT5:	   	   1047-­‐1108AA	  CT6:	   	   1108-­‐1163AA	  CT7:	   	   1047-­‐1082AA	  CT8:	   	   1082-­‐1163AA	  CT10:	   1277-­‐1339AA	  CT11:	   1339-­‐1396AA	  CT12:	   1277-­‐1374AA	  CT13:	   1374-­‐1396AA	  NT1:	   	   1-­‐256AA	  NT2:	   	   250-­‐505AA	  NT3:	   	   499-­‐750AA	  NT4:	   	   1-­‐150AA	  NT5:	   	   150-­‐250AA	  NT6:	   	   1-­‐201AA	  NT7:	   	   201-­‐250AA	  NT15:	   395-­‐423AA	  MutCT5:	   1047-­‐1108AA	  substitutions	  (L1087Q/Q1088A/K1092A/K1097A)	  	  	  	  MutCT11:	   1339-­‐1396AA	  substitutions	  (W1351S/A1358S/W1364S)	  MutNT5:	   150-­‐250AA	  substitutions	  (V172S/A176S/F179S/L185S)	  MutNT15:	   395-­‐423AA	  substitutions	  (I405A/Q406A/R410-­‐412A/L415A)	  
	  	   xi	  
	  Substitution	  mutagenesis	  to	  full-­‐length	  TRPM2	  CaM	  consensus	  binding	  sites	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1.1 General	  Introduction	  
	   Ca2+	  cellular	  rise	  is	  involved	  in	  many	  physiological	  processes	  and	  yet	  Ca2+	  is	  toxic	  in	  high	  concentrations	  in	  the	  cytoplasm	  (Saimi	  and	  Kung,	  2002).	  Ca2+	  dysfunction	  is	  often	   associated	   with	   periods	   of	   oxidative	   stress,	   leading	   to	   cellular	   damage	   and	  degeneration	   (Hara	   et	   al.,	   2002).	   A	   protein	   channel	   named	   Transient	   receptor	  potential	  melastatin	   type-­‐2	   (TRPM2)	   has	   generated	   great	   interest	   due	   to	   its	  wide	  expression	  throughout	  the	  brain	  (Nagamine	  et	  al.,	  1998),	  involvement	  in	  important	  regulatory	   cells	   such	   as	   β	   pancreatic	   cells	   (Togashi	   et	   al.,	   2006)	   and	   several	   cell	  types	  of	   the	   immune	  system	  (Perraud	  et	  al.,	  2001).	  Furthermore,	  TRPM2	  can	  alter	  the	   basal	   intracellular	   [Ca2+]	   under	   oxidative	   stress	   (Hara	   et	   al.,	   2002)	   and	  intracellular	  Ca2+	  has	  been	  shown	  to	  be	  required	  for	  channel	  activation	  	  (Tong	  et	  al.,	  2006).	   This	   acts	   as	   a	   positive	   feedback	   mechanism	   whereby	   Ca2+	   entry	   through	  TRPM2	  further	  increases	  TRPM2	  activation.	  Conversely	  published	  reports	  suggest	  a	  negative	   feedback	   mechanism	   involving	   Ca2+,	   which	   limits	   TRPM2	   activation	  (Perraud	   et	   al.,	   2003).	   However	   the	   mechanism	   responsible	   for	   TRPM2	   Ca2+-­‐dependent	  inactivation	  have	  not	  been	  well	  characterized.	  	  	  I	   will	   begin	   with	   an	   introduction	   to	   TRPM2,	   its	   topography	   and	   important	  physiological	   regulators.	   This	  will	   lead	   to	   a	   history	   of	   the	   discoveries	   that	   outline	  our	  current	  understanding	  of	  TRPM2	  regulation.	   I	  will	  continue	  with	  a	  description	  of	  the	  future	  research	  frontiers,	  a	  current	  lack	  of	  specific	  antagonists	  for	  TRPM2	  and	  the	   role	   TRPM2	   plays	   in	   physiological	   cellular	   processes.	   Finally	   I	   will	   outline	  calmodulin	   (CaM),	   a	   ubiquitously	   expressed	   Ca2+	   sensor	   and	  mediator	   of	   TRPM2,	  providing	  novel	  insight	  into	  TRPM2	  Ca2+-­‐dependent	  inactivation	  (CDI).	  Results	  will	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explore	   novel	   CaM	   consensus	   binding	   sites	   and	   their	   regulation	   of	   CDI.	  Measurements	   will	   occur	   through	   substitution	   mutagenesis	   of	   TRPM2	   CaM	  candidate	  sites	  and	  whole-­‐cell	  patch-­‐clamp	  recordings.	  I	  also	  provide	  novel	   insight	  suggesting	   mutations	   within	   a	   TRPM2	   variant	   found	   in	   a	   Guamanian	   genetic	  population	  results	  in	  a	  gain	  of	  function	  and	  will	  discuss	  the	  potential	  significance	  of	  this	  finding.	  	  
	  
1.2 TRP	  channels	  and	  TRPM2	  	   Transient	   receptor	   potential	   melastatin	   type-­‐2	   (TRPM2)	   is	   a	   Ca2+	   permeable	  non-­‐selective	   cation	   channel	   activated	   by	   oxidative	   stress	   (Hara	   et	   al.,	   2002),	  adenosine	  diphosphate	  ribose	  (ADPR)	  (Perraud	  et	  al.,	  2001)	  and	  intracellular	  Ca2+-­‐Calmodulin	   (CaM)	   (Tong	  et	   al.,	   2006).	  First	   isolated	   from	  adult	   and	   fetal	  brains	   in	  1998,	   it	   shares	  marked	  homology	   to	   the	  Drosophila	  TRP	  channel	   (Nagamine	  et	  al.,	  1998).	  The	  gene	  structure	  for	  TRPM2	  consists	  of	  32	  exons	  spanning	  90kb	  on	  human	  chromosome	  21	  mapping	  a	  1503	  amino	  acid	  long	  protein	  (Nagamine	  et	  al.,	  1998).	  	  The	  transient	  receptor	  potential	  family	  of	  ion	  channels	  derives	  their	  name	  from	  a	  homologous	  protein	  studied	  in	  Drosophila	  and	  involved	  in	  the	  photo	  transduction	  cascade	   (Montell	   and	   Rubin,	   1989).	   A	   mutation	   to	   this	   channel	   resulted	   in	   a	  transient	  response	  to	  bright	  light	  conditions	  (Montell	  and	  Rubin,	  1989).	  Drosophila	  acted	  as	   though	  blind	  during	   continuous	   light	   exposure,	  but	  quickly	   returned	   to	   a	  baseline	  response	  when	  the	  stimulus	  was	  removed	  (Montell	  and	  Rubin,	  1989).	  The	  transient	   response	   nomenclature	   has	   been	   maintained	   even	   though	   most	   TRP	  channels	  have	  no	  role	  in	  the	  photo	  transduction	  cascade	  (Montell	  and	  Rubin,	  1989).	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Unlike	  many	   families	   of	   proteins	   grouped	  by	   ligand	   selectivity	  or	   function,	   the	  TRP	   superfamily	   is	   grouped	   according	   to	   homology	   since	   very	   little	   was	   known	  about	   each	   channel	  when	   first	   discovered	   (Clapham,	   2003).	   The	   TRP	   superfamily	  are	   expressed	   throughout	   the	   nervous	   system	   and	   differ	   widely	   in	   their	   ion	  selectivity,	   activation	   mechanics	   and	   physiological	   functions,	   which	   range	   from	  sensory	   transduction	   to	   cell	   death	   (Montell,	   2005;	   Clapham,	   2003).	   Despite	   the	  disparity	   within	   the	   superfamily	   they	   share	   several	   common	   characteristics	  including	  6	   transmembrane	  domains,	   tetrameric	   channel	   structure,	   a	  minimum	  of	  20%	   sequence	   homology	   and	   permeability	   to	   cations	   (Montell,	   2005;	   Clapham,	  2003).	  All	   TRP	   channels	   share	   a	   similar	  pore	   structure,	   are	   structurally	   similar	   to	  other	   cation	   channels	   but	   lack	   a	   positively	   charged	   residue	   required	   for	   voltage	  sensing	  (Yu	  and	  Catterall,	  2004).	  Most	  TRP	  channels	  have	  splice	  variants	  including	  several	   identified	   in	   TRPM2	   (Clapham,	   2003;	   Zhang	   et	   al.,	   2003a;	   Kuhn	   and	  Luckhoff,	   2004;	   Uemura	   et	   al.,	   2005).	   Finally,	   TRP	   channels	   are	   of	   great	   scientific	  interest	   because	  many	   remain	   active	   at	   resting	  membrane	   potentials	   where	   cells	  spend	  most	  of	  their	  time	  (Clapham,	  2003).	  When	   first	   isolated	   TRPM2	   was	   given	   the	   designation	   TRPC7	   despite	   it	   not	  belonging	   to	   the	  so-­‐called	  “short”	  subfamily	  of	  human	  TRP	  channels	   (Nagamine	  et	  al.,	  1998).	  Nomenclature	  proceeded	  from	  TRPC7	  (Nagamine	  et	  al.,	  1998)	  to	  LTRPC2	  grouped	   into	   the	   “long”	   TRP	   channel	   subfamily	   based	   on	   open	   reading	   frames	   of	  roughly	   1600	   amino	   acids	   (Harteneck	   et	   al.,	   2000).	   Finally	   it	  was	   assigned	   to	   the	  melastatin	  subfamily	  of	  TRP	  channels	  as	  TRPM2,	  designating	  it	  the	  second	  member	  of	  a	   family	  derived	  purely	   from	  homology	  (Montell	  et	  al.,	  2002).	  Currently	  28	  TRP	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family	   members	   have	   been	   identified	   and	   separated	   into	   six	   subfamilies:	   TRPC	  (canonical),	   TRPV	   (vanilloid),	   TRPM	   (melastatin),	   TRPA	   (ankyrin),	   TRPP	  (polycystin)	  and	  TRPL	  (mucolipin),	  based	  on	  homology	  (Jiang	  et	  al.,	  2010).	  	   The	   melastatin	   sub-­‐family	   of	   TRP	   channels	   arose	   from	   TRPM1	   (originally	  named	   melastatin)	   because	   of	   the	   different	   expression	   levels	   observed	   between	  metastatic	   and	   non-­‐metastatic	   melanoma	   cells	   (Duncan	   et	   al.,	   1998).	   	   Aberrant	  melanoma	   cells	   lacking	   TRPM1	   were	   unable	   to	   apoptose	   resulting	   in	   aggressive	  melanoma	   tumors	   (Duncan	  et	  al.,	  1998).	  8	  members	  of	   the	  TRPM	  sub-­‐family	  have	  been	  classified	  and	  are	  expressed	  in	  a	  variety	  of	  tissues	  and	  cell	  types	  including	  both	  excitable	   and	   non-­‐excitable	   (Montell,	   2005;	   Fleig	   and	   Penner,	   2004).	  Many	   of	   the	  sub-­‐family	  members	  have	  several	  alternative	  splice	  variants,	  which	  are	  assumed	  to	  act	   in	   conjunction	   with	   unspliced	   members	   to	   alter	   channel	   function	   in	   the	  tetrameric	  subunit	  (Fleig	  and	  Penner,	  2004).	  Most	  of	  the	  variability	  exists	  in	  the	  C-­‐terminal	   of	   the	   channel,	   with	   three	   members	   being	   classified	   as	   highly	   unusual	  “chanzymes”	   (channel-­‐enzymes);	   TRPM2	   (NUDT9-­‐H)	   is	   unique	   from	   TRPM6/7	  (αkinase)	   in	   its	   purported	   enzymatic	   site	   (Montell,	   2005).	   Many	   members	   are	  grouped	   into	  pairs	  with	  TRPM2	  and	  TRPM8	  being	   the	  nearest	  evolutionary	  break,	  each	   sharing	   42%	   homology	   and	   similar	   Ca2+	   permeability	   (Kuhn	   et	   al.,	   2007;	  Montell,	  2005).	  Early	  TRPM2	  research	  focused	  on	  a	  wide	  variety	  of	  tissues	  including	  neutrophil	  granulocytes	   (Heiner	   et	   al.,	   2003),	   U937	   monocyte	   cells	   (Perraud	   et	   al.,	   2001)	  microglia	  (Kraft	  et	  al.,	  2004),	  CRI-­‐G1	  insulinoma	  cells	  (Inamura	  et	  al.,	  2003).	  	  TRPM2	  has	  been	  well	  defined	  in	  heterologous	  expression	  systems	  such	  as	  CHO-­‐K1	  cells	  and	  
	  	   6	  
HEK293	  cells	  (McHugh	  et	  al.,	  2003;	  Kuhn	  and	  Luckhoff,	  2004).	  More	  recently	  great	  interest	   has	   been	   derived	   from	   TRPM2	   expression	   in	   cell	   types	   involved	   in	  important	   physiological	   functions	   such	   as	   cardiomyocytes	   (Yang	   et	   al.,	   2006),	  pancreatic	   β-­‐cells	   (Togashi	   et	   al.,	   2006),	   endothelial	   cells	   (Hecquet	   et	   al.,	   2008),	  hippocampal	   neurons	   (Olah	   et	   al.,	   2009),	   and	   immune	   cells	   such	   as	   lymphocytes,	  macrophages	   and	  monocytes	   (Perraud	   et	   al.,	   2001;	   Sano	   et	   al.,	   2001;	   Beck	   et	   al.,	  2006;	  Yamamoto	  et	  al.,	  2008).	  Here,	  TRPM2	  has	  been	  shown	   to	   regulate	  a	  host	  of	  important	  physiological	  functions	  including:	  insulin	  secretion	  (Inamura	  et	  al.,	  2002;	  Uchida	   et	   al.,	   2011),	   cytokine	   production	   (Yamamoto	   et	   al.,	   2009;	   Knowles	   et	   al.,	  2011),	   endothelial	   permeability	   (Hecquet	   et	   al.,	   2008;	   Dietrich	   and	   Gudermann,	  2008),	  hippocampal	  LTD	  (Xie	  et	  al.,	  2011)	  microglia	  activation	  (Fonfria	  et	  al.,	  2006),	  and	   neuronal/pancreatic	   cell	   death	   in	   response	   to	   oxidative	   stress	   (Jiang	   et	   al.,	  2010).	   Interestingly	  TRPM2	   is	   not	   limited	   to	   the	   plasma	  membrane	   and	  has	   been	  identified	   in	   the	   lysosomal	  organelle	   involved	   in	   release	  of	  Ca2+	   from	   intracellular	  stores	  during	  oxidative	  stress	  or	  insulin	  release	  (Lange	  et	  al.,	  2009).	  	  The	  diverse	  cellular	  tissues	  in	  which	  TRPM2	  has	  been	  identified,	  and	  activation	  of	   TRPM2	   by	   ROS,	   has	   made	   TRPM2	   an	   attractive	   candidate	   for	   extensive	   study	  (Perraud	  et	  al.,	  2001).	  TRPM2	  is	  currently	  a	  target	  for	  diabetes	  (Scharenberg,	  2009;	  Romero	  et	  al.,	  2010;	  Zhang	  et	  al.,	  2012),	  stroke	  (Fonfria	  et	  al.,	  2006;	  Jia	  et	  al.,	  2011),	  bipolar	  disorder	  (Xu	  et	  al.,	  2009;	  Roedding	  et	  al.,	  2012),	  prostate	  cancer	  (Zhang	  et	  al.,	   2010)	   and	   inflammation	   (Yamamoto	   et	   al.,	   2009;	   Haraguchi	   et	   al.,	   2012),	  cardiovascular	  (Takahasi	  et	  al.,	  2012)	  and	  neurodegenerative	  diseases	  (Jiang	  et	  al.,	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2010;	   Fonfria	   et	   al.,	   2004;	   Kanata	   et	   al.,	   2012;	   Hermosura	   and	   Garruto,	   2007;	  Hermosura	  et	  al.,	  2008).	  	  
	  
1.3 Topography	  of	  TRPM2	  	   TRPM2	  (figure	  1.1)	  consists	  of	  intracellular	  N-­‐	  and	  C-­‐terminal	  tails	  separated	  by	  6	   transmembrane	  domains	  and	  a	  pore-­‐forming	   loop	  (Perraud	  et	  al.,	  2003).	  The	  N-­‐terminal	   is	   approximately	   700	   amino	   acids	   in	   length,	   thought	   to	   be	   required	   for	  channel	  expression/trafficking	  and	  consists	  of	  4	  highly	  conserved	  regions	  amongst	  TRPM	  family	  members	  (Perraud	  et	  al.,	  2003).	  Coiled-­‐coil	  regions	  (CCR)	  are	  common	  protein-­‐protein	   interaction	   sites	   and	   have	   been	   well	   defined	   in	   many	   protein	  families	   (Lupas	   et	   al.,	   1991);	   one	   such	   (CCR),	   on	   the	   N-­‐term	   at	   654-­‐684AA,	   was	  mutated	   and	   found	   to	   inhibit	   channel	   expression	   and	   trafficking,	   but	   not	   subunit	  interactions	   in	   the	   tetramer	   (Mei	   and	   Jiang,	   2009).	   A	   calmodulin	   (CaM)	   IQ-­‐like	  consensus	  motif	  is	  located	  at	  406-­‐416AA	  of	  hTRPM2	  and	  is	  responsible	  for	  the	  Ca2+-­‐CaM	  dependent	  gating	  of	  TRPM2	  (Tong	  et	  al.,	  2006).	  	   	  
	  	   8	  
	  
Figure	  1.1	  –	  Schematic	  of	  TRPM2	  transmembrane	  topology	  and	  key	  structural	  domains	  (not	  to	  scale).	  The	  channel	  consists	  of	  a	  cytosolic	  700AA	  N-­‐term	  (left)	  highly	  conserved	  region	  including	  a	  Ca2+-­‐CaM	  binding	  site	  required	  for	  channel	  gating.	  6	  transmembrane	  segments	  and	  a	  pore	  forming	  loop	  account	  for	  a	  300AA	  span	  of	  TRPM2	  followed	  by	  500AA	  for	  the	  intracellular	  C-­‐terminal	  end	  (right).	  A	  highly	  conserved	  TRP	  box	  follows	  the	  S6	  transmembrane	  domain;	  a	  C-­‐term	  coiled-­‐coil	  region	  (CCR)	  has	  been	  implicated	  in	  channel	  trafficking,	  expression,	  subunit	  formation	  of	  the	  tetrameric	  structure	  and	  protein-­‐protein	  interaction.	  Finally	  the	  nucleoside	  diphosphate	  coupled	  to	  a	  varying	  moiety	  X	  (NUDIX)	  domain,	  consisting	  of	  the	  homologous	  NUDT9	  enzymatic	  region,	  gives	  TRPM2	  the	  unique	  distinction	  of	  being	  a	  chanzyme	  (although	  adenosine	  diphosphate	  ribose-­‐ase	  activity	  is	  highly	  suppressed).	  Adenosine	  diphosphate	  ribose	  (ADPR)	  binding	  is	  required	  for	  TRPM2	  channel	  gating	  at	  this	  site	  in	  addition	  to	  Ca2+-­‐CaM	  at	  the	  N-­‐term.	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The	   transmembrane	   sequence	   spans	   roughly	   300	   amino	   acids,	   consisting	   of	   6	  transmembrane	   sequences	   and	   a	   pore	   forming	   hydrophobic	   loop	   (between	  segments	  5	   and	  6)	   that	   is	   thought	   to	   form	   the	   channel	   pore	   in	   tetrameric	  TRPM2	  (Perraud	  et	  al.,	  2003).	  It	  has	  been	  suggested	  that	  the	  highly	  conserved	  nature	  of	  the	  S5	  and	  S6	  domain	  amongst	  TRPM	  family	  members	  is	  critical	  for	  the	  cationic	  current	  (Perraud	  et	  al.,	  2003).	   	  Highly	  conserved	  cysteine	  residues	  at	  996	  and	  1008AA	  are	  both	  required	  within	  the	  pore	  for	  channel	  functioning	  (Mei	  et	  al.,	  2006a).	  Mutants	  to	  these	   TRPM2	   sites	   showed	   normal	   expression	   and	   trafficking	   but	   gating	   was	  abolished	  (Mei	  et	  al.,	  2006a).	  Furthermore	  a	  substitution	  mutation	  targeting	  I1045K	  on	   the	   distal	   end	   of	   the	   S6	   domain	   was	   responsible	   for	   discriminating	   charge,	  switching	   the	   channel	   from	   cation	   to	   anion	   currents	   (Kuhn	   et	   al.,	   2007).	   An	   area	  dubbed	  the	  TRP	  box,	  overlapping	  the	  S6	  domain	  of	  TRPM2	  at	  the	  C-­‐term	  distal	  end,	  is	  highly	  conserved	  amongst	  all	  members	  of	  the	  TRP	  family.	  	  The	  role	  of	  the	  area	  is	  unknown	  but	  presumed	  to	  be	  required	  for	  the	  assembly	  and	  function	  of	  the	  TRPM2	  pore	  region	  (Montell	  et	  al.,	  2005).	  The	   C-­‐terminal	   of	   TRPM2	   spans	   the	   remaining	   roughly	   500	   amino	   acids,	  consisting	  of	  a	  100	  amino	  acid	  CCR,	  a	  spacer	  and	  finally	  the	  nucleoside	  diphosphate	  coupled	  to	  a	  varying	  moiety	  X	  (NUDIX)	  domain.	  The	  NUDIX	  contains	  the	  NUDT9-­‐H	  enzymatic	   adenosine	   diphosphate	   ribose	   (ADPR)	   hydrolase	   binding	   region,	  which	  gave	  TRPM2	  the	  unique	  chanzyme	  designation	  (Perraud	  et	  al.	  2003;	  Montell,	  2005).	  The	   CCR	   region	   is	   hypothesized	   to	   serve	   several	   important	   functions:	   trafficking,	  gating	  and	  tetrameric	  assembly	  (Jiang,	  2007a).	  The	  CCR	  is	  also	  a	  predicted	  site	  for	  an	   unknown	   protein-­‐protein	   interaction	   possibly	   responsible	   for	   TRPM2	   gating	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(Perraud	   et	   al.,	   2003).	   Site-­‐directed	  mutagenesis	   of	   the	  CCR	   substantially	   reduced	  subunit	   interaction	   and	   currents.	   	   This	   was	   not	   due	   to	   altered	   expression,	   but	  instead	  due	  to	  reduced	  trafficking	  of	  the	  subunit	  and	  thereby	  proper	  localization	  at	  the	   membrane	   (Mei	   et	   al.,	   2006b).	   It	   was	   hypothesized	   the	   CCR	   functions	   by	  changing	  the	  energy	  and	  conformation	  of	  the	  linker	  region	  upon	  activation	  (Mei	  et	  al.,	  2006b).	  The	  linker	  region	  between	  CCR	  and	  NUDT9	  domain	  is	  unlikely	  to	  serve	  an	   important	   physiological	   role,	   when	   removed	   no	   difference	   between	   WT	   and	  mutants	   were	   found;	   furthermore	   the	   sequence	   is	   not	   highly	   conserved	   between	  human	  and	  mouse	  TRPM2	  (Perraud	  et	  al.,	  2003).	  The	   NUDT9-­‐H	   region	   (1236-­‐1503AA),	   named	   after	   its	   homologous	   enzymatic	  domain	   responsible	   for	   ADPRase	   activity	   in	   mitochondria,	   has	   proven	   to	   be	   of	  significant	  early	  interest	  and	  vital	  to	  gating	  TRPM2	  via	  ADPR	  binding	  (Perraud	  et	  al.,	  2003).	   The	   NUDIX	   region	   consists	   of	   2	   domains:	   the	   C-­‐term	   core	   contains	   the	  structures	  necessary	  for	  ADPRase	  activity	  and	  the	  N-­‐term	  acts	  as	  a	  CAP	  domain	  by	  enhancing	   the	  ADPR	  affinity	   of	   binding	   (Perraud	   et	   al.,	   2003).	   The	  domain	   shares	  39%	  sequence	  homology	  to	  human	  NUDT9	  ADPR	  pyrophosphatase.	   Importantly,	  a	  glutamate	   residue	  at	  position	  320	  has	  been	   replaced	  by	   isoleucine	   (E320I),	  which	  greatly	  diminishes	  (~1%)	  the	  enzymatic	  activity	  of	  the	  domain,	  when	  compared	  to	  the	  activity	  of	  NUDT9	  (Shen	  et	  al.,	  2003).	  TRPM2	   function	  was	  greatly	  reduced	  by	  reestablishing	  full	  enzymatic	  activity	  through	  substitution	  mutagenesis	  at	  sites	  1405	  and	   1406	   (Kuhn	   and	   Luckhoff,	   2004);	   this	   suggests	   hydrolysis	   of	   ADPR	   is	   not	  required	   for	   channel	   gating,	   instead	   the	   domain	   has	   been	   adapted	   as	   an	   ADPR	  binding	  site	  only	  (Perraud	  et	  al.,	  2005).	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Several	  splice	  variants	  of	  TRPM2	  have	  been	  discovered.	  The	  first	  splice	  variant	  TRPM2-­‐S	   (“short”)	   is	   missing	   everything	   beyond	   transmembrane	   segment	   2	   (4	  transmembrane	  segments	  and	  the	  C-­‐terminal).	  It	  is	  commonly	  found	  in	  hemapoetic	  cells,	   cloned	   from	  bone	  marrow	  and	   is	  a	   result	  of	  a	   stop	  codon	  between	  exons	  16	  and	   17.	   Interestingly	   it	   shows	   similar	   membrane	   localization	   and	   is	  immunoprecipitated	   along	  with	   full	   length	  TRPM2	   (Zhang,	   2003a).	   Another	   set	   of	  splice	   variants	  missing	   either	   exon	  11	   (TRPM2-­‐ΔN),	   exon	  27	   (TRPM2-­‐ΔC)	  or	  both	  (TRPM2-­‐ΔNΔC)	  was	  identified	  in	  neutrophil	  granulocytes;	   intriguingly	  the	  TRPM2-­‐ΔC	  variant	  is	  missing	  1292-­‐1325AA,	  which	  overlaps	  with	  the	  ADPR	  NUDIX	  domain	  (Wehage	   et	   al.,	   2002;	  Kuhn	   and	  Luckhoff,	   2004).	   Finally,	   a	   short	   form	  of	   hTRPM2	  found	   in	   the	   striatum	   (caudate	  nucleus	   and	  putamen)	   and	  nicknamed	  SSF-­‐TRPM2	  (striatum	   short-­‐form	   TRPM2)	   may	   be	   expressed	   on	   the	   plasma	   membrane.	   It	   is	  transcribed	   from	   intron	   4	   onwards	   and	   is	   missing	   214AA	   of	   the	   N-­‐terminal,	  therefore	  being	  1289AA	  long	  (Uemura	  et	  al.,	  2005).	  	  The	  TRPM2-­‐S	  variant	  has	  been	  shown	   to	   traffic	   and	   express	   on	   the	   cell	   membrane	   forming	   tetramers	   with	   full-­‐length	   TRPM2.	   As	   subunits	   lack	   an	   ADPR	   binding	   domain	   the	   subunits	   interrupt	  functional	  TRPM2	  tetrameres;	   transfection	  of	  TRPM2-­‐S	  was	  a	  method	  successfully	  employed	   in	   early	   TRPM2	   research	   to	   reduce	   the	   functional	   expression	   of	   the	  channel	  on	  the	  membrane	  (Wehage	  et	  al.,	  2002;	  Zhang,	  2003a;	  Kuhn	  and	  Luckhoff,	  2004;	  Uemera	  et	  al.,	  2005;).	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1.4 Physiological	  roles	  of	  TRPM2	  
	   Expression	  of	  TRPM2	  throughout	  the	  body/CNS	  and	  role	  in	  oxidative	  mediated	  Ca2+	  influx	  makes	  it	  a	  strong	  candidate	  to	  mediate	  many	  physiological	  processes.	  In	  addition,	  a	  role	  for	  TRPM2	  in	  cellular	  death	  and	  apoptosis	  was	  suggested	  (Nadler	  et	  al.,	   2001).	   Furthermore	   TRPM2	   knockouts	   or	   knockdown	   with	   RNAi	   strategies	  protects	  cells	  from	  oxidative-­‐stress	  mediated	  cellular	  death	  (Miller,	  2004;	  Grubisha	  et	   al.,	   2006).	   TRPM2	   is	   localized	   in	   mouse	   dendritic	   cells	   and	   is	   required	   for	  dendritic	   cell	   maturation	   via	   chemokine	   production	   and	   thereby	   cell	   migration	  (Toledo	  et	  al.,	  2011).	  However,	  TRPM2	  holds	  roles	  beyond	  cellular	  death	  mediating	  important	  physiological	  processes	  and	  maintaining	  cellular	  homeostasis.	  Ca2+	   influx	   is	  required	   for	   insulin	  release	   in	  pancreatic	  beta	  cells	  endogenously	  expressing	   TRPM2	   (Inamura	   et	   al.,	   2002).	   TRPM2	   is	   not	   limited	   to	   the	   plasma	  membrane	   and	  may	   release	   Ca2+	   from	   intracellular	   lysomal	   stores	   during	   insulin	  release	  (Lange	  et	  al.,	  2009).	  TPRM2	  is	  not	  inherently	  required	  for	  functional	  insulin	  release,	  but	  instead	  seems	  to	  be	  involved	  when	  Beta	  cells	  are	  stressed	  (Scharenberg,	  2009).	  TRPM2	  activation	  may	  instead	  lead	  to	  apoptosis	  of	  Beta	  cells	  when	  damaged	  from	   oxidative	   stress,	   or	   to	   mediate	   cytokines	   to	   attract	   inflammatory	   agents	  (Scharenberg,	  2009).	  Much	   attention	   has	   been	   dedicated	   to	   the	   role	   of	   TRPM2	   in	   the	   inflammatory	  process	  due	  its	  expression	  in	  monocytes,	  neutrophils	  and	  lymphocytes	  (Yamamoto	  et	  al.,	  2009).	  The	  role	  of	   inflammation	  in	  the	  system	  is	  to	  taxi	  fluids	  containing	  the	  necessary	  cellular	  proteins	  and	  nutrients	  to	  eliminate	  injuring	  agents	  and	  trigger	  the	  repairing	   process	   (Yamamoto	   et	   al.,	   2009).	   Increased	   intracellular	   calcium	   via	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TRPM2	   is	   essential	   for	   function	   of	   activated	  microglia	   that	   release	   cytokines	   and	  nitrous	  oxide,	  suggesting	  a	  role	  for	  the	  channel	  in	  macrophage	  function	  (Kraft	  et	  al.,	  2004).	  TRPM2	  Ca2+	  influx	  is	  also	  thought	  to	  directly	  mediate	  cytokine	  release,	  which	  has	   a	   role	   in	   mediating	   recruitment	   of	   inflammatory	   cells	   to	   the	   site	   of	   injury	  (Yamatoto	   et	   al.,	   2009).	   Finally,	   during	   inflammation	   phagocytes	   produce	   ROS	   to	  promote	  host	  defense,	  however	   if	   left	  unchecked,	  ROS	  can	  be	  damaging	  to	  healthy	  tissue	  (Die	  et	  al.,	  2012).	  TRPM2	  activated	  by	  ROS	  acts	  as	  a	  negative	  feedback	  loop	  by	  depolarizing	   phagocytes	   and	   restricting	   ROS	   production	   (Di	   et	   al.,	   2012).	   Mice	  deficient	   in	  TRPM2	  given	  an	  endotoxin	  had	  a	   larger	   inflammatory	   response,	  more	  damage	  to	  lungs	  and	  reduced	  survival	  versus	  wild-­‐type	  mice	  (Die	  et	  al.,	  2012).	  Several	   less	  often	  discussed	  physiological	  roles	  of	  TRPM2	  have	  been	   identified.	  Knock	  out	  of	  TRPM2	  abolishes	  sweet	  and	  sour	  tastes,	  but	  has	  no	  effect	  on	  acidic	  or	  bitter	   transduction	  (Zhang	  et	  al.,	  2003b).	  The	  channel	  also	  participates	   in	   immune	  response,	  which	   is	   triggered	  by	  Ca2+	  (Sano	  et	  al.,	  2001)	  requiring	  chemotaxis	   from	  sites	   of	   infection	   to	   lymphoid	   organs	   (Toledo	   et	   al.,	   2011).	   Reduced	   activity	   of	  cytokines	  in	  TRPM2	  KO	  mice	  resulted	  in	  uncontrolled	  Listerosis	  infection,	  suggesting	  a	   role	   in	   innate	   immunity	   (Knowles	   et	   al.,	   2011).	   TRPM2	   is	   expressed	   in	   cardiac	  fibroblasts	  and	  its	  expression	  is	  induced	  by	  hypoxic	  stress	  (Takahashi	  et	  al.,	  2012).	  	  TRPM2	   is	   also	   critical	   for	  N-­‐Methyl-­‐D-­‐aspartatic	   acid	   (NMDA)	  mediated	   long	   term	  depression	   (LTD)	   through	   regulation	   of	   GSK3β	   and	   the	   scaffolding	   protein	   PSD95	  (Xie	  et	  al.,	  2011).	  TRPM2	  knockout	  results	  in	  decreased	  activation	  of	  GSK3β	  (Xie	  et	  al.,	   2011).	   GSK3β	   internalizes	   AMPA	   receptors,	   which	   has	   been	   shown	   to	   reduce	  hippocampal	  LTD	  (Xie	  et	  al.,	  2011).	   	  Finally	  TRPM2	  may	  contribute	  to	  neuropathic	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pain	   by	   aggravating	   inflammatory	   response	   and	   sensitizing	   the	   pain-­‐signaling	  pathway	   (Haraguchi	   et	   al.,	   2012).	   The	   modification	   of	   TRPM2	   regulation	   may	   be	  used	  to	  treat	  and	  identify	  a	  variety	  of	  diseases.	  	  
1.5 ADPR,	  H2O2	  and	  βNAD+	  mediated	  TRPM2	  gating	  
	   TRPM2	  was	  studied	  for	  its	  novel	  gating	  mechanisms	  induced	  by	  three	  seemingly	  unique	  signaling	  pathways:	  ADPR	  (Perraud	  et	  al.,	  2001),	  H2O2	  (Hara	  et	  al.,	  2002)	  and	  βNAD+	   (Sano	   et	   al.,	   2001).	   Before	   the	   characterization	   of	   TRPM2,	   ADPR	   had	   no	  defined	   role	   in	   vertebrates,	   although	   it	   had	   been	   found	   to	   be	   produced	   in	   many	  contexts	   including	  apoptosis,	   the	  pyridine	  nucleotide	  cycle	  and	  cADPR	  breakdown	  in	  the	  mitochondria	  (Perraud	  et	  al.,	  2001).	  Research	  focused	  around	  the	  NUDT9-­‐H	  domain	  of	  TRPM2,	  which	   is	  homologous	   to	   the	  mitochondrial	  pyrophosphatase	  of	  ADPR	   (Perraud	   et	   al.,	   2001).	   The	   identification	   of	   NUDT9H	   as	   a	   specific	   ADPR	  hydrolyase	   led	   directly	   to	   the	   finding	   that	   TRPM2	   is	   gated	   through	   intracellular	  ADPR	  (Perraud	  et	  al.,	  2001).	  	  TRPM2	  mediated	  cell	  death	  and	  metabolism	  of	  ADPR	  drew	  more	  interest	  to	  the	  field	  (Sano	  et	  al.,	  2001).	  This	  lead	  to	  the	  finding	  that	  10mM	  of	  H2O2	  evoked	  currents	  in	   92%	   of	   TRPM2	   expressing	   cells	   providing	   a	   direct	   link	   to	   oxidative	   stress	  mediated	   cell	   death	   (Hara	   et	   al.,	   2002).	   Importantly,	   suppressing	   endogenous	  TRPM2	   expression	   using	   an	   antisense	   oligonucleotide	   significantly	   protected	  against	  H2O2	  mediated	   cell	   death	   in	  Rat	  RIN-­‐5F	   cells	   and	  monocyte	  U937	   cell	   line	  (Hara	  et	  al.,	  2002).	  The	  findings	  were	  replicated	  using	  TRPM2-­‐S	  (a	  splice	  variant	  of	  TRPM2)	   co-­‐expression	   to	   reduce	   H2O2	   mediated	   currents	   and	   subsequent	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susceptibility	   to	   cell	   death	   and	   apoptosis	   (Zhang,	   2003a).	   Additionally,	   H2O2-­‐mediated	   currents	   were	   isolated	   in	   the	   tetracycline	   induced	   HEK293	   TRPM2	  expression	   cell	   line;	   current-­‐voltage	   relationship	  was	   linear	   and	   reversed	   at	   0mV	  consistent	  with	   a	   non-­‐selective	   cation	   channel	   (McHugh	   et	   al.,	   2003).	   These	   early	  findings,	   especially	   by	   the	   groups	   supporting	   βNAD+	   and	   H2O2	  mediated	   TRPM2	  currents,	  would	  soon	  be	  explained	  by	  a	  unifying	  theory	  with	  ADPR	  as	  the	  mediator	  of	  TRPM2	  activation	  (Scharenberg,	  2005).	  Conflicting	   evidence	   of	   the	   precise	   mechanism	   through	   which	   TRPM2	   was	  pharmacologically	   activated	   was	   common.	   H2O2	   mediated	   gating	   of	   TRPM2	   was	  believed	   to	   be	   independent	   from	   ADPR	   as	   the	   TRPM2-­‐ΔC	   splice	   variant	   (missing	  1292-­‐1325AA	   and	   accordingly	   part	   of	   the	   NUDT9H	   region)	   prevented	   gating	   by	  ADPR	  but	  curiously	  not	  in	  response	  to	  H2O2	  (Wehage	  et	  al.,	  2002).	  Furthermore	  cells	  co-­‐expressing	   SSF-­‐TRPM2	   still	   maintained	   an	   H2O2-­‐mediated	   current	   despite	   the	  complete	   lack	  of	  a	  NUDT9-­‐H	  binding	  domain	  (Uemera	  et	  al.,	  2005).	  However	  H2O2	  activation	  without	  ADPR	  binding	  was	  not	  reproduced	  by	  another	  group	  (Kuhn	  and	  Luckhoff.,	   2004).	   Characteristic	   H2O2-­‐mediated	  currents	   were	   slow	   to	   develop	   (3-­‐6min	   delay),	   defined	   by	   a	   second	   Ca2+	   rise	   not	   seen	   in	   cells	   without	   TRPM2	   and	  could	  be	  abolished	  by	  mannitol,	  a	  radical	  species	  scavenger,	  suggesting	  H2O2	  action	  was	  via	  intracellular	  free	  radicals	  (Wehage	  et	  al.,	  2002).	  	  
	   Meanwhile	   βNAD+	  was	   also	   implicated	   as	   an	   activator	   of	   TRPM2	   channels	  and	   at	   the	   time	  was	   believed	   to	   interact	   directly	   with	   the	   NUDT9-­‐H	   domain	   in	   a	  manner	   similar	   to	   ADPR	   (Sano	   et	   al.,	   2001).	   TRPM2	   mRNA	   was	   isolated	   from	  neutrophil	   granulocytes	   and	   characteristic	  TRPM2	   currents	   evoked	  by	  both	  ADPR	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and	   βNAD+	   (Heiner	   et	   al.,	   2003).	   The	   slow	   βNAD+	   evoked	   inward	   currents	   were	  thought	  to	  be	  a	  result	  of	  weaker	  binding	  affinity	  than	  ADPR	  alone,	  although	  βNAD+	  worked	   synergistically	   with	   ADPR	   (Sano	   et	   al.,	   2001).	   It	   has	   been	   suggested	   that	  ADPR	  contamination	   is	   common	  amongst	  NAD	  commercial	   samples	   (Scharenberg,	  2005).	  Another	  explanation	  of	  slow	  currents	  was	  slow	  wash	  out	  of	  ATP,	  which	  can	  suppress	  βNAD+	  (Sano	  et	  al.,	  2001).	  	  βNAD+-­‐mediated	   TRPM2	   currents	   were	   inconsistent	   in	   their	   reproduction	   by	  several	  groups	  (Kuhn	  and	  Luckhoff,	  2004;	  Wehage	  et	  al.,	  2002),	  this	  may	  have	  been	  a	  result	  of	  ADPR	  contamination	  in	  earlier	  studies	  (Scharenberg,	  2005).	  βNAD+	  gating	  of	  TRPM2	  was	  also	  abolished	  with	  any	  ADPR-­‐insensitive	  splice	  variants	  (Kuhn	  and	  Luckhoff,	   2004;	   Perraud	   et	   al.,	   2005).	   However	   it	   was	   quickly	   speculated	   the	  structure	   of	   βNAD+	   seemed	   unlikely	   to	   bind	   to	   the	   NUDIX	   region	   (Kolisek	   et	   al.,	  2005),	   indeed	   crystal	   structure	   analysis	   revealed	   the	   NUDT9-­‐H	   is	   unable	   to	  accommodate	   the	   additional	   nicotinaminde	   group	   required	   for	   βNAD+	   binding	  (Perraud	  et	  al.,	  2005).	  Radiolabeled	  βNAD+	  failed	  to	  efficiently	  compete	  for	  the	  ADPR	  binding	  domain	  (less	  than	  20-­‐fold)	  suggesting	  it	  does	  not	  bind	  directly	  with	  TRPM2	  as	   previously	   speculated	   (Grubisha	   et	   al.,	   2006).	   Furthermore,	   the	   physiological	  relevance	   of	   very	   high	   1mM	   βNAD+	   was	   called	   into	   question;	   perhaps	   ADPR	  contamination	  during	  recordings	  was	  to	  blame	  (Kolisek	  et	  al.,	  2005;	  Perraud	  et	  al.,	  2005).	  Research	   refocused	   on	   ADPR	   as	   the	   main	   pharmacological	   gating	   agent	   of	  TRPM2.	  	  TRPM2	  currents	  were	  inhibited	  using	  an	  enzyme	  to	  prevent	  accumulation	  of	   ADPR	   in	   the	   cytosol	   by	   hydrolyzing	   ADPR;	   this	   eliminated	   the	   effects	   of	   ADPR	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contamination	   via	   βNAD+	  hydrolysis	   to	   ADPR	   (Perraud	   et	   al.,	   2005).	   Interestingly	  enzymatic	   activity	   at	   the	   NUDT9-­‐H	   domain	   of	   ADPR	   is	   not	   required	   for	   TRPM2	  gating	  as	  previously	  speculated	  (Perraud	  et	  al.,	  2001).	  	  	  
1.6	  Production	  of	  ADPR	  
	   Since	  oxidative	  and	  nitrosative	  stress	  do	  not	  appear	  to	  gate	  TRPM2	  directly,	  the	  processes	  must	  be	  linked	  to	  ADPR-­‐mediated	  activation.	  This	  is	  further	  evidenced	  by	  a	  mutant	  preventing	  ADPR	  binding,	  which	  also	  prevented	  channel	  gating	  via	  ROS	  (Perraud	  et	  al.,	  2005).	  Two	  pathways	  have	  been	  proposed	  for	  ADPR	  release	  into	  the	  cytosol.	  The	  first:	  mitochondria	  are	  induced	  to	  produce	  ADPR	  and	  release	  it	  to	  the	  cytosol	  under	  stress	  gating	  of	  TRPM2	  (Perraud	  et	  al.,	  2005).	  Mitochondrial	  permeability	  transition	  pores	  (mPTP)	  are	  often	  recruited	  during	  oxidative	  stress	  or	  neuronal	  stress	  resulting	  from	  traumatic	  brain	  injury	  or	  stroke.	  Proteins	  underlying	  the	  mPTP	  are	  recruited	  to	  form	  a	  pore	  in	  the	  inner	  membrane	  of	  mitochondria	  allowing	  molecules	  less	  than	  1500	  Daltons	  to	  pass	  through	  the	  membrane	  such	  as	  ADPR	  (Perraud	  et	  al.,	  2005).	  ADPR	  is	  derived	  from	  its	  precursor	  NAD	  and	  the	  mitochondria	  are	  a	  major	  cellular	  store	  for	  NAD	  (Perraud	  et	  al.,	  2005).	  Accumulation	  of	  cytosolic	  ADPR	  release	  from	  the	  mitochondria	  is	  critical	  to	  nitrosative	  and	  oxidative	  stress-­‐gating	  of	  TRPM2,	  providing	  evidence	  that	  H2O2	  is	  an	  upstream	  releasing	  agent	  of	  ADPR	  from	  the	  mitochondria	  (Perraud	  et	  al.,	  2005).	  	  The	   second	   pathway	   involves	   polyADPR-­‐polymerase(PARP)	   and	   polyADPR-­‐glycohydrolase	   (PARG).	   PARP-­‐1	   is	   a	   113kDa	   nuclear	   enzyme	   which	   is	   recruited	  following	   DNA	   damage	   and	   hydrolyses	   βNAD+	   to	   ADPR	   (Davidovic	   et	   al.,	   2001).	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Following	   DNA	   breakage	   resulting	   from	   oxidants,	   alkylating	   agents	   or	   ionizing	  radiation	   (Virag	   and	   Szabo,	   2002),	   the	   zinc	   fingers	   of	   the	  DNA	  binding	   domain	   of	  PARP-­‐1	  recognize	  the	  damaged	  area	  (Davidovic	  et	  al.,	  2001).	  Binding	  allosterically	  activates	  the	  catalytic	  domain	  of	  PARP-­‐1	  allowing	  posttranslational	  modification	  of	  the	   substrate	   βNAD+.	  PARG	   occurs	   late	   in	   the	   process	   catabolizing	   histone	   bound	  pADPR,	  allowing	  histones	  to	  bind	  DNA	  and	  form	  nucleosomes	  once	  more	  (Davidovic	  et	  al.,	  2001).	  PARG	  catalyzes	   the	  hydrolysis	  of	  branched	  polymers	  producing	  ADP-­‐ribose	  (Soldani	  et	  al.,	  2001)	  and	  degrades	  PARP-­‐1	  (Soldani	  and	  Scovassi,	  2002).	  	  	  	  It	   has	   been	   proposed	   that	   H2O2	   results	   in	   DNA	   damage	   possibly	   through	  peroxide,	  resulting	  in	  increased	  production	  of	  ADPR	  via	  PARP-­‐1	  and	  thereby	  feeding	  back	  on	  TRPM2	  activation	  (Miller,	  2004).	  TRPM2	  activation	  leads	  to	  Ca2+	  influx	  and	  PARP	  cleavage,	  thereby	  creating	  a	  negative	  feedback	  loop	  (Zhang	  et	  al.,	  2006).	  The	  role	  of	  PARP-­‐1	  on	  H2O2-­‐mediated	  TRPM2	  activation	  was	  examined	  in	  HEK293	  cells	  (Fonfria	   et	   al.,	   2004).	   A	   series	   of	   structurally	   distinct	   PARP	   inhibitors	   were	   used	  with	   varying	   potency	   that	   inhibited	   H2O2-­‐induced	  TPRM2	   currents	   (Fonfria	   et	   al.,	  2004).	  PARP	  inhibitors	  did	  not	  influence	  ADPR	  mediated	  currents	  therefore	  they	  are	  not	   directly	   interacting	   with	   the	   NUDT9-­‐H	   domain	   (Fonfria	   et	   al.,	   2004).	   It	   was	  found	   that	   over-­‐activation	   of	   PARP-­‐1	   catabolizes	   all	   βNAD+,	  a	   precursor	   for	   ATP,	  causing	  cellular	  dysfunction	  (Fonfria	  et	  al.,	  2004).	  	  One	   question	   remained	   unanswered:	   whether	   generation	   of	   ADPR	   in	  intracellular	   stores	   is	   sufficient	   to	   gate	   TRPM2.	   Basal	   ADPR	   levels	   are	   close	   to	   or	  above	   modulatory	   requirements	   as	   determined	   by	   a	   novel	   reverse-­‐phase	   HPLC	  technique	  used	  to	  quantify	  ADPR	  (Gasser	  et	  al.,	  2005).	  This	  lends	  strong	  evidence	  to	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a	  quick	  burst	  of	  ADPR	  as	  a	  modulatory	  mechanism	  of	  TRPM2,	  which	  is	  maintained	  by	  additional	  hydrolysis	  of	  NAD	  to	  ADPR	  (Gasser	  et	  al.,	  2005).	  ADPR	  alone	  has	  been	  shown	  to	  reach	  sufficient	  cytosolic	  concentrations	  to	  gate	  TRPM2	  channels	  (Buelow	  et	   al.,	   2008).	   The	   H2O2	   direct	   gating	   of	   TRPM2	   has	   been	   ruled	   out	   in	   favour	   of	  downstream	  regulation	  by	  ADPR	  binding	  (Scharenberg,	  2005).	  Nevertheless,	  while	  H2O2	   does	   not	   bind	   directly	  with	   TRPM2,	   ROS	   are	   the	  most	   likely	   beginning	   to	   a	  chain	  of	  events	  that	  evokes	  Ca2+	  influx	  through	  TRPM2	  channels.	  	  
1.7	  Ca2+	  and	  TRPM2	  
	   Early	   TRPM2	   research	   implicated	   a	   Ca2+-­‐dependent	   gating	   of	   the	   channel	   in	  addition	   to	   ADPR	   requirement	   (Perraud	   et	   al.,	   2001).	   It	   was	   initially	   unclear	  whether	   Ca2+-­‐dependence	   of	   gating	   occurs	   at	   the	   intra-­‐	   or	   extra-­‐cellular	  environment.	   When	   intracellular	   Ca2+	   stores	   were	   depleted	   ADPR	   alone	   was	   no	  longer	   sufficient	   to	   evoke	   TRPM2	   currents	   (Perraud	   et	   al.,	   2001).	   However	  intracellular	   buffering	   of	   Ca2+	   greatly	   attenuates	   H2O2	   mediated	   currents	   despite	  extracellular	  Ca2+	  concentrations	  (McHugh	  et	  al.,	  2003).	  Other	  divalent	  cations	  (such	  as	   Mg2+)	   could	   not	   substitute	   for	   Ca2+	   in	   promoting	   TRPM2	   channel	   activation	  (Mchugh	   et	   al,	   2003).	   	   It	   is	   now	   thought	   that	   TRPM2	   activation	   is	   dependent	   on	  intracellular	   Ca2+	   and	   then	   maintained	   by	   influx	   of	   Ca2+	   from	   the	   extracellular	  environment	   (Csanady	   and	   Torocsik,	   2009).	   When	   intracellular	   Ca2+	   falls	   below	  100nM,	  TRPM2	  inactivates	  (Starkus	  et	  al.,	  2007).	  	  Extremely	   high	   ADPR	   in	   the	   absence	   of	   Ca2+	   is	   sufficient	   to	   evoke	   TRPM2	  currents	   (Starkus	   et	   al.,	   2007).	   On	   the	   other	   end	   of	   the	   spectrum	   100µM	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intracellular	  Ca2+	  alone	  is	  also	  sufficient	  to	  gate	  TRPM2	  and	  several	  splice	  variants	  lacking	   an	   ADPR	   binding	   domain	   (Du	   et	   al.,	   2009a).	   Of	   course,	   the	   physiological	  relevance	  of	  these	  two	  studies	  can	  be	  called	  into	  question	  since	  the	  concentration	  of	  ADPR	  and	  Ca2+	  used	  are	  not	   at	   all	  physiological.	   	   For	  example,	   an	  analytical	  HPLC	  method	   (Gasser	   et	   al.,	   2005)	   was	   employed	   to	   measure	   ADPR	   concentrations	  (Heiner	  et	  al.,	  2006).	  These	  studies	  estimated	  that	  the	  physiological	  concentration	  of	  ADPR	  is	  in	  the	  range	  of	  5µM.	  	  Similarly,	  resting	  levels	  of	  intracellular	  Ca2+	  are	  1µM.	  	  Importantly,	  within	  their	  respective	  physiological	  range	  neither	  Ca2+	  nor	  ADPR	  can	  promote	  TRPM2	  channel	  alone.	  Accordingly,	  given	  physiological	  levels	  of	  ADPR	  and	  Ca2+	   it	   is	  more	   likely	  both	  work	  in	  concert	  to	  regulate	  TRPM2	  (Heiner	  et	  al.,	  2006;	  Casanady	  and	  Torocsik,	  2009).	  Indeed	  ADPR	  and	  Ca2+	  show	  a	  synergistic	  effect;	  even	  in	  the	  presence	  of	  100nM	  Ca2+,	  ADPR	  was	  further	  able	  to	  increase	  currents	  2.5-­‐fold	  (Due	  et	  al.,	  2009a).	  Single	   channel	   TRPM2	   analysis	   identified	   four	   sites,	   likely	   one	   per	   channel	  subunit,	  which	  was	  required	  to	  initially	  gate	  and	  maintain	  TRPM2	  current	  (Csanady	  and	  Torocsik,	   2009).	   Calmodulin	   (CaM)	   a	  ubiquitously	   expressed	  Ca2+	   sensor	   (see	  section	  1.11	  for	  a	  thorough	  review	  of	  CaM)	  appears	  to	  be	  responsible	  for	  the	  Ca2+-­‐dependent	  activation	  of	  TRPM2	  (Tong	  et	  al.,	  2006).	  Additional	  100nM	  CaM	  added	  to	  the	  patch	  pipette	  significantly	   increased	  ADPR	  mediated	  TRPM2	  currents	   (Starkus	  et	   al.,	   2007).	   2uM	   Calmidazolium,	   a	   CaM	   inhibitor,	   prevented	   ADPR	   mediated	  TRPM2	  currents	   (Starkus	  et	  al.,	  2007).	  A	  dominant	  negative	  mutated	   form	  of	  CaM	  was	  able	   to	  compete	  with	  endogenous	  CaM	  and	  restrict	  TRPM2	  mediated	  current,	  hinting	  at	  an	  intracellular	  binding	  domain	  (Tong	  et	  al.,	  2006).	  Immunoprecipitation	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implicates	   a	   direct	   interaction	   between	   CaM	   and	   TRPM2;	   strong	   binding	   was	  identified	   in	   the	  N-­‐terminal	   (1-­‐730AA)	  and	  weak	  binding	   in	   the	  C-­‐terminal	   (1060-­‐1503AA)	  in	  the	  presence	  of	  100uM	  free	  Ca2+	  buffered	  with	  5mM	  EGTA	  (Tong	  et	  al.,	  2006).	  This	  was	  taken	  as	  evidence	  that	  CaM	  was	  associating	  with	  the	  N-­‐term	  only	  to	  activate	  TRPM2	  (Tong	  et	  al.,	  2006).	  An	  IQ-­‐like	  consensus	  binding	  motif	  on	  the	  406-­‐416AA	  N-­‐terminal	   of	   the	   channel	   received	   substitution	  mutations	   to	   key	   residues	  (TRPM2-­‐CaMMut(NTIQ))	  which	  produced	   a	  mutant	   incapable	   of	   activation	   (Tong	   et	  al.,	   2006).	   Currents	   can	   not	   be	   elicited	   from	   TRPM2-­‐CaMMut(NTIQ)	   regardless	   of	  intracellular	  Ca2+	  or	  ADPR	  (Du	  et	  al.,	  2009a).	  It	  is	  now	  fairly	  agreed	  upon,	  TRPM2	  is	  gated	  by	  both	  ADPR	   	  binding	   to	  a	  C-­‐term	  NUDT9-­‐H	  domain	  concurrent	  with	  Ca2+-­‐CaM	  binding	  to	  an	   intracellular	  N-­‐term	  IQ-­‐like	  motif	  (Perraud	  et	  al.,	  2005;	  Tong	  et	  al.,	  2006).	  
	  
	  
1.8 Other	  TRPM2	  regulation	  mechanisms	  
	   Several	   other	   pharmacological	   modulators	   of	   TRPM2	   gating	   have	   been	  uncovered	  recently	  that	  alter	  ADPR	  mediated	  currents.	  Heat	  alone	  has	  been	  found	  to	  potentiate	   hTRPM2	   and	  works	   synergistically	  with	   βNAD+	  and	  ADPR	   activation	   of	  TRPM2	   (Togashi	   et	   al.,	   2006).	   cADPR	   is	   an	   intermediary	   cyclase	   converted	   from	  βNAD+	  by	  CD-­‐38	  and	  can	  then	  be	  converted	  to	  ADPR	  (Togashi	  et	  al.,	  2006;	  Kolisek	  et	  al.,	  2005).	  Cyclic-­‐ADPR	  was	  originally	  thought	  not	  to	  mediate	  TRPM2	  (Perraud	  et	  al.,	  2001),	   however	   under	   body	   temperatures	   it	   can	   successfully	   gate	   the	   channel	  (Togashi	   et	   al.,	   2006).	   Heat	   maximizes	   TRPM2	   current	   at	   a	   35°C	   threshold,	  importantly	   EC50	   of	   βNAD+	   was	   not	   altered	   (Togashi	   et	   al.,	   2006).	   The	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concentrations	  of	  cADPR	  required	  to	  gate	  TRPM2	  channel	  directly	  (100	  uM)	  are	  not	  physiologically	   relevant,	   but	   with	   small	   amounts	   cADPR	   can	   greatly	   potentiate	  ADPR	  and	  βNAD+	  evoked	  TRPM2	  currents	  (Kolisek	  et	  al.,	  2005).	  	  Tyrosine	   phosphorylation	   status	   of	   TRPM2	   is	   thought	   to	   be	   an	   important	  regulator	  because	  of	  research	  with	  PTPL1,	  a	  tyrosine	  phosphatase	  with	  a	  role	  in	  cell	  survival	   and	   tumorigenesis	   (Zhang	   et	   al.,	   2007).	   PTPL-­‐1	   promotes	   TRPM2	  dephosphorylation,	   decreased	   intracellular	   calcium	   currents	   and	   increased	   cell	  survival	   from	   H2O2	   mediated	   cell	   death	   (Zhang	   et	   al.,	   2007).	   	   PTPL-­‐1	   was	  immunoprecipitated	   with	   TRPM2,	   the	   mechanism	   remains	   unknown	   but	   PTPL-­‐1	  may	   be	   dephosphorylating	   tyrosine	   at	   the	   CaM,	   ADPR	   or	   pore	   region	   thereby	  altering	   binding	   affinity	   or	   channel	   gating	   kinetics	   (Zhang	   et	   al.,	   2007).	   Other	  proteins	   dephosphorylated	   by	   PTPL-­‐1	   are	   often	   phosphorylated	   by	   Src	   family	  kinases	  (Zhang	  et	  al.,	  2007).	  Our	  lab	  has	  preliminary	  evidence	  to	  suggest	  Fyn	  but	  not	  Src	  is	  the	  kinase	  responsible	  for	  TRPM2	  tyrosine	  phosphorylation	  (MacDonald	  Lab,	  Unpublished).	  	  Glutathione	   (a	   naturally	   occurring	   antioxidant)	   inhibits	   TRPM2	  gating,	   shifting	  the	  dose	  response	  curve	  of	  ADPR	  3.5-­‐fold.	  The	  modification	  occurs	  independent	  of	  any	   cysteine	   residues	   (thiol-­‐independent),	   currently	   the	   mechanism	   glutathione	  uses	  to	  modulate	  TRPM2	  is	  unknown	  (Belrose	  et	  al.,	  2012).	  Acidic	  pH	  may	  block	  TRPM2	  channels	  at	  IC50	  5.3pH	  extracellular	  and	  IC50	  6.7	  pH	  intracellular	   (Du	   et	   al.,	   2009b).	   Low	   extracellular	   pH	  may	   also	   irreversibly	   block	  TRPM2;	  likely	  due	  to	  different	  preparations	  this	  has	  been	  argued	  to	  occur	  at	  4.0	  pH	  (Du	  et	  al.,	  2009b),	  5.0	  pH	  (Starkus	  et	  al.,	  2010)	  or	  6.0	  pH	  (Yang	  et	  al.,	  2010).	  Several	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conflicting	  hypothesis	  of	  pH	  regulation	  of	  TRPM2	  have	  been	  proposed:	  intracellular	  permeation	  of	   ions	   through	  the	  pore	   interrupts	  Ca2+	  binding	  at	  channel	  regulation	  sites	  (Starkus	  et	  al.,	  2010;	  Csanady,	  2010).	  However	  Du	  et	  al.,	  2009b	  and	  Yang	  et	  al.,	  2010	   argue	   protons	   bind	   at	   amino	   acid	   sites	   near	   the	   pore.	   Changing	   channel	  conformation	   or	   bound	   protons	   could	   decrease	   local	   Ca2+	   concentrations	   and	  thereby	  Ca2+	  influx	  required	  to	  promote	  TRPM2	  activation	  (Du	  et	  al.,	  2009b;	  Yang	  et	  al.,	  2010).	  	  
	  
	  
1.9 	  Antagonists	  of	  TRPM2	  
	   The	   development	   of	   pharmacological	   agents	   capable	   of	   selectively	   inhibiting	  TRPM2	  has	  lagged	  the	  significant	  advances	  made	  in	  understanding	  TRPM2	  function.	  However,	  several	  non-­‐specific	   inhibitors	  have	  been	  discovered	  that	  can	  be	  used	   in	  series	   with	   other	   inhibitors.	   Flufenamic	   acid	   (FFA)	   is	   an	   antagonist	   that	   inhibits	  TRPM2	   with	   minimal	   recovery	   (~10-­‐15%)	   observed	   after	   washout	   (Hill	   et	   al.,	  2004a).	  FFA	  can	  only	  block	  TRPM2	  extracellularly	  and	  is	  potentiated	  by	  low	  pH	  (Hill	  et	   al.,	   2004a).	   Similarly	   antagonists	   (antifungal	   imidazoles)	   clotrimazole	   and	  econazole	  both	   inhibit	  TRPM2	   in	   extracellular	   solutions	   at	   concentrations	   ranging	  from	  3μM	  to	  20μM	  (Hill	  et	  al.,	  2004b).	  Interestingly	  FFA	  and	  antifungal	   imidazoles	  block	   TRPM2	   in	   RAT	   CRI-­‐G1	   cells	   but	   currents	   are	   fully	   recovered	   on	   washout,	  suggesting	   a	   cell	   specific	   effect	   of	   these	   antagonists	   (Hill	   et	   al.,	   2004a;	   Hill	   et	   al.,	  2004b).	   Problematically,	   FFA	   destabilizes	   cellular	   membranes	   (Hill	   et	   al.,	   2004a)	  and	  antifungal	  imidazoles	  are	  far	  from	  specific	  (Hill	  et	  al.,	  2004a).	  FFA	  blocks	  CaM,	  which	   is	  necessary	  Ca2+	   sensor	   for	  many	   cellular	  processes	   and	  TRPM2	  activation	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(Hill	  et	  al.,	  2004b;	  Tong	  et	  al.,	  2006).	  It	  has	  been	  suggested	  FFA	  acts	  as	  a	  weak	  acid	  irreversibly	  blocking	  TRPM2	  channels	  through	  the	  same	  mechanism	  outlined	  in	  pH	  sensitivity	   of	   TRPM2	   (Naziroglu	   et	   al.,	   2007).	  N-­‐(p-­‐amycinnamoyl)anthranilic	   acid	  (ACA)	  also	  acts	  as	  a	  weak	  acid	  blocking	  TRPM2,	  however	  inactivation	  was	  found	  to	  be	  pH	  dependent	  (Kraft	  et	  al.,	  2006).	  Antagonism	  was	  fast	  and	  unable	  to	  recover	  at	  pH	  6.0,	  but	  was	  slow	  and	  fully	  recovered	  at	  pH	  7.4	  (Kraft	  et	  al.,	  2006).	  TRPM2	   antagonists	   FFA	   and	   ACA	   have	   been	   used	   to	   partially	   block	   H2O2	  mediated	   cell	   death	   in	   transfected	  HEK203	   cells	   (Wilkinson	   et	   al.,	   2008).	   Current	  antagonists	   remain	   limited	   by	   their	   slow	   inhibition	   or	   irreversible	   inhibition	   of	  TRPM2	  (Togashi	  et	  al.,	  2008).	  Other	  antagonists	  such	  as	  2-­‐APB	  provide	  a	  reversible	  block	   of	   TPRM2	   upon	   wash-­‐out	   (Togashi	   et	   al.,	   2008).	   However	   2-­‐APB	   has	   been	  shown	   to	   block	   other	   TRP	   channels	   and	   GAP	   junctions,	   and	   no	   specific	   TRPM2	  blocker	  has	  yet	  been	  identified	  (Togashi	  et	  al.,	  2008).	  	  
	  	  
	  
1.10 Guam	  hTRPM2	  P1018L	  and	  CDI	  
	  	   TRPM2	   has	   been	   associated	   with	   Western	   Pacific	   amyotrophic	   lateral	  sclerosis	   (ALS)	   and	   Parkinsonism	   Dementia	   (PD).	   ALS	   type	   symptoms	   associated	  with	  muscle	  weakness	  are	  defined	  by	  neurodegeneration	  of	  the	  motor	  neurons	  and	  is	  eventually	  fatal	  (Rowland,	  2001).	  Parkinsonism	  dementia	  is	  also	  highly	  correlated	  in	  this	  population,	  a	  disease	  defined	  by	  symptoms	  of	  both	  Parkinson’s	  and	  dementia	  in	  the	  same	  individual	  (Hermosura	  and	  Garruto,	  2007).	  	  Epidemiological	   studies	   were	   interested	   in	   Guamanian	   diseases	   due	   to	  clustering	  amongst	  families,	  but	  little	  progress	  was	  made	  to	  identify	  candidate	  genes	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(Hermosura	   and	   Garruto,	   2007).	   Three	   factors	   are	   thought	   to	   contribute	   to	   the	  disease:	  the	  environmental	  conditions	  in	  Guam	  (low	  Mg2+	  and	  Ca2+),	  high	  incidence	  of	  ALS	  and	  PD	  and	  altered	  Ca2+metabolism	  amongst	  patients	  fed	  a	  similar	  diet,	  and	  a	  genetic	  mutation	   to	  TRPM2	  observed	   in	   this	   population	   (Hermosura	   and	  Garruto,	  2007;	   Hermosura	   et	   al.,	   2008).	   A	   missense	   mutation	   was	   identified	   in	   hTRPM2	  Guam	   genetic	   populations	   substituting	   a	   Proline	   for	   a	   Leucine	   at	   1018AA	  (Hermosura	  et	  al.,	  2008).	  Computer	  modeling	  suggests	  the	  substitution	  relaxes	  the	  structural	   integrity	   of	   the	   pore-­‐forming	   loop	   of	   hTRPM2,	   the	   Proline	   identified	   is	  highly	   conserved	   amongst	   species	   and	   other	   TRPM	   channels	   (Hermosura	   et	   al.,	  2008).	   Intriguingly	   Ca2+	   rise	   was	   significantly	   inhibited	   in	   P1018L	   hTRPM2	  transfected	   cells	   versus	   WT	   activated	   by	   H2O2	   (Hermosura	   et	   al.,	   2008).	   Finally	  P1018L	  hTRPM2	  showed	   inactivation	  over-­‐time,	   a	  phenomenon	   they	   claimed	  was	  not	   seen	   in	   wild-­‐type	   channels	   and	   was	   only	   increased	   by	   raised	   ADPR	   and	  extracellular	   but	   not	   intracellular	   Ca2+	   concentrations	   (Hermosura	   et	   al.,	   2008).	  Considerable	   evidence	   has	   lead	   to	   a	   focus	   of	   the	   role	   of	   TRPM2	   in	  neurodegeneration.	   Furthermore,	   knowledge	   of	   TRPM2	   inactivation	   over	   time	   is	  limited	  and	  rarely	  discussed	   in	   the	   literature.	  Our	   lab	  has	  grown	   interested	   in	   the	  mechanism	  behind	  TRPM2	  inactivation,	  which	  has	  not	  been	  well	  defined.	  	  
1.11 Ca2+-­‐dependent	  inactivation	  
	   When	  TRPM2	  ADPR	  dependence	  was	   initially	   characterized,	   some	   inactivation	  was	   observed	   in	  whole-­‐cell	   recordings	   that	   could	   be	   abolished	  when	   intracellular	  Ca2+	   concentrations	   were	   buffered	   to	   100nM	  with	   2-­‐bis(o-­‐aminophenoxy)ethane-­‐
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N,N,N',N'-­‐tetraacetic	  acid	  (BAPTA)	  a	  Ca2+	  chelator	  (Perraud	  et	  al.,	  2001).	  What	  has	  been	   defined	   as	   a	   rundown	   of	   current	   was	   observed	   in	   both	   human	   (Sano	   et	   al.,	  2001)	   and	   rat	   (Hill	   et	   al.,	   2006)	   TRPM2	   channel	   recordings.	   Rundown	   was	   not	  successfully	   reduced	   by	   additional	   CaM,	   protein	   kinases	   and	   ATP	   or	   lowering	  intracellular	   Mg2+	   (Csanady	   and	   Torocsik,	   2009).	   Additionally	   25uM	   dioctanoyl	  phosphatidylinositol	   4,5-­‐biphosphate,	  which	   has	   been	   shown	   to	   rescue	   other	   TRP	  channels	   from	   desensitization	   had	   no	   effect	   (Zhang	   et	   al.,	   2004;	   Csanady	   and	  Torocsik,	  2009).	  Preliminary	  evidence	  of	  TRPM2	  inactivation	  from	  our	  laboratory	  has	  given	  us	  a	  clearer	  understanding	  of	   the	  kinetic	  and	  mechanistic	  process.	  HEK293	  cells	   stably	  expressing	   doxycycline	   inducible	   TRPM2	   were	   utilized	   in	   whole-­‐cell	   patch-­‐clamp	  recordings.	  0.3μM	  ADPR,	  1mM	  Ca2+	  buffered	  with	  10mM	  EGTA	  in	  the	  patch	  pipette	  and	   2mM	   Ca2+	   in	   the	   extracellular	   fluid	   (ECF)	   were	   utilized	   to	   evoke	   TRPM2	  currents.	  What	  we	  observe	  (figure	  1.2)	  is	  a	  slow	  increase	  in	  current	  reaching	  peak	  amplitude	  (Ip),	   followed	  by	  a	  marked	  decrease	  reaching	  a	  steady	  state	  (Iss).	  When	  measuring	  and	  referring	  to	  inactivation	  we	  define	  it	  as	  the	  ratio	  between	  the	  Iss/Ip.	  It	   was	   originally	   speculated	   that	   hydrolysis	   of	   ADPR	   at	   the	   NUDT9-­‐H	   domain	  may	   reduce	   ADPR	   intracellular	   concentrations	   and	   inactivate	   TRPM2	   over-­‐time	  (Minke	  and	  Cook,	  2002).	  However,	  we	  now	  know	  enzymatic	  activity	  at	  the	  NUDT9H	  site	   is	  not	   required	   for	  ADPR	  mediated	  TRPM2	  gating	   (Perraud	  et	   al.,	   2005;	  Kuhn	  and	  Luckhoff,	  2004).	  An	  alternative	  explanation	  of	  TRPM2	  inactivation	  involves	  the	  internalization	  of	   the	   channel	   in	   response	   to	  Ca2+,	   seen	   in	   other	   cation	  permeable	  channels	   (Dargent	   et	   al.,	   1994).	   Preliminary	   evidence	   from	   our	   lab	   (Appendix	   –	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Figure	  A1)	  indicates	  TRPM2	  inactivation	  recovers	  over	  time	  when	  exposed	  to	  0mM	  Ca2+	  ECF.	  A	  time	  course	  of	  recovery	  was	  performed	  and	  peak	  recovery	  was	  observed	  at	  3	  minutes.	  Furthermore,	  increased	  concentrations	  of	  ADPR	  from	  0.3mM	  to	  1mM	  (Appendix	  –Figure	  A2)	  increased	  the	  recovery	  time	  from	  inactivation,	  the	  opposite	  effect	   if	   we	   expect	   inactivation	   to	   be	   a	   result	   of	   depleted	   ADPR.	   This	   indicates	  activation	   is	   neither	   regulated	   by	   hydrolysis	   of	   ADPR	   cytosolic	   stores	   nor	   the	  internalization	   of	   TRPM2	   channels	   in	   response	   to	   Ca2+	   currents,	   but	   rather	   some	  unknown	  mechanism.	  A	   critical	   finding	   by	   Perraud	   et	   al,	   2001	   has	   identified	   inactivation	   as	   an	  intracellular	   Ca2+-­‐dependent	   process	   that	   can	   be	   abolished	   by	   buffering	   Ca2+	  with	  BAPTA.	  Interestingly,	  inactivation	  in	  TRPM2	  is	  also	  a	  CaM-­‐dependent	  process:	  when	  intracellular	  CaM	   is	   increased	  beyond	  endogenous	   concentrations	  using	  100μM	   in	  the	  patch	  pipette	  there	  was	  a	  significant	  increase	  in	  inactivation	  (Appendix	  –	  Figure	  A3).	  Recall	  CaM	  is	  also	  responsible	  for	  the	  activation	  of	  TRPM2	  by	  interacting	  with	  an	  IQ-­‐like	  CaM	  binding	  site	  on	  the	  intracellular	  N-­‐terminal	  of	  the	  channel	  (Tong	  et	  al.,	   2006).	   How	   CaM	   could	   be	   regulating	   TRPM2	   inactivation	   remains	   to	   be	  discovered.	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Figure	  1.2	  –	  Representative	  trace	  of	  a	  whole-­‐cell	  voltage-­‐clamp	  recording	  at	  -­‐60mV	  using	  HEK293	  cells	  stably	  expressing	  TRPM2	  channels.	  Currents	  were	  elicited	  with	  0.3mM	   ADPR	   and	   alternating	   applications	   of	   0mM	   Ca2+	   and	   2mM	   Ca2+	   ECF	   via	   a	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1.12 Calmodulin,	  inactivation	  and	  VGCC	  binding	  
	   Calmodulin	   is	   a	   ubiquitously	   expressed	   protein	   involved	   in	   a	   wide	   variety	   of	  regulatory	   functions	   in	  nearly	   every	  eukaryotic	   cell	   (Crivici	   and	   Ikura,	  1995).	   It	   is	  known	   to	   activate	   more	   than	   40	   classes	   of	   proteins	   such	   as	   Ca2+	   channels,	   TRP	  channels	  and	  Ca2+	  release	  channels	  from	  internal	  organelle	  stores	  (Saimi	  and	  Kung,	  2002).	   CaM	   has	   been	   essentially	   rediscovered	   multiple	   times	   throughout	   the	  literature	   due	   to	   its	   ubiquitous	   involvement	   in	   many	   physiological	   processes	  (Jurado	  et	  al.,	  1999).	  The	  nomenclature	  Calmodulin	  was	  finally	  assigned	  in	  1979	  and	  has	  been	  widely	  used	  ever	  since	  (Lynch	  and	  Cheung,	  1979).	  CaM	  is	  a	  small	  soluble	  protein	   (17kDa)	   reaching	   concentrations	   of	   1-­‐10uM	   in	   the	   brain,	   nearly	   half	   of	  which	   is	  associated	  with	   the	  membrane	  (Saimi	  and	  Kung,	  2002).	  CaM	  has	  a	  100%	  conserved	   identity	   in	   vertebrates	   and	   its	   repeated	   expression	   found	   over	   several	  different	  genes;	  homology	   is	  essential	   for	   the	  diverse	   interactions	  of	  CaM	  amongst	  many	  different	  vertebrate	  proteins	  (Friedberg,	  1990).	  CaM	   consists	   of	   4EF	   hands,	   two	   on	   each	   terminal,	   forming	   globular	   lobes	  connected	   by	   an	   alpha	   helix	   giving	   the	   three	   dimensional	   representation	   of	   a	  dumbbell	   (Babu	   et	   al.,	   1985).	   The	   alpha-­‐helix	   is	   a	   hydrophobic	   region	   involved	   in	  protein	   interaction	   (Babu	   et	   al.,	   1985).	   CaM	   functions	   through	   its	   different	  conformational	   affinities	   for	   Ca2+	   (Klevit	   et	   al.,	   194).	   Ca2+	   binding	   changes	   the	  conformation	  of	  CaM,	  promoting	  opening	  the	  EF	  hands	  to	  expose	  the	  hydrophobic	  binding	  region	  (Saimi	  and	  Kung,	  2002).	  Ca2+	  bound	  to	  CaM	  EF	  hands	  3	  and	  4	  on	  the	  C-­‐term	  does	   exist	   naturally	   in	   solution;	   this	   is	   due	   to	   a	  much	   stronger	   affinity	   for	  Ca2+	  at	  EF	  hands	  1	  and	  2	  on	  the	  N-­‐term	  (Klevit	  et	  al.,	  1984).	  While	  up	  to	  16	  different	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conformational	  states	  of	  CaM	  may	  exist,	  most	  interactions	  of	  CaM	  can	  be	  summed	  up	  as	  3-­‐4	  Ca2+	  occupied	  EF	  hands	  or	  CaM	   in	  absence	  of	  Ca2+	   (ApoCaM)	   (Jurado	  et	  al.,	  1999).	  	  CaM	   complexes	   are	   varied;	  much	   of	   the	   structural	   information	   gained	   is	   from	  model	   peptides	   of	   target	   binding	   domains	   and	   mutated	   CaM	   (Crivici	   and	   Ikura,	  1995).	   Binding	   sites	   are	   then	  mapped	   by	   deletions,	   truncations	   and	   site	   directed	  substitution	  mutations	   (Crivici	   and	   Ikura,	   1995).	   Several	   types	   of	   CaM	   consensus	  binding	  sites	  have	  been	  identified	  (Hoeflich	  and	  Ikura,	  2002).	  Three	  types	  of	  motifs	  are	  defined	  by	  aromatic	  amino	  acids	  bridged	  by	  bulky	  hydrophobic	  and	  basic	  amino	  acids	  and	  are	  named	  according	  to	  the	  relative	  position	  of	  these	  key	  amino	  acids	  (i.e.	  the	  so-­‐called	  1-­‐10,	  1-­‐14	  and	  1-­‐16	  CaM	  binding	  motifs)	   (Hoeflick	  and	   Ikura,	  2002).	  IQ-­‐like	   motifs	   are	   defined	   by	   amino	   acid	   consensus	   site	   IQXXXRGXXXR,	   but	  substitutions	  are	  common	  (Jurado	  et	  al.,	  1999).	  ApoCaM	  has	  been	  shown	  to	  bind	  to	  IQ-­‐like	  motifs,	  interaction	  with	  these	  sites	  increases	  CaM	  affinity	  to	  Ca2+	  up	  to	  1000-­‐fold	   which	   is	   thought	   to	   hasten	   the	   responsiveness	   to	   Ca2+	   (Jurado	   et	   al.,	   1999).	  ApoCaM	   shows	   much	   greater	   homology	   amongst	   binding	   sites	   than	   Ca2+-­‐CaM	  diversity	   (Jurado	   et	   al.,	   1999).	   Interestingly,	   IQ-­‐like	   motifs	   often	   overlap	   with	  phosphorylation	  sites	  of	  protein	  kinase	  C	  and	  are	  dephosphorylated	  by	  calcineurin,	  phosphorylation	   is	   thought	   to	   inhibit	  CaM	  binding	  (Apel	  et	  al.,	  1990).	  Several	  CaM	  inhibitors	   are	   commonly	   used	   for	   experimentation:	   W7,	   Calmidozolium	   and	  mastoparan	  (Saimi	  and	  Kung,	  2002).	  Research	   into	  CaM-­‐mediated	   regulation	  of	  TRP	  channels	   can	  be	   traced	  back	   to	  the	  photo	  transduction	  cascade	  of	  TRP	  in	  Drosophila	  (Phillips	  et	  al.,	  1992).	  CaM	  has	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been	   shown	   to	   regulate	   activation	   of	   TRPM2	   on	   an	   N-­‐term	   IQ-­‐like	   consensus-­‐binding	   site	   (Tong	   et	   al.,	   2006).	   Results	   were	   determined	   using	   Ca2+	   imaging	   of	  single	  transfected	  cells	  (Tong	  et	  al.,	  2006).	  Immunoprecipitation	  of	  CaM	  and	  TRPM2	  terminal	  fragments	  revealed	  strong	  binding	  to	  the	  N-­‐terminal	  (1-­‐760AA)	  and	  weak	  binding	   to	   the	   C-­‐terminal	   (1060-­‐1503AA)	   (Tong	   et	   al.,	   2006).	   Substitution	  mutagenesis	  was	  carried	  out	  to	  an	  IQ-­‐like	  motif	  site	  on	  the	  N-­‐term	  that	  reduced	  but	  did	   not	   eliminate	   CaM	   binding,	   suggesting	   a	   second	   CaM	   binding	   site	   may	   exist	  (Tong	   et	   al.	   2006).	   CaM	   binding	   to	   the	   N-­‐term	   IQ-­‐like	  motif	   is	   essential	   for	   Ca2+-­‐dependent	  activation	  of	  TRPM2	  and	  can	  no	  longer	  be	  activated	  with	  ADPR	  (Tong	  et	  al.,	  2006;	  Starkus	  et	  al.,	  2007;	  Du	  at	  al.,	  2009a).	  Intriguingly,	   preliminary	   evidence	   exists	   for	   CaM-­‐dependent	   regulation	   of	  TRPM2	   Ca2+-­‐dependent	   inactivation	   (CDI)	   from	   our	   own	   unpublished	   laboratory	  findings	   (Appendix	   –	   Figure	   A3).	   Supplementing	   the	   patch	   pipette	   solution	   with	  100uM	  CaM	  increased	  the	  CDI	  observed	  from	  TRPM2	  transfected	  HEK293	  cells.	  The	  CaM-­‐dependence	  of	  TRPM2	  CDI	  cannot	  be	  elucidated	  by	  traditional	  means.	  CaM	  is	  required	   for	  channel	  activation	  and	  CaM	   inhibitors	  make	   it	   impossible	   to	  measure	  inactivation	   from	   an	   inactivated	   channel.	   A	   substitution	  mutagenesis	   strategy	   has	  been	  adopted	  for	  CDI	  linked	  to	  CaM	  consensus	  sites	  in	  other	  TRP	  homologs	  (Singh	  et	  al.,	  2002),	  however	  the	  efficacy	  may	  be	  limited	  for	  our	  use	  if	  CaM	  mutants	  interfere	  with	  channel	  activation.	  Ca2+-­‐CaM	   regulation	   of	   inactivation	   is	   common	  within	   other	   ion	   channels	   and	  most	   commonly	   associated	   with	   L-­‐type	   Ca2+	   channels	   (Zhulke	   and	   Reuter,	   1998)	  and	  NMDA	  (Zhang	  et	  al.,	  1998).	  CaM	  is	  constitutively	  bound	  to	  an	  IQ-­‐like	  consensus	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site	  of	  L-­‐type	  channels	  (Zhulke	  and	  Reuter,	  1998;	  Peterson	  et	  al.,	  1999).	  The	  group	  carried	   out	   a	   series	   of	   truncation	   mutations	   to	   determine	   the	   minimum-­‐binding	  domain	  (Zhulke	  and	  Reuter,	  1998).	  Two	  strategies	  were	  then	  employed;	  a	  dominant	  negative	   expression	   of	   a	   CaM	  mutant	   with	   alanine	   substitutions	   in	   3	   of	   the	   4	   EF	  hands	   was	   shown	   to	   abolish	   CDI	   in	   L-­‐type	   channels	   (Peterson	   et	   al.,	   1999).	  Furthermore	   amino	   acid	   substitutions	   replacing	   the	   IQ-­‐like	   consensus	   sites	   with	  Alanine	   also	   abolished	   CDI	   (Zuhlke	   et	   al.,	   1999).	   Ultimately	   Apo-­‐CaM	  bound	   to	   L-­‐type	  channels	  was	  determined	  to	  both	  facilitate	  channel	  activity	  and	  later	  inhibit	  the	  channel	   in	  a	  Ca2+-­‐dependent	  manner	  (Zuhlke	  et	  al.,	  1999;	  Peterson	  et	  al.,	  1999).	  A	  similar	   substitution	   mutagenesis	   strategy	   for	   a	   CaM	   consensus	   site	   on	   the	   NR1	  subunit	  of	  NMDA	  abolished	  CDI	  (Zhang	  et	  al.,	  1998).	  It	   is	   unclear	   whether	   constitutively	   bound	   endogenous	   ApoCaM	   prevented	   a	  dominant	   negative	   effect	   of	   CaM	   mutants	   transfected	   into	   our	   HEK293	   TRPM2	  expression	   system.	   Nevertheless	   we	   hypothesize	   TRPM2	   CDI	   might	   be	   occurring	  through	   an	   additional	   CaM	   binding	   site.	   This	   is	   further	   evidenced	   by	   TRPM2-­‐CaMMut(NTIQ)	  generated	  by	  Tong	  et	  al.,	  2006,	  which	  reduced	  but	  did	  not	  eliminate	  CaM	  immunoprecipitation.	  Furthermore	  multiple	  CaM	  sites	  are	  found	  in	  TrpL	  (TRP-­‐like	  homolog)	  channels	  seen	  in	  Drosophila	  photo	  transduction	  cascade,	  each	  with	  a	  different	   regulatory	   role	   (Scott	   et	   al.,	   1997).	   In	   fact	   other	   proteins	   have	   been	  identified	   with	   multiple	   CaM	   binding	   sites,	   one	   responsible	   for	   activation	   and	  another	   CDI	   such	   as	   Caldesmon	   (Wang	   et	   al.,	   1989)	   and	   Phosphofructokinase	  (Buschmeier	  et	  al.,	  1987).	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1.13	  Rationale	  and	  Hypothesis	  	   Given:	  1)	  Ca2+-­‐dependence	  of	  TRPM2	  inactivation,	  2)	  differing	  sensitivities	  of	  Ca2+	  for	  activation	  and	  inactivation,	  3)	  undiscovered	  CaM	  consensus	  binding	  sites	  4)	  the	  precedence	  of	  CaM-­‐mediated	  CDI	  with	  a	  number	  of	  Ca2+	  permeable	  channels	  and	  5)	  ineffectiveness	  of	  dominant	  negative	  CaM	  mutants;	  I	  hypothesize	  that	  the	  CDI	  of	  TRPM2	   involves	   Ca2+-­‐CaM	   binding	   to	   an	   undefined	   CaM	   consensus	   motif	   distinct	  from	  that	  of	  activation	  (NTIQ).	  We	  adopted	  a	  strategy	  similar	  to	  those	  previously	  outlined	  to	  determine	  the	  site	   of	   CaM-­‐dependent	   TRPM2	   CDI.	   CDI	   was	   further	   characterized	   by	   varying	  extracellular	  Ca2+	  and	  voltage	  steps.	  Using	  an	  in	  silico	  TRPM2	  CaM	  consensus	  search	  to	  identify	  candidate	  sites,	  we	  developed	  a	  series	  of	  overlapping	  TRPM2	  truncations	  to	   elucidate	   minimum	   binding	   domains.	   CaM-­‐Sepharose	   pull-­‐downs	   of	   stably	  expressed	   TRPM2	   intracellular	   truncations	   measrured	   CaM	   binding	   to	   each	  fragment.	  A	  series	  of	  substitution	  mutations	  to	  key	  amino	  acids	  was	  used	  to	  abolish	  CaM	   binding	   in	   each	   region,	   truncated	   fragments	   were	   then	   generated	   and	  compared	  to	  WT	  for	  CaM-­‐Sepharose	  binding.	  Full	  length	  TRPM2	  incorporating	  CaM	  consensus	   site	   substitution	   mutations	   was	   transfected	   into	   HEK293	   cells	   and	  currents	  measured	  with	  whole-­‐cell	  patch-­‐clamp	  recordings.	  We	  predicted	  abolished	  CaM	   binding	   at	   an	   unknown	   TRPM2	   CaM	   consensus	   domain	   via	   substitution	  mutations	  lead	  to	  sustained	  TRPM2	  currents	  and	  no	  CDI	  developing	  over	  time.	  	   	  Research	   by	   Hermosura	   et	   al.,	   2008	   that	   identifies	   a	   proline	   to	   leucine	  substitution	   in	   hTRPM2	   causing	   inactivation	   over	   time,	   we	   are	   interested	   if	   this	  increased	  activation	  is	  the	  same	  as	  our	  novel	  observation	  of	  TRPM2	  CDI.	  Given	  the	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2.1	  Whole-­‐cell	  patch	  clamp	  recording	  
	   Dr.	   A.M.	   Sharenberg	   (University	   of	   Washington	   and	   Children’s	   Hospital	   and	  Medical	  Center,	  Seattle,	  Washington)	  provided	  the	  TREX-­‐293,	  cells	  stably	  expressing	  TRPM2,	   utilized	   for	   electrophysiological	   recordings.	   Tetracycline-­‐controlled	  transcriptional	   activation	   prevents	   transcription	   of	   TRPM2	   unless	   reversibly	  induced	  by	  the	  antibiotic	  tetracycline.	  TRPM2	  was	  flag-­‐tagged	  for	  Western	  blotting	  analysis.	   Cells	   were	   maintained	   in	   culture	   at	   37°C	   with	   5%	   CO2	   in	   Dulbecco’s	  Modified	  Eagle	  Medium	  (Sigma).	  Media	  contained	  10%	  fetal	  bovine	  serum.	  TRPM2	  cells	   were	   plated	   on	   35mm	   dishes	   24-­‐48	   hours	   prior	   to	   TRPM2	   induction	   with	  Doxycycline	   (1µg	   ml-­‐1),	   a	   stable	   derivative	   of	   tetracycline	   12-­‐24	   hours	   prior	   to	  recordings.	  	  The	   extracellular	   recording	   solution	   contained	   the	   following:	   140mM	   NaCl,	  25mM	  Hepes,	  5.4mM	  KCl,	  33mM	  Glucose	  and	  1mM	  MgCl2	  The	  pH	  of	  the	  solution	  was	  adjusted	   to	   7.4	   using	   NaOH,	   and	   an	   osmolarity	   of	   310-­‐315	   was	   reached	   using	  millipore	   H2O.	   	   Three	   working	   solutions	   were	   generated	   with	   varying	  concentrations	  of	  Ca2+	  (2mM	  CaCl2,	  0.5mM	  CaCl2)	  and	  a	  calcium	  free	  solution	  using	  2mM	  BaCl2	  to	  maintain	  total	  divalent	  cation	  concentrations.	  ICF	  was	  made	  no	  more	  than	  5	  days	  prior	   to	  recordings,	  aliquoted	  to	  500µl	  and	  frozen.	  The	  ICF	  contained:	  135mM	  CsGluc,	   10mM	  Hepes,	   10mM	  EGTA,	   4mM	  Mg-­‐ATP,	   2mM	  MgCl2,	   and	   1mM	  CaCl2.	  	  	  T-­‐Rex293	  cells	  stably	  expressing	  TRPM2	  were	  voltage-­‐clamped	  at	  -­‐60mV	  during	  whole-­‐cell	   recordings	   (unless	   indicated)	   using	   Axopatch-­‐1B	   amplifier	   (Molecular	  Devices,	  Sunnyvale,	  CA).	  Currents	  were	  evoked	  through	  the	  addition	  of	  0.3mM	  ADPR	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(unless	   indicated)	   to	   the	   ICF	   on	   the	   day	   of	   recording	   via	   the	   patch	  pipette	  with	   a	  resistance	   between	   3	   and	   5	   MΩ.	   Utilizing	   a	   multi-­‐barreled	   fast	   perfusion	   system	  (figure	   2.1),	   cells	   were	   exposed	   to	   either	   the	   calcium	   free	   or	   calcium	   containing	  solutions.	  TRPM2	  was	  primed	  with	  2mM	  Ca2+	  solution	  until	  it	  reached	  a	  1nA	  current	  followed	  by	  a	  minimum	  of	  3	  minutes	  in	  0mM	  Ca2+	  solution	  prior	  to	  data	  collection.	  Data	  was	  recorded	  by	  3-­‐minute	  applications	  of	  Ca2+	  solution,	  followed	  by	  a	  5-­‐minute	  0mM	  Ca2+	  TRPM2	  recovery	  phase.	  Membrane-­‐holding	  voltage	  was	  raised	  by	  20mV	  increments	  between	  Ca2+	  sweeps.	  All	  data	  collected	  was	  filtered	  at	  2kHz,	  digitized	  and	  acquired	  using	  pClamp	  (Molecular	  Devices).	  
	  
2.2	  JetPrime	  (Polyplus)	  transfections	  of	  Hek293	  Cells	  
	   Less	  than	  24	  hours	  prior,	  Hek293	  cells	  were	  plated	  on	  a	  6	  cm	  dishes	  resulting	  in	  approximately	  60%	  cell	  confluence	  at	  time	  of	  transfections.	  200µl	  of	  JetPrime	  buffer	  solution,	  3µg	  of	  DNA	  (flag-­‐hTRPM2,	  flag-­‐mTRPM2,	  mTRPM2-­‐CaMMut(CT1-­‐14),	  mTRPM2-­‐CaMMut(CTIQ),	  mTRPM2-­‐CaMMut(NT1-­‐14)	  or	  mTRPM2-­‐CaMMut(NTIQ))	  and	  1µg	  of	  green	  fluorescent	  protein	  (PLB-­‐GFP)	  were	  combined	  in	  a	  sterile	  microtube	  and	  vortexed.	  6µl	  of	  JetPrime	  enzyme	  was	  added	  to	  the	  mixture	  and	  vortexed	  for	  10	  seconds.	  Following	  a	  ten	  minute	  incubation	  at	  room	  temperature	  the	  mixture	  was	  added	  drop	  wise	  to	  Hek293	  cells,	  shaken,	  and	  incubated	  for	  4	  hours	  at	  37°C	  with	  5%	  CO2.	  Following	  the	  incubation	  cells	  were	  washed	  using	  PBS	  and	  the	  media	  was	  replaced.	  24	  hours	  after	  transfection	  cells	  were	  plated	  at	  1/36	  ratio	  and	  used	  for	  electrophysiological	  whole-­‐cell	  recordings	  the	  following	  day	  (section	  2.1).	  UV	  exposure	  was	  used	  to	  visualize	  successfully	  transfected	  cells	  having	  been	  co-­‐transfected	  with	  GFP.	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Figure	   2.1	   –	   Whole-­‐cell	   patch-­‐clamp	   recording	   setup	   from	   HEK293	   cells	   stably	  expressing	   inducible	  TRPM2	  channels.	   0.3mM	  ADPR	   is	   added	   to	   the	  patch	  pipette	  solution	   to	   activate	   the	   channel.	   Cells	   are	   exposed	   to	   Ca2+	   free	   ECF	   or	   ECF	   with	  variable	   concentrations	   of	   Ca2+	   using	   a	  multi-­‐barreled	   fast	   perfusion	   system.	  Cells	  are	  voltage	  clamped	  and	  maintained	  at	  -­‐60mV	  unless	  noted.	  (Michael	  Jackson)	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2.3	  Generation	  of	  TRPM2	  Intracellular	  Truncations	  	   Forward	   and	   reverse	   primers	   were	   generated	   from	   pIRES-­‐puro-­‐flag-­‐mTRPM2	  template	  using	  Vector	  NTI	  software	  (Invitrogen).	  Primers	  included	  an	  AscI	  and	   NotI	   enzymatic	   regions	   used	   for	   sub-­‐cloning.	   TRPM2	   truncations	   (figure	   2.1)	  were	   designed	   to	   overlap	   candidate	   CaM	   consensus	   sites	   identified	   using	   in	   silico	  screening.	   Truncations	   were	   sub	   cloned	   into	   a	   pTNT-­‐GST	   vector	   containing	   the	  required	   promoter	   region	   for	   the	   TNT	   Quick-­‐Coupled	   Reticulocyte	   system	  (Promega)	   and	   were	   GST	   tagged	   to	   increased	   molecular	   weight	   and	   ensure	  sufficient	   lysine	   incorporation	   during	   experiments.	   The	   following	   constructs	  were	  generated	  for	  this	  project:	  	  Construct	   Forward	  Primer	  (5’-­‐>3’)	   Reverse	  Primer	  (3’-­‐>5’)	  pTNT-­‐GST-­‐CT1(1047-­‐1163)	   AGAGGCGCGCCAAACTACACCTT	   AATATGCGGCCGCCTAGTCCATGTCCAGCAGATCCA	  pTNT-­‐GST-­‐CT2(1163-­‐1278)	   AATTAGGCGCGCCAATGGACCAGGTGAAGAGGTCAG	   TAATGCGGCCGCCTACTTCTCAGCGGTGTAAAAGGG	  pTNT-­‐GST-­‐CT3(1278-­‐1395)	   AATAGGCGCGCCAGAGAAGGATGTGGCTCTCACAGAC	   TAATTAGCGGCCGCCTATGGTAGCATCTCCCCTGGCT	  pTNT-­‐GST-­‐CT4(1395-­‐1507)	   zTATTAGGCGCGCCACTACCACGGAAGCTGAAACGGGT	   AATATGCGGCCGCCTACTTGAGCTGCTTATGCCTCT	  pTNT-­‐GST-­‐CT5(1047-­‐1082)	   AGAGGCGCGCCAAACTACACCTT	   AATATGCGGCCGCCTACTTGAGCTGCTTATGCCTCT	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pTNT-­‐GST-­‐CT6(1108-­‐1163)	   AGGCGCGCCAAAGAACAAGCTGGAGAAGAACGAGGA	   AATATGCGGCCGCCTAGTCCATGTCCAGCAGATCCA	  pTNT-­‐GST-­‐CT7(1047-­‐1082)	   AGAGGCGCGCCAAACTACACCTT	   TAATTAGCGGCCGCCTAAAACCAGCTGAGGCTCCCAC	  pTNT-­‐GST-­‐CT8(1082-­‐1163)	   TTAATTAAGGCGCGCCACCACTCATCCTCCTCAGCCA	   AATATGCGGCCGCCTAGTCCATGTCCAGCAGATCCA	  pTNT-­‐GST-­‐CT10(1277-­‐1339)	   AATAGGCGCGCCAGAGAAGGATGTGGCTCTCACAGAC	   TAATTAGCGGCCGCCTAAAACCAGCTGAGGCTCCCAC	  pTNT-­‐GST-­‐CT11(1339-­‐1396)	   AATAGGCGCGCCATTTGGTCCCAACCACACTCTGCA	   TAATTAGCGGCCGCCTATGGTAGCATCTCCCCTGGCT	  pTNT-­‐GST-­‐CT12(1277-­‐1374)	   AATAGGCGCGCCAGAGAAGGATGTGGCTCTCACAGAC	   AATTAGCGGCCGCCTACATCACTAGCACCTCCAGCA	  pTNT-­‐GST-­‐CT13(1374-­‐1396)	   AATTAGGCGCGCCAATGAAGCTGCCTCGCTCTGAGCA	   TAATTAGCGGCCGCCTATGGTAGCATCTCCCCTGGCT	  pTNT-­‐GST-­‐NT1(1-­‐256)	   TAGGCGCGCCAATGGAGTCCTT	   ATTATGCGGCCGCCTACATGGGATGGATCAGTCCCT	  pTNT-­‐GST-­‐NT2(250-­‐505)	   ATTATAGGCGCGCCAGAGGGACTGATCCATCCCATG	   AATGCGGCCGCCTAATTCTCCAGAAAGAGCCTCACG	  pTNT-­‐GST-­‐NT3(499-­‐750)	   ATTAGGCGCGCCAGTGAGGCTCTTTCTGGAGAATGG	   ATTAATGCGGCCGCCTAGCCATTGTCCACACAGAGC	  pTNT-­‐GST-­‐NT4(1-­‐150)	   TAGGCGCGCCAATGGAGTCCTT	   AATTAATTAATTGCGGCCGCCTAGGAGGGCGTGTCCTGGGAGA	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pTNT-­‐GST-­‐NT5(150-­‐250)	   TAGGCGCGCCATCCAGTGTCATCTACCAGCTCATGA	   ATTATGCGGCCGCCTACATGGGATGGATCAGTCCCT	  pTNT-­‐GST-­‐NT6(1-­‐201)	   TAGGCGCGCCAATGGAGTCCTT	   TTAATTGCGGCCGCCTATCCAGTGATGATCCAGGCCC	  pTNT-­‐GST-­‐NT7(201-­‐250)	   TTAATTAAGGCGCGCCAGGAGGATCCCACACAGGCGT	   ATTATGCGGCCGCCTACATGGGATGGATCAGTCCCT	  pTNT-­‐GST-­‐NT15(395-­‐423)	   AAGGCGCGCCAGAAAACCAGATTGTGGAATGGACCA	   TTAAGCGGCCGCCTAATCCTTGCCTTCCCGGAAGAT	  pTNT-­‐GST-­‐MutCT5(1047-­‐1082)	   AGAGGCGCGCCAAACTACACCTT	   AATATGCGGCCGCCTACTTGAGCTGCTTATGCCTCT	  pTNT-­‐GST-­‐MutCT11(1339-­‐1396)	  
AATAGGCGCGCCATTTGGTCCCAACCACACTCTGCA	   TAATTAGCGGCCGCCTATGGTAGCATCTCCCCTGGCT	  
pTNT-­‐GST-­‐MutNT5(150-­‐250)	   TAGGCGCGCCATCCAGTGTCATCTACCAGCTCATGA	   ATTATGCGGCCGCCTACATGGGATGGATCAGTCCCT	  pTNT-­‐GST-­‐MutNT15(395-­‐423)	   AAGGCGCGCCAGAAAACCAGATTGTGGAATGGACCA	   TTAAGCGGCCGCCTAATCCTTGCCTTCCCGGAAGAT	  
Table	  1	  -­‐	  Summary	  of	  TRPM2	  truncation	  constructs	  generated	  and	  primers	  utilized	  for	  PCR.	  Note:	  Constructs	  marked	  *Mut	  contain	  the	  substitution	  mutations	  outlined	  in	  figure	  2.2,	  all	  other	  constructs	  were	  generated	  from	  an	  mTRPM2	  cDNA	  template.	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Figure	  2.2	  –	  Schematic	  of	  TRPM2	  truncations	  generated	  for	  CaM-­‐Sepharose	  binding	  experiments.	  A	  series	  of	  overlapping	  truncations	  were	  generated	  strategically	  based	  on	  results	   from	   in	  silico	   screening	  of	  TRPM2	   for	  CaM	  consensus	  sites.	  Truncations	  were	  expressed	  in	  a	  GST-­‐tagged	  vector	  with	  promoter	  regions	  required	  for	  the	  TNT	  Reticulocyte	  Quick-­‐Coupled	  Kit	   (Promega).	   Candidate	   CaM	  binding	   sites	   identified	  by	  in	  silico	  screening	  are	  indicated	  by	  blue	  rectangles.	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DNA	   fragments	   were	   generated	   utilizing	   KOD	   polymerase	   (EMDMillipore)	  touch	  down	  PCR.	  Samples	  were	  run	  on	  a	  1.5%	  Agarose	  gel	  (1µl	  Ethidium	  Bromide	  per	  20ml	  gel)	  to	  visualize	  products	  under	  UV	  exposure.	  	  Bands	  containing	  the	  DNA	  fragments	  were	  excised	  from	  the	  gel	  and	  purified	  with	  Gene	  Elute	  gel	  extraction	  kit	  (Sigma	   Aldrich).	   Extraction	   followed	   manufacturers	   guidelines,	   centrifugation	  occurred	   at	   16000RCF	   for	   1min	   and	   50µl	   of	   elution	   solution	   was	   used	   for	   each	  column.	   Digestions	   were	   prepared	   for	   the	   eluted	   fragments	   consisting	   of	   2µl	  10000U/ml	  AscI,	  1µl	  20000U/ml	  NotI,	  10µl	  digestion	  Buffer	  #4,	  10µl	  10X	  BSA,	  and	  100µl	  H2O.	  Digestions	  were	   incubated	   at	   37°C	   for	  1	  hour.	   Samples	  were	   run	  on	   a	  1.5%	  Agarose	  gel	  (1µl	  Ethidium	  Bromide	  per	  20ml	  gel)	  to	  visualize	  products	  under	  UV	  exposure.	   	  Bands	  containing	  the	  DNA	  fragments	  were	  excised	  from	  the	  gel	  and	  purified	  with	   GeneEluteTM	   Gel	   Extraction	   Kit	   (Sigma-­‐Aldrich).	   Extraction	   followed	  manufacturers	  guidelines;	  35µl	  of	  elution	  solution	  was	  used	  for	  each	  column.	  	  pTNT-­‐GST	  AscI,	  NotI,	  cip	  vector	  was	  prepared	  including	  a	  Kozak	  region	  and	  Poly-­‐A	   tail	   required	   for	   the	   TNT	   quick-­‐coupled	   transcription/translation	   system	  (Promega).	   Ligation	   reaction	  mixture	  was	  prepared	  with	   a	  3:1	   fragment	   to	   vector	  (50ng)	  ratio,	  DNA	  ligase	  and	  DNA	  ligase	  buffer	  for	  1	  hour	  at	  room	  temperature.	  DNA	  was	   transformed	   into	   50µl	   JM109	   bacteria	   (Promega)	   following	   manufacturers	  guidelines	  (40	  second	  heat	  shock	  at	  42°C,	  1	  hour	  incubation	  at	  37°C	  275	  Rev/min).	  Bacteria	   was	   grown	   overnight	   on	   LB-­‐Amp	   agar	   plates	   incubated	   at	   37°C.	   Several	  colonies	  were	  identified	  per	  plate	  and	  grown	  overnight	  in	  5ml	  LB-­‐Amp	  incubated	  at	  37°C	   275	   Rev/min.	   Plasmid	   DNA	   was	   extracted	   using	   a	   GenEluteTM	   Plasmid	  Miniprep	  Kit	   (Sigma-­‐Aldrich)	   following	  manufacturers	  guidelines;	  100µl	  of	  elution	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solution	  was	  used	   for	  each	  column.	  Plasmid	  DNA	  was	  analyzed	  using	  a	   restriction	  enzyme	   digestion	   for	   sites	   AscI	   and	   NotI	   and	   visualized	   on	   a	   1.5%	   Agarose	   (1µl	  Ethidium	   Bromide	   per	   20ml)	   gel.	   Positive	   candidates	   were	   confirmed	   with	  sequencing.	  	  
	  
2.4	  TNT	  Quick-­‐Coupled	  Transcription/Translation	  System	  (Promega)	  
	  	   Plasmid	  DNA	  was	   transcribed	   and	   translated	  using	   the	  TNT	  Quick-­‐Coupled	  Transcription/Translation	  System	  (Promega)	  according	  to	  manufacturers	  protocol.	  Plasmid	   DNA	  was	  maximized	   to	   7µl	   based	   on	   the	   least	   concentrated	   sample.	   2ul	  FluoroTectTM	  GreenLys	  (Promega)	  was	  supplanted	   into	   the	  mixture	   to	   fluorescently	  label	   finished	   protein	   products.	   The	   reaction	  mixture	  was	   incubated	   in	   a	   thermal	  cycler	  for	  60	  minutes	  at	  30	  oC.	  	  
	  
2.5	  Calmodulin-­‐Sepharose	  pull-­‐down	  of	  TRPM2	  truncations	  
	   30µl	  of	  well-­‐packed	  CaM-­‐Sepharose	  were	  prepared	  and	  washed	  using	  a	  2mM	  Ca2+	   or	   5mM	   EGTA	   pH	   8.0,	   150mM	   NaCl	   and	   50mM	   Tris-­‐HCl	   pH	   7.4	   solution.	  Solution	  was	  lightly	  mixed	  and	  centrifuged	  for	  1	  min	  at	  500RCF	  and	  wash	  solution	  extracted	   from	  the	  beads	  using	  a	  27G	  needle.	  Beads	  were	  washed	  three	  times	  and	  4µl	  of	  protein	  generated	  from	  each	  TNT	  reaction	  (section	  2.4)	  were	  added	  to	  a	  final	  volume	   of	   500µl	   from	   wash	   solution.	   Incubated	   overnight	   at	   4°C	   on	   a	   nutating	  rotator,	   samples	  were	  wash	  5	   times	   in	   the	  method	  previously	  described.	   	  Washed	  beads	  were	  made	   to	   a	   final	   volume	   of	   60µl	  with	   SDS-­‐BM	   loading	   buffer.	   Samples	  including	  1µl	  of	  input	  (section	  2.4)	  and	  SDS-­‐BM	  loading	  buffer	  were	  heated	  at	  60°C	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for	  three	  minutes.	  A	  10-­‐12%	  SDS-­‐page	  was	  performed	  to	  visualize	  samples	  (20µl	  of	  bead	   solution,	   total	   volume	   of	   input)	   and	  was	   imaged	   using	   a	   fluorescent	   filtered	  VersaDocTM	  MP	  system	  (Biorad).	  	  
	  
	  
2.6	  TRPM2-­‐CaM	  Candidate	  Site-­‐Directed	  Mutagenesis	  
	  	   Substitution	   mutagenesis	   was	   outsourced	   and	   performed	   by	  TopGeneTechnologies	  (Montreal,	  QC).	  Single-­‐point	  substitution	  mutations	  to	  several	  amino	   acids	   within	   CaM	   candidate	   sites	   of	   TRPM2	   were	   performed.	   Utilizing	  mTRPM2	  as	  a	  template	  two	  overlapping	  fragments	  of	  TRPM2	  were	  generated	  using	  PCR	   and	   primers	   incorporating	   designated	   substitution	   mutations.	   The	   resulting	  PCR	   products	   were	   run	   on	   an	   Agarose	   gel	   and	   purified	   with	   GenEluteTM	   Gel-­‐Extraction	   Kit	   (Sigma-­‐Aldrich)	   following	  manufacturers	   guidelines.	   The	   fragments	  were	   digested	   with	   either	   AscI	   or	   NotI	   as	   previously	   described	   (section	   2.3)	   and	  ligated	  to	  pIRESpuro-­‐flag	  plasmid.	  Ligated	  plasmid	  DNA	  was	  transformed	  to	  JM109	  bacteria,	   grown	   overnight	   on	   LB-­‐Amp	   Agar	   plates	   (37°C),	   and	   several	   colonies	  grown	  in	  5ml	  of	  LB-­‐Amp	  (37°C	  275Rev/min)	  as	  previously	  described	  (section	  2.3).	  Plasmid	   DNA	   was	   purified	   from	   bacteria	   using	   GenEluteTM	   Plasmid	   Miniprep	   Kit	  (Sigma-­‐Aldrich),	  and	  verified	  by	  an	  AscI	  and	  NotI	  digestion	  and	  the	  mTRPM2-­‐coding	  region	   sequenced	   as	   previously	   described	   (section	   2.3).	   I	   performed	   additional	  sequencing	   analysis	   for	   the	   full-­‐length	   of	   all	  mutants	   generated	   to	   ensure	   correct	  mutants	  were	  generated.	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2.7	  Western	  Blotting	  
	  HEK293	  cells	   transfected	  with	  mTRPM2-­‐CaMMut	  outlined	   in	   figure	  2.3	  were	  grown	  for	   48	   hours	   to	   confluency	   as	   previously	   described	   (section	   2.2).	   Western	   blot	  analysis	   was	   also	   performed	   on	   Trex293-­‐stable	   C-­‐term	   and	   N-­‐term	   TRPM2	   cells.	  Lysis	  buffer	  was	  generated	  using	  150mM	  NaCl,	  0.1%	  NP-­‐40,	  2mM	  CaCl2,	  50mM	  Tris-­‐HCL	  (pH	  7.5)	  and	  1	  Mini-­‐complete	  protease	   inhibitor	  cocktail	   tablet	   (Roche).	  Each	  6cm	   dish	   was	   treated	   with	   200µl	   of	   lysis	   solution	   and	   collected	   in	   a	   microtube.	  Lysates	  were	  incubated	  at	  4°C	  for	  30	  minutes	  on	  a	  nutating	  platform,	  centrifuged	  at	  16000RCF	  at	  4°C	  for	  30	  minutes	  and	  the	  supernatant	  collected.	  A	  BCA	  protein	  assay	  (Thermo)	  was	  performed	  to	  determine	  protein	  concentrations.	  40µg	  of	  protein	  was	  made	  to	  a	  final	  volume	  of	  18µl	  with	  SDS-­‐BM	  loading	  buffer	  and	  H2O	  and	  incubated	  at	  37°C	  for	  10	  minutes.	  An	  SDS-­‐page	  was	  performed	  using	  a	  10%	  protein	  gel	  to	  10ml	  (4.0ml	  H2O,	  3.3ml	  30%	  acrylamide	  mix,	  2.5ml	  1.5M	  Tris	   (pH	  8.8),	  0.1ml	  10%	  SDS,	  0.1ml	  10%	  APS,	  and	  0.004ml	  TEMED),	  a	  5%	  stacking	  gel	  was	  generated	  in	  the	  same	  manner	   substituting	   1.0M	   Tris	   (pH	   6.8).	   The	   protein	   was	   transferred	   to	   a	  nitrocellulose	   membrane	   and	   verified	   with	   Ponceau	   S	   stain	   (Sigma-­‐Aldrich).	   The	  membrane	  was	  washed	  with	  TBS-­‐T	  and	  blocked	  for	  1	  hour	  with	  5%	  milk/TBS-­‐T	  on	  a	  belly-­‐dance	  shaker.	  The	  membrane	  was	  incubated	  with	  1:10000	  anti-­‐flag	  HRP	  for	  2	  hours	  then	  washed	  3	  times	  with	  TBS-­‐T	  for	  10	  minutes.	  Finally	  the	  membrane	  was	  exposed	   to	   ECL	   reagent	   (0.5ml	   Supersignal	   West	   Pico	   Stable	   Peroxide	   Solution	  [Thermo]	   and	   0.5ml	   Supersignal	  West	   Pico	   Luminal/Enhancer	   [Thermo]).	   Finally	  the	  blot	  was	  imaged	  using	  chemiluminescence	  on	  a	  VersaDocTM	  MP	  system	  (Biorad).	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2.8	  Drugs	  and	  Peptides	  
	  The	   sources	   of	   drugs	   and	   materials	   for	   this	   study	   are	   as	   follows:	   NaCl,	   Glucose,	  CaCl2,	  MgCl2,	  BaCl2,	  Gluconic	  acid,	  CsOH,	  ADPR,	  Mg(ATP)2,	  EGTA	   ,	  Ponceau	  S	  Stain,	  GenEluteTM	  Plasmid	  Miniprep	  Kit,	  GenEluteTM	  Plasmid	  Midiprep	  Kit,	  GenEluteTM	  Gel-­‐Extraction	  Kit,	  BSA,	  Dulbecco’s	  Modified	  Eagle	  Medium	  (Sigma-­‐Aldrich),	  Supersignal	  West	  Pico	  Stable	  Peroxide	  Solution,	  Supersignal	  West	  Pico	  Luminal/Enhancer,	  BCA	  Protein	   Assay	   kit	   (Thermo),	   Hepes	   (Bioshop),	   Mini-­‐complete	   protease	   inhibitor	  cocktail	   tablet	   (Roche),	   TNT	   Quick-­‐Coupled	   Transcription/Translation	   System,	  JM109	  bacteria,	  FluoroTectTM	  GreenLys	  (Promega),	  KOD	  polymerase	  (EMDMillipore),	  Doxycycline	   (Pfizer),	   JetPrime	   (Polyplus),	   AscI,	   NotI,	   cip	   (New	   England	   Biolab)	  CaM1-­‐Sepharose	  (GE	  Healthcare).	  	  	  
	  
2.9	  Statistical	  Analysis	  
	  All	  population	  data	  are	  expressed	  as	  mean	  ± 	  SEM.	  Two-­‐way	  ANOVA	  were	  used	  to	  compare	   between	   two	   groups,	   as	   well	   as	   student’s	   t-­‐test.	   Student’s	   t-­‐test	   was	  performed	  on	  the	  average	  of	  Inactivation	  (Iss/Ip)	  %	  between	  two	  groups.	  Paired	  t-­‐test	  was	   used	   to	   compare	  within	   groups;	   Inactivation	   (Iss/Ip)	  %	   between	   0.5mM	  and	  2mM	  Ca2+.	  The	  significance	  level	  was	  held	  constant	  at	  p<0.05.	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3.1	  Extracellular	  Ca2+	  modulation	  of	  TRPM2	  CDI	  
	  	   	   A	   whole-­‐cell	   patch-­‐clamp	   recording	   protocol	   (section	   2.1)	   was	  designed	  to	  measure	  TRPM2	  currents.	  TRPM2	  was	  stably	  transfected	  into	  T-­‐REX293	  cells	  with	   a	   tetracycline-­‐inducible	   promoter	   region.	   T-­‐REX293	   cells	  were	   induced	  with	   doxycycline	   24-­‐48	   hours	   prior	   to	   recordings.	   TRPM2	  was	   activated	  with	   ICS	  containing	  0.3mM	  ADPR.	  Currents	  were	   initially	   allowed	   to	  develop	   to	  1nA	   in	   the	  presence	   of	   Ca2+	   because	   ADPR	   diffusion	   into	   the	   cytoplasm	   limits	   initial	   current	  onset.	   Extracellular	   solution	   containing	   varying	   concentrations	   of	   Ca2+	   was	  administered	   via	   a	   multi-­‐barreled	   fast	   perfusion	   system.	   Administration	   of	   0mM	  Ca2+	  ECS	   rapidly	   inhibits	  TRPM2	  current.	  The	   recording	  protocol	   consists	  of	  3min	  applications	  of	  0.5mM	  or	  2mM	  Ca2+	  ECS	  followed	  by	  5	  minutes	  of	  Ca2+-­‐free	  solution.	  During	   Ca2+	   administration	   (figure	   1.2)	   I	   observed	   a	   slow	   increase	   in	   current	  reaching	   peak	   amplitude	   (Ip).	   This	   is	   followed	   by	   a	  marked	   	   current	   inactivation	  over	  several	  minutes,	  reaching	  a	  maintained	  steady	  state	  (Iss).	  When	  measuring	  and	  referring	  to	  CDI	  we	  define	  it	  as	  the	  ratio	  between	  the	  Iss/Ip.	  3-­‐minute	  application	  of	  Ca2+-­‐containing	   ECS	   was	   sufficient	   to	   fully	   resolve	   TRPM2	   CDI.	   Previous	  unpublished	   findings	   from	   our	   laboratory	   (Figure	   A1)	   indicate	   full	   recovery	   from	  TRPM2	   CDI	   may	   be	   achieved	   with	   Ca2+-­‐free	   ECS	   administration.	   5-­‐minute	  applications	   of	   0mM	  Ca2+	   ECS	   ensured	   full	   recovery	   between	   Ca2+-­‐containing	   ECS	  administration.	  	  	   An	   experimental	   protocol	   was	   designed	   to	   test	   the	   extracellular	   Ca2+	  relationship	  of	  TRPM2	  CDI.	  Depolarizing	  the	  cellular	  membrane,	  which	  reduces	  the	  driving	   force	  of	  Ca2+	   through	  TRPM2	  channels,	   can	   further	  modulate	  TRPM2	  CDI.	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During	  Ca2+-­‐free	   applications,	   holding	   voltage	  was	   varied	   in	  20mV	   increments.	  By	  varying	   holding	   voltage	   between	   -­‐100mV	   to	   -­‐20mV,	   I	   extrapolated	   the	   current-­‐voltage	  relationship	  (IV-­‐curve)	  of	  TRPM2	  CDI.	  An	  I/V	  curve	  relationship	  of	  TRPM2	  CDI	   was	   determined	   for	   0.5mM,	   2mM	   and	   5mM	   Ca2+	   ECS	   applications.	   Two	  extracellular	  Ca2+	  concentrations	  are	  shown,	  2mM	  (Figure	  3.1A)	  or	  0.5mM	  (Figure	  3.1B).	   CDI	   of	   TRPM2	   channels	   are	   relatively	   large	  with	   2mM	   applications	   of	   Ca2+	  (Figure	   3.1A)	   and	   CDI	   is	   reduced	   in	   a	   linear	   fashion	  with	   changes	   in	   voltage.	   The	  extrapolation	   of	   the	   linear	   IV	   relationship	   roughly	   mimics	   the	   Ca2+	   ionic	   driving	  forces	  and	  the	  reversal	  potential	  of	  Ca2+	  (Figure	  3.1C).	  	  	  Preliminary	  evidence	  from	  our	  laboratory	  has	  indicated	  reduced	  TRPM2	  CDI	  when	   Ca2+	   administration	   in	   the	   ECS	  was	   lowered	   to	   0.5mM.	   The	   voltage-­‐current	  relationship	   was	   determined	   for	   0.5mM	   Ca2+	   (Figure	   3.1B).	   The	   significantly	  reduced	   CDI	   observed	   from	   lower	   [Ca2+]	   decreased	   in	   a	   linear	   fashion,	   but	   was	  rarely	  observed	  above	  -­‐60mV.	  If	  [Ca2+]	  increased	  to	  5mM	  resulted	  in	  no	  significant	  changes	   to	  TRPM2	  CDI	  observed	  versus	  2mM	  extracellular	  Ca2+	   (not	   shown).	  This	  would	   suggest	   maximal	   TRPM2	   CDI	   has	   reached	   a	   plateau	   at	   2mM	   Ca2+	   ECS.	  Increasing	   Ca2+	   beyond	   this	   concentration	   is	   not	   sufficient	   to	   alter	   activation	   and	  subsequently	   inactivation.	  Both	  processes	   are	   all	   tightly	   regulated	  by	   intracellular	  [Ca2+],	  but	  maintained	  by	  Ca2+	  influx	  from	  the	  ECS.	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Figure	   3.1	   –	   Effect	   of	   varying	   the	   membrane	   holding	   potential	   on	   TRPM2	   CDI.	  Representative	  traces	  of	  recordings	  from	  TRPM2	  expressing	  HEK293	  cells	  evoked	  in	  the	  presence	  of	  either	  A.	  2mM	  Ca2+	  ECS	  or	  B.	  0.5mM	  Ca2+.	  CDI	  (steady-­‐state	  to	  peak	  ratio)	  is	  markedly	  reduced	  when	  using	  lower	  [Ca2+]	  ECS.	  5	  min	  applications	  of	  Ca2+-­‐free	   ECS	   abolish	   TRPM2	   currents	   and	   allow	   full	   recovery	   from	   TRPM2	   CDI.	  Membrane	  voltage	  was	  varied	  between	   -­‐100mV	   to	   -­‐20mV	   in	  20mV	  steps	  and	  was	  raised	  at	  the	  halfway	  mark	  during	  the	  0mM	  Ca2+	  recovery	  period.	  C.	  Analysis	  of	  CDI	  between	   [Ca2+]	   treatments	   and	   voltage	   steps	   was	   plotted	   and	   analyzed.	   Both	  concentrations	   resulted	   in	   a	   linear	   decrease	   in	   TRPM2	  CDI	   as	   voltage	  was	   raised.	  Notably	  CDI	  reverses	  around	   the	  Ca2+	   reversal	  potential	  of	  Ca2+	   in	   the	  2mM	  [Ca2+]	  treatment	  (n=6).	  	  
	  	   53	  
	  
3.2	  CaM-­‐Sepharose	  pull-­‐down	  of	  TRPM2	  C-­‐terminal	  truncation	  
	  	   Electrophysiological	   recordings	   from	   T-­‐Rex293	   cells	   stably	   expressing	  TRPM2	  indicate	  CDI	  of	  TRPM2	  currents.	  Furthermore	  TRPM2	  currents	  are	  activated	  and	   inactivated	   with	   different	   sensitivity	   to	   Ca2+.	   We	   have	   evidence	   that	   CaM	  binding,	   which	   is	   unique	   from	   the	   site	   of	   activation	   (NTIQ),	   might	   mediate	   CDI.	  Previous	   findings	   by	   Tong	   et	   al.,	   2006	   only	   pursued	   the	   interaction	   of	   CaM	  with	  TRPM2	  within	  the	  N-­‐terminal	  of	  TRPM2.	  However	  Tong	  et	  al.,	  2006	  still	   identified	  modest	  binding	  within	  the	  C-­‐terminal	  that	  was	  not	  pursued	  further.	  To	  examine	  the	  potential	   interaction	  of	  CaM	  with	  the	  C-­‐term	  of	  TRPM2,	  we	  generated	  a	  truncation	  mutant	  of	  mTRPM2	  (Figure	  3.2A)	  consisting	  of	  only	  its	  C-­‐term	  domain.	  The	  C-­‐term	  of	   TRPM2	   was	   generated	   by	   PCR	   from	   full-­‐length	   mTRPM2	   and	   flag-­‐tagged	   for	  detection	  by	  Western	  blotting.	  HEK293	  cells	  stably	  expressing	  flag	  tagged	  mTRPM2	  or	  mTRPM2	  C-­‐term	  truncation	  were	  induced	  with	  doxycycline	  48	  hours	  followed	  by	  cell	   lysis	   and	   protein	   extraction.	   CaM-­‐Sepharose	   pull-­‐down	   was	   performed	   with	  both	   full	   length	   and	   C-­‐term	   truncation	   fragments	   and	   CaM	   binding	   assessed.	   The	  binding	   solution	   contained	   2mM	   Ca2+.	   C-­‐term	   mTRPM2	   truncations	   were	  successfully	  pulled	  down	  (Figure	  3.2B)	  with	  CaM-­‐Sepharose.	  This	  provides	  evidence	  for	   additional	   CaM	   binding	   sites	   on	   the	   TRPM2	   intracellular	   tail	   not	   previously	  analyzed	  in	  the	  literature	  (n=3).	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Figure	   3.2	   –	   CaM-­‐Sepharose	   pulldown	   of	   mTRPM2	   C-­‐terminal	   fragment.	   A.	  Schematic	  of	  the	  C-­‐term	  mTRPM2	  fragment	  generated	  by	  PCR	  and	  tagged	  with	  flag	  for	  Western	  blotting	  resolution	  (Natalie	  Lavine).	  B.	  Western	  blot	  of	  full	  length	  and	  C-­‐terminal	   truncated	   mTRPM2	   lysates	   pulled	   down	   with	   CaM-­‐Sepharose	   in	   a	   2mM	  Ca2+	   binding	   solution.	   The	   C-­‐term	   was	   found	   to	   associate	   with	   CaM	   beads,	  suggesting	  the	  existence	  of	  previously	  unrecognized	  CaM	  -­‐binding	  sites	  within	  this	  portion	  of	  TRPM2	  channels.	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3.3	  –	  A	  systematic	  analysis	  of	  TRPM2	  C-­‐term	  CaM	  candidate	  sites	  	  	   Previous	  findings	  have	  identified	  an	  IQ-­‐like	  CaM	  consensus	  region	  located	  on	  the	  intracellular	  N-­‐terminal	  of	  TRPM2	  channels	  located	  at	  region	  406-­‐414AA	  (Tong	  et	  al.,	  2006).	  Endogenous	  CaM	  binding	   to	   this	  N-­‐term	   IQ-­‐like	  motif	   is	  essential	   for	  the	  Ca2+-­‐CaM	  activation	  of	  TRPM2	  channels	  (Tong	  et	  al.,	  2006).	  	  TRPM2	  current	  can	  no	  longer	  be	  elicited	  from	  a	  TRPM2	  mutant	  with	  substitution	  mutations	  at	  this	  site,	  regardless	   of	   [ADPR]	   or	   [Ca2+]	   utilized	   (Csandy	   and	   Torocsik,	   2009).	   Tong	   et	   al.,	  identified	  weak	  binding	  of	  CaM	  within	  the	  C-­‐terminal	  of	  TRPM2	  channels	  and	  hinted	  at	   additional	   CaM	  binding	   sites	   that	  were	   not	   abolished	   by	   an	  NTIQ	  mutation.	  We	  postulated	  that	  additional,	  previously	  unrecognized	  sites	  that	  mediate	  CDI	  could	  be	  identified	  within	  TRPM2.	  	  	   CaM	  binding	  sites	  are	   loosely	  defined	  by	  a	  consensus	  amino	  acid	  sequence,	  several	  of	  which	  have	  been	  identified	  including	  an	  IQ-­‐like	  and	  1-­‐8-­‐14	  sites	  (Jurado	  et	   al.,	   1999).	   Using	   the	   Calmodulin	   Target	   Database	   resource	   (©	   2002	   Ikura	   Lab,	  Ontario	   Cancer	   Institute),	   the	   two	   terminal	   chains	   of	   TRPM2	   were	   individually	  analyzed	   for	   CaM	   consensus	   binding	   sites.	   The	   in	   silico	   screening	   for	   the	   TRPM2	  intracellular	   N-­‐terminal	   successfully	   identified	   the	   known	   IQ-­‐like	   motif.	   The	  successful	  identification	  of	  the	  CaM	  site	  responsible	  for	  TRPM2	  activation	  provides	  	  validation	  of	  the	  approach.	  In	  total	  three	  additional	  candidate	  CaM	  consensus	  sites	  have	   been	   identified,	   and	   their	   relative	   locations	   to	   other	   important	   structural	  components	   of	   TRPM2	   summarized	   on	   the	   TRPM2	   protein	   schematic	   outlined	   in	  Figure	   3.2.	   An	   IQ-­‐like	   site	   was	   found	   at	   1084-­‐1105AA	   C-­‐terminal	   roughly	  overlapping	  the	  coiled-­‐coil	  region	  (Figure	  3.3).	  1-­‐8-­‐14	  consensus	  sites	  located	  at	  the	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N-­‐terminal	   and	  C-­‐terminal	   of	   TRPM2	  were	   also	   identified	   at	   161-­‐197AA,	  which	   is	  within	  a	  conserved	  portion	  of	   the	  N-­‐terminal	  chain,	  and	  at	  1344-­‐1373AA	  of	   the	  C-­‐terminal	   within	   the	   initial	   N-­‐distal	   portion	   of	   the	   NUDIX	   domain	   (Perraud	   et	   al.	  2003;	  Montell,	  2005).	  	  Using	  the	  TRPM2	  CaM	  binding	  domains,	  identified	  from	  in	  silico	  screening,	  a	  series	   of	  mTRPM2	   truncations	  were	   developed.	   The	   fragments	  were	   generated	   in	  order	  to	  determine	  whether	  CaM	  associates	  with	  the	  consensus	  sites	  we	  identified	  through	   in	  silico	   screening.	  Truncations	  were	  generated	  using	  PCR	  and	  sub-­‐cloned	  into	  a	  vector	  with	  the	  promoter	  region	  for	  the	  TNT	  reticulocyte	  kit.	  The	  TNT	  Quick-­‐Coupled	   Transcription/Translation	   kit	   consists	   of	   a	   master	   mix	   of	   cellular	  machinery	  and	  amino	  acids.	  Truncated	  TRPM2	  fragments	  sub	  cloned	  into	  vector	  are	  transcribed	   and	   translated	   into	   protein,	   which	   is	   subsequently	   used	   for	   CaM-­‐Sepharose	  pulldown.	  The	  second	  feature	  of	  the	  protocol	  is	  a	  fluorescent	  lysine	  that	  is	   supplanted	   into	   the	  master	  mix	   and	  produces	   fluorescent	  proteins.	  Truncations	  ranged	  from	  30-­‐250	  amino	  acids	  in	  length.	  The	  variability	  in	  truncation	  size	  would	  create	  problems	  resolving	  bands	  run	  on	  a	  gel	  and	  would	  not	  ensure	  sufficient	  lysine	  incorporation.	   We	   therefore	   tagged	   with	   GST	   to	   both	   increase	   size	   and	   ensure	  fluorescent	  lysine	  uptake.	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Figure	  3.3	  –	  Schematic	  of	  TRPM2	  candidate	  CaM	  sites	  identified	  with	  in	  silico	  screening.	  IQ-­‐like	  sites	  are	  located	  at	  406-­‐414AA	  and	  1084-­‐1105AA.	  The	  first	  of	  which	  is	  responsible	  for	  Ca2+-­‐CaM	  activation	  of	  TRPM2	  channels	  (Tong	  et	  al.,	  2006)	  and	  the	  second	  overlaps	  with	  the	  CCR	  located	  within	  the	  C-­‐term	  of	  TRPM2.	  Two	  additional	  candidate	  CaM	  sites	  are	  located	  at	  161-­‐197AA	  and	  1344-­‐1373AA,	  they	  are	  both	  consistent	  with	  the	  1-­‐8-­‐14-­‐type	  consensus	  motif.	  161-­‐197AA	  is	  associated	  with	  a	  conserved	  N-­‐term	  region	  and	  1344-­‐1373AA	  with	  the	  NUDIX	  region	  located	  on	  the	  C-­‐term.	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mTRPM2	   truncated	   into	   four	   roughly	   equivalent	   parts,	  was	   incubated	  with	  CaM-­‐Sepharose	  beads.	  Ca2+	  sensitivity	  of	  binding	  was	  determined	  using	  either	  2mM	  Ca2+	  or	  Ca2+-­‐free	  (5mM	  EGTA	  containing)	  binding	  solutions.	  Figure	  3.4	  summarizes	  these	  results.	  Three	  C-­‐term	  fragments	  (CT1,	  CT3	  and	  CT4)	  were	  found	  to	  associate	  with	  CaM.	   In	  contrast,	  pulldown	  of	  a	  GST-­‐only	  negative	  control	  by	  CaM-­‐Sepharose	  was	   minimal.	   Furthermore,	   an	   assessment	   of	   the	   Ca2+	   dependence	   revealed	   that	  CaM	   association	   was	   reduced,	   but	   not	   completely	   abolished	   when	   binding	   was	  carried	   out	   in	   the	   absence	   of	   Ca2+.	   Figure	   3.4D	   provides	   a	   numerical	   index	   of	   the	  binding	   results	   by	  performing	   a	   quantitative	   analysis	   comparing	   relative	   signal	   of	  input	   and	   pulldown	   gels.	   Fragment	   CT4	   was	   inconsistent	   with	   predicted	   binding	  sites	   from	   the	   in	   silico	   screening.	   An	   additional	   unknown	   binding	   site	   may	   exist	  within	  this	  fragment,	  but	  it	  was	  not	  pursued	  at	  this	  time.	  To	  confirm	  the	  specific	  association	  of	  CaM	  to	  target	  sequences	  identified	  by	  silico	  screening,	  a	  second	  round	  of	  deletion	  constructs	  were	  generated	   in	  order	   to	  resolve	   the	  minimum	  binding	   domains	  within	   fragments	   CT1	   and	   CT3.	   Figure	   3.5	  identifies	  a	  binding	  pattern	  consistent	  with	   the	  predicted	   IQ-­‐like	  CaM	  binding	   site	  identified	   between	   1084-­‐1105AA.	   Consistent	  with	   previous	   findings,	   CaM	   binding	  was	  reduced	  but	  not	  completely	  abolished	  with	  5mM	  EGTA;	  this	  is	  consistent	  with	  the	   previously	   reported	   association	   of	   ApoCaM	  with	   IQ-­‐like	   motifs	   (Jurado	   et	   al.,	  1999).	  Figure	  3.5D	  provides	  a	  numerical	  index	  of	  the	  binding	  results	  by	  performing	  a	   semi-­‐quantitative	   relative	   analysis	   comparing	   input	   and	   binding	   fragments	  relative	  to	  CT8.	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Figure	   3.4	   –	   CaM-­‐Sepharose	   pulldown	   of	   mTRPM2	   C-­‐terminal	   truncations.	   A.	  TRPM2	  C-­‐terminal	  fragment	  design.	  Blue	  boxes	  represent	  in	  silico	  CaM	  binding	  sites.	  Four	   fragments	   were	   generated	   and	   tagged	   with	   GST	   to	   test	   for	   CaM	   binding.	  B.	  Input	  of	  protein	  fragments	  generated	  using	  TNT	  Quick	  Coupled	  translation	  system	  incorporating	  fluorescent	  lysine	  and	  resolved	  directly	  from	  an	  SDS-­‐page	  gel.	  C.	  CaM-­‐1	  Sepharose	  beads	  incubated	  overnight	  with	  fragments.	  Beads	  were	  washed	  with	  a	  buffer	  containing	  either	  5mM	  EGTA,	  or	  2mM	  Ca2+.	  CT1	  and	  CT3	  bound	  as	  expected,	  CT2	  was	  not	  capable	  of	  binding.	  However,	  CT4	  displayed	  unexpected	  CaM	  binding,	  hinting	  at	  an	  undefined	  CaM	  consensus	  site	  in	  this	  region	  (n=3)	  D.	  Relative	  binding	  strength	  of	  fragments	  versus	  relative	  signal	  strength	  of	  inputs	  (n=3).	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Figure	   3.5	   –	   CaM-­‐Sepharose	   pulldown	   of	  mTRPM2	   CT1	   truncations	   containing	   a	  consensus	   IQ-­‐like	   site	   at	   1084-­‐1105AA.	   A.	   Input	   of	   protein	   fragments	   generated	  using	   TNT	  Quick	   Coupled	   translation	   system	   incorporating	   fluorescent	   lysine	   and	  resolved	   directly	   from	   an	   SDS-­‐page	   gel.	   B.	   CaM-­‐1	   Sepharose	   beads	   incubated	  overnight	  with	  fragments.	  Beads	  were	  washed	  with	  a	  buffer	  containing	  either	  5mM	  EGTA,	   or	  2mM	  Ca2+.	  All	   binding	  patterns	   are	   consistent	  with	   sites	   identified	  by	   in	  silico	   screening.	   (n=3)	   C.	   TRPM2	   CT1-­‐terminal	   fragment	   design.	   Blue	   boxes	  represent	   in	   silico	  CaM	   binding	   sites.	   Four	   fragments	   were	   generated	   and	   tagged	  with	  GST	  to	  test	  for	  CaM	  binding.	  D.	  Relative	  binding	  strength	  of	  fragments	  versus	  relative	  signal	  strength	  of	  inputs	  (n=3).	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   We	   next	   examined	   the	   CT3	   fragment	   harbouring	   a	   predicted	   1-­‐8-­‐14	   CaM	  consensus	   site	   associated	  with	   the	   region	   1344-­‐1373AA.	   Four	   further	   truncations	  outlined	   in	   Figure	   3.5C	  were	   incubated	  with	   CaM-­‐Sepharose	  with	   both	   2mM	   and	  5mM	   EGTA	   binding	   solutions.	   The	   predicted	   fragments	   CT11	   and	   CT12	   bound	  successfully	  to	  CaM-­‐Sepharose	  beads,	  however	  unexpected	  binding	  was	  identified	  in	  fragment	  CT10.	  Whether	   this	  non-­‐specific	  binding	   translates	   to	   full-­‐length	  TRPM2	  remains	   to	   be	   determined.	   Similar	   to	   previous	   findings,	   CaM	   binding	   was	   not	  completely	   abolished	   in	   a	   Ca2+-­‐free	   5mM	   EGTA	   binding	   solution.	   Figure	   3.6D	  provides	  a	  numerical	  index	  of	  the	  binding	  results	  by	  performing	  a	  semi-­‐quantitative	  relative	  analysis	  comparing	  input	  and	  binding	  fragments	  relative	  to	  CT11.	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Figure	   3.6	   -­‐	   CaM-­‐Sepharose	   pulldown	   of	   mTRPM2	   CT3	   truncations	   containing	  theoretical	   1-­‐8-­‐14-­‐consensus	   site	   at	   1344-­‐1373AA.	  A.	   Input	   of	   protein	   fragments	  generated	   using	   TNT	   Quick	   Coupled	   translation	   system	   incorporating	   fluorescent	  lysine	   and	   resolved	   directly	   from	   an	   SDS-­‐page	   gel.	   B.	   CaM-­‐1	   Sepharose	   beads	  incubated	  overnight	  with	   fragments.	   Beads	  were	  washed	  with	   a	   buffer	   containing	  either	   5mM	   EGTA,	   or	   2mM	   Ca2+.	   CT10	   showed	   unexpected	   CaM	   binding	   not	  characteristic	   with	   any	   theoretical	   CaM	   sites.	   (n=3)	   C.	   TRPM2	   CT3-­‐terminal	  fragment	   design.	   Blue	   boxes	   represent	   in	   silico	  CaM	  binding	   sites.	   Four	   fragments	  were	   generated	   and	   tagged	  with	  GST	   to	   test	   for	   CaM	  binding.	  D.	  Relative	   binding	  strength	  of	   fragments	  versus	  relative	  signal	  strength	  of	   inputs	  on	  a	  representative	  gel	  (n=3).	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3.5	  –	  A	  systematic	  analysis	  of	  TRPM2	  N-­‐term	  CaM	  candidate	  sites	  	  	   The	  N-­‐terminal	   of	  TRPM2	  was	  divided	   into	   three	  overlapping	   fragments	   of	  roughly	  equivalent	  sizes.	  The	  candidate	  1-­‐8-­‐14	  site	  lies	  within	  fragment	  NT1	  while	  the	   IQ-­‐like	   CaM	   site,	   responsible	   for	   activation	   (Tong	   et	   al.,	   2006),	   falls	   within	  fragment	  NT2	   (Figure	   3.7A).	   All	   three	   fragments	   demonstrated	   strong	   association	  with	   CaM-­‐Sepharose,	   which	   was	   only	   partially	   reduced	   with	   5mM	   EGTA	   binding	  solutions.	   Figure	   3.7D	   provides	   a	   numerical	   index	   of	   the	   binding	   results	   by	  performing	   a	   semi-­‐quantitative	   analysis	   comparing	   input	   and	   binding	   fragments	  relative	   to	  NT1.	   Literature	   exists	   concerning	   two	   IQ-­‐like	   CaM	   sites	   falling	   on	  NT3	  believed	   to	   be	   responsible	   for	   the	   abolished	   current	   observed	   in	   TRPM2-­‐ΔN	  (missing	   537-­‐556AA);	   however,	   mutation	   to	   either	   site	   resulted	   in	   no	   significant	  alterations	  to	  full-­‐length	  TRPM2	  function	  compared	  to	  wild-­‐type	  (Kuhn	  et	  al.,	  2009).	  The	   CaM	   sites	   on	   NT3	   are	   not	   believed	   to	   be	   responsible	   for	   CaM	   regulation	   of	  TRPM2	  (Kuhn	  et	   al.,	   2009)	  and,	   accordingly,	  were	  not	  pursued	  any	   further	   in	   this	  thesis.	  	   Truncations	   to	   NT1	   containing	   1-­‐8-­‐14-­‐consensus	   CaM	   candidate	   site	   161-­‐197AA	  were	   carried	   out	   in	   a	   similar	   fashion	   to	   those	   previously	   outlined	   (Figure	  3.8C).	   Only	   those	   truncations	   overlapping	   the	   predicted	   consensus	   site	   strongly	  bound	  to	  CaM-­‐Sepharose,	  confirming	  that	  this	  consensus-­‐binding	  site	  is	  the	  sole	  site	  responsible	   for	   CaM	   binding	   in	   this	   region	   (Figure	   3.8).	   Figure	   3.8D	   provides	   a	  numerical	   index	  of	   the	  binding	   results	   by	  performing	   a	   semi-­‐quantitative	   analysis	  comparing	  input	  and	  binding	  fragments	  relative	  to	  NT5.	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3.5	  The	  effects	  of	  substitution	  mutagenesis	  at	  TRPM2	  candidate	  CaM	  sites	  
	  
	   Substitution	  mutagenesis	  was	  carried	  out	  at	  the	  four-­‐candidate	  CaM	  binding	  sites	   as	   summarized	   in	   Figure	   2.3.	   Four	   truncations	   were	   selected	   (Figure	   3.9A)	  including	  one	  newly	  generated	  fragment	  overlapping	  the	  IQ-­‐like	  site	  responsible	  for	  TRPM2	  activation	  (named	  NT15).	  These	  truncations	  contained	  a	  minimal	  amount	  of	  extraneous	  amino	  acids	  and	  the	  CaM	  candidate	  site	  and	  have	  been	  previously	  tested	  in	  sections	  3.4	  and	  3.5.	  Truncations	  mimicking	  those	  selected	  but	  incorporating	  the	  outlined	  substitution	  mutations	  were	  created	  to	  compare	  CaM	  binding	  change	  from	  WT	  to	  mutated	  CaM	  candidate	  sites.	  As	  implicated	  by	  Tong	  et	  al.,	  2006,	  substitution	  mutations	   to	   the	  NTIQ	   site	   did	   not	   fully	   abolish	   CaM-­‐Sepharose	   pulldown.	   I	   found	  consistent	  binding	  patterns	  for	  truncation	  NTIQ;	  binding	  at	  this	  site	  was	  significantly	  reduced	   but	   not	   completely	   abolished	   relative	   to	   a	   GST	   control.	   A	   reduction	   in	  binding	  was	  observed	  (Figure	  3.9)	  in	  fragments	  NT15	  and	  CT11,	  but	  no	  significant	  reduction	  occurred	   for	   fragments	  NT5	  and	  CT5	   (n=3).	  Relative	  binding	  analysis	   is	  summarized	  in	  future	  sub-­‐sections	  relating	  to	  each	  specific	  fragment.	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Figure	   3.7	   -­‐	   CaM-­‐Sepharose	   pulldown	   of	   mTRPM2	   N-­‐terminal	   truncations.	   A.	  TRPM2	  N-­‐terminal	  fragment	  design.	  Blue	  boxes	  represent	  in	  silico	  CaM	  binding	  sites.	  Three	   fragments	  were	   generated	   and	   tagged	  with	  GST	   to	   test	   for	   CaM	  binding.	  B.	  Input	  of	  protein	  fragments	  generated	  using	  TNT	  Quick	  Coupled	  translation	  system	  incorporating	  fluorescent	  lysine	  and	  resolved	  directly	  from	  an	  SDS-­‐page	  gel.	  C.	  CaM-­‐1	  Sepharose	  beads	  incubated	  overnight	  with	  fragments.	  Beads	  were	  washed	  with	  a	  buffer	  containing	  either	  5mM	  EGTA,	  or	  2mM	  Ca2+.	  NT1	  and	  NT2	  bound	  as	  expected.	  However	   NT3	   displayed	   unexpected	   CaM	   binding.	   (n=3)	   D.	   Relative	   binding	  strength	  of	   fragments	  versus	  relative	  signal	  strength	  of	   inputs	  on	  a	  representative	  gel	  (n=3).	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Figure	   3.8	   -­‐	   CaM-­‐Sepharose	   binding	   of	   mTRPM2	   CT1	   truncations	   containing	  theoretical	   1-­‐8-­‐14-­‐consensus	   site	   at	   161-­‐197AA.	   A.	   Input	   of	   protein	   fragments	  generated	   using	   TNT	   Quick	   Coupled	   translation	   system	   incorporating	   fluorescent	  lysine	   and	   resolved	   directly	   from	   an	   SDS-­‐page	   gel.	   B.	   CaM-­‐1	   Sepharose	   beads	  incubated	  overnight	  with	   fragments.	   Beads	  were	  washed	  with	   a	   buffer	   containing	  2mM	   Ca2+.	   All	   binding	   patterns	   are	   consistent	   with	   sites	   identified	   by	   in	   silico	  screening.	  (n=3)	  C.	  TRPM2	  NT1-­‐terminal	  fragment	  design.	  Blue	  boxes	  represent	   in	  
silico	  CaM	  binding	  sites.	  Four	  fragments	  were	  generated	  and	  tagged	  with	  GST	  to	  test	  for	   CaM	   binding.	  D.	   Relative	   binding	   strength	   of	   fragments	   versus	   relative	   signal	  strength	  of	  inputs	  on	  a	  representative	  gel	  (n=3).	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Figure	   3.9	   -­‐	   CaM-­‐Sepharose	   pulldown	   of	   mTRPM2	   CaM	   candidate	   site	   mutated	  fragments.	   A.	   TRPM2	   schematic	   of	   approximate	   truncation	   fragments	   locations	  overlapping	   candidate	   CaM	   sites.	   Four	   new	   fragments	   were	   generated	   with	  substituted	  amino	  acids	   (Figure	  2.3)	  and	   tagged	  with	  GST	   to	   test	   for	  CaM	  binding.	  
B/C.	   2	   representative	   gels	   of	   input	   protein	   fragments	   generated	   using	  TNT	  Quick	  Coupled	   translation	   system	   incorporating	   fluorescent	   lysine	   and	   resolved	   directly	  from	  an	  SDS-­‐page	  gel.	  	  D/E.	  2	  representative	  gels	  CaM-­‐1	  Sepharose	  beads	  incubated	  overnight	  with	   fragments.	  Beads	  were	  washed	  with	  a	  buffer	  containing	  2mM	  Ca2+.	  Fragment	  binding	   to	  CaM	  was	   reduced	   (NT15,	  CT11)	  or	  unchanged	   (CT10,	  NT10)	  but	  in	  all	  cases	  was	  not	  completely	  abolished	  by	  any	  of	  the	  mutations.	  (n=3).	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3.6	  Assessment	  of	  CaM	  site	  NTIQ	  and	  flag-­‐mTRPM2-­‐CaMMut(NTIQ)	  
	  	   Tong	  et	  al.,	  2006	  identified	  a	  CaM	  binding	  site	  located	  on	  the	  N-­‐term	  (Figure	  3.10A)	  of	  TRPM2	   responsible	   for	  Ca2+-­‐CaM	  mediated	   activation.	  My	   first	   objective	  was	  to	  reproduce	  the	  CaM	  binding	  mutant	  previously	  generated	  by	  Tong	  et	  al.,	  2006.	  Furthermore	   the	   regulatory	   changes	   of	   flag-­‐mTRPM2-­‐CaMMut(NTIQ)	   would	   be	  assessed	  using	  our	  novel	   and	  distinct	   electrophysiological	   recording	  protocol	   as	   a	  reference	  for	  future	  mutants.	  I	  successfully	  reproduced	  results	  produced	  by	  Tong	  et	  al.,	   2006.	   Protein	   expression	   of	   flag-­‐mTRPM2-­‐CaMMut(NTIQ)	   was	   confirmed	   from	  HEK293	   cell	   lysates	   on	   a	  Western	  blot	   tested	  with	   anti-­‐flag.	   CaM	  binding	   analysis	  was	  assessed	  for	  truncated	  fragment	  NT15	  containing	  the	  normal	  NTIQ	  site	  versus	  -­‐
MutNT15	   using	   flag-­‐mTRPM2-­‐CaMMut(NTIQ)	   as	   a	   PCR	   template	   (Figure	   3.9).	  Substitution	  mutations	  at	   the	  NTIQ	  site	  resulted	   in	  a	  significant	  decrease	  (p=0.009,	  NT15=1.0,	   MutNT15=0.57±0.157,	   n=3)	   to	   CaM-­‐Sepharose	   binding	   to	   the	   truncated	  mTRPM2	  fragment	  versus	  wild	  type	  (Figure	  3.10C).	  Finally,	  TRPM2	  transfected	  into	  HEK293	   cells	   was	   assessed	   (n=6)	   using	   	   whole-­‐cell	   patch-­‐clamp	   recordings	   with	  0.3mM	  ADPR	  in	  the	  patch	  pipette	  and	  0.5mM	  or	  2mM	  Ca2+	  ECS	  applications	  (Figure	  3.10D).	   Flag-­‐mTRPM2-­‐CaMMut(NTIQ)	   resulted	   in	   a	   complete	   abolishment	   (n=6)	   of	  current	   to	   either	   Ca2+	   ECS	   applications	   (3.10E).	   Furthermore,	   when	   ADPR	   was	  increased	  to	  5mM	  (n=6)	  to	  test	  for	  a	  potential	  shift	  in	  ADPR	  responsiveness,	  TRPM2	  currents	  were	   still	  not	  produced	   (Figure	  3.10E).	  These	   results	  are	   consistent	  with	  the	  produced	  by	  Tong	  et	  al.,	  2006	   that	   the	  role	  of	   the	  NTIQ	  CaM	  site	   is	   to	   regulate	  TRPM2	  Ca2+-­‐CaM	  mediated	  channel	  activation.	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Figure	   3.10	   –	   Analysis	   of	   flag-­‐mTRPM2-­‐CaMMut(NTIQ)	   A.	   TRPM2	   schematic	  highlighting	   the	  mutation’s	   location	   on	   the	   N-­‐terminal.	  B.	   Protein	   lysates	   of	   flag-­‐mTRPM2-­‐CaMMut(NTIQ)	   from	   transfected	   HEK293	   cells	   confirm	   expression	   when	  probed	   for	   anti-­‐flag	   on	   a	   Western	   blot	   (n=3).	   C.	   A	   truncated	   NT15	   fragment	  generated	   from	   a	   flag-­‐mTRPM2-­‐CaMMut(NTIQ)	   template	   (MutNT15)	   resulted	   in	   a	  significant	   decrease	   in	   CaM-­‐Sepharose	   binding	   (p=0.009,	   NT15=1.0,	  
MutNT15=0.57±0.157,	   n=3).	   D.	   Sample	   trace	   whole-­‐cell	   patch-­‐clamp	   recording	   of	  Hek293	   transfected	   with	   mTRPM2	   exposed	   to	   ECF	   with	   0.5mM	   or	   2mM	   Ca2+	  treatments.	  E.	  Sample	  trace	  whole-­‐cell	  patch-­‐clamp	  recording	  of	  Hek293	  transfected	  with	   flag-­‐mTRPM2-­‐CaMMut(NTIQ)	   exposed	   to	   ECS	   with	   0.5mM	   or	   2mM	   Ca2+	  treatments	  (n=6).	  F.	  Sample	  trace	  using	  5mM	  ADPR.	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3.7	  Assessment	  of	  CaM	  site	  CT1-­‐14	  and	  flag-­‐mTRPM2-­‐CaMMut(CT1-­‐14)	  
	   The	  next	  mutant	  to	  be	  tested,	  flag-­‐mTRPM2-­‐CaMMut(CT1-­‐14),	  overlaps	  with	  the	  NUDIX	  domain	  of	  TRPM2,	  responsible	  for	  ADPR	  activation	  of	  the	  channel	  (Perraud	  et	   al.,	   2003).	   Protein	   expression	   of	   Flag-­‐mTRPM2-­‐CaMMut(CT1-­‐14)	   was	   confirmed	  from	   HEK293	   cell	   lysates	   on	   a	  Western	   blot	   tested	   with	   anti-­‐flag	   (Figure	   3.11B).	  CaM	   binding	   analysis	   was	   assessed	   for	   truncated	   fragment	   CT11	   containing	   the	  normal	  CT1-­‐14	  site	  versus	  MutCT11	  (Figure	  3.9).	   Substitution	  mutations	  at	   the	  CT1-­‐14	  site	  resulted	  in	  a	  significant	  decrease	  (p=0.002,	  CT11=1.0,	  MutCT11=0.61±0.09,	  n=3)	  to	   CaM-­‐Sepharose	   binding	   to	   the	   truncated	   mTRPM2	   fragment	   versus	   wild	   type	  (Figure	   3.11C).	   Finally,	   TRPM2	   transfected	   into	  HEK293	   cells	  was	   assessed	   (n=6)	  using	  whole-­‐cell	  patch-­‐clamp	  recordings	  with	  0.3mM	  ADPR	  in	  the	  patch	  pipette	  and	  0.5mM	  or	  2mM	  Ca2+	  ECS	  applications	  (Figure	  3.11D).	  Flag-­‐mTRPM2-­‐CaMMut(CT1-­‐14)	  resulted	   in	   no	   significant	   change	   of	   CDI	   to	   either	   0.5mM	   (Figure	   3.11F)	   (p=0.760,	  mTRPM2=0.933±0.0503,	   mTRPM2-­‐CaMMut(CT1-­‐14)=0.825±0.0675,	   n=6)	   or	   2mM	  (Figure3.11G)	   (p=0.115,	   mTRPM2=0.284±0.0169,	   mTRPM2-­‐CaMMut(CT1-­‐
14)=0.318±0.0107,	  n=6)	  Ca2+	  ECS	  application.	  These	  results	  suggest	   the	  CT1-­‐14	  CaM	  binding	   site	   has	   no	   regulatory	   role	   for	   either	   TRPM2	   activation	   or	   inactivation,	  because	  reduction	  in	  CaM	  binding	  as	  a	  result	  of	  substitution	  mutagenesis	  caused	  no	  change	  in	  current	  amplitude	  or	  CDI.	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Figure	   3.11	   –	   Analysis	   of	   flag-­‐mTRPM2-­‐CaMMut(CT1-­‐14)	   A.	   TRPM2	   schematic	  highlighting	   the	  mutation’s	   location	   on	   the	   N-­‐terminal.	  B.	   Protein	   lysates	   of	   flag-­‐mTRPM2-­‐CaMMut(CT1-­‐14)	  from	  transfected	  HEK293	  cells	  confirmed	  expression	  when	  probed	   for	   anti-­‐flag	   on	   a	   Western	   blot	   (n=3).	   C.	   A	   truncated	   CT11	   fragment	  generated	   from	   a	   flag-­‐mTRPM2-­‐CaMMut(CT1-­‐14)	   template	   (MutCT11)	   resulted	   in	   a	  significant	   decrease	   (p<0.05)	   in	   CaM-­‐Sepharose	   binding	   (p=0.002,	   CT11=1.0,	  
MutCT11=0.61±0.09,	   n=3)	   D.	   Sample	   trace	   whole-­‐cell	   patch-­‐clamp	   recording	   of	  Hek293	   transfected	   with	   mTRPM2	   exposed	   to	   ECF	   with	   0.5mM	   or	   2mM	   Ca2+	  treatments.	  E.	  Sample	  trace	  whole-­‐cell	  patch-­‐clamp	  recording	  of	  Hek293	  transfected	  with	   flag-­‐mTRPM2-­‐CaMMut(CT1-­‐14)	   exposed	   to	   ECS	   with	   0.5mM	   or	   2mM	   Ca2+	  treatments	   (n=6).	  F.	  No	   significant	   change	   to	   CDI	   of	   TRPM2	  was	   found	   at	   0.5mM	  Ca2+	  or	  (G.)	  2mM	  Ca2+	  ECS	  applications	  for	  the	  mutant	  versus	  control	  (p<0.05)	  (n=6)	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3.8	  Assessment	  of	  CaM	  site	  CTIQ	  and	  flag-­‐mTRPM2-­‐CaMMut(CTIQ) The	   flag-­‐mTRPM2-­‐CaMMut(CTIQ)	   mutant	   overlaps	   with	   the	   CCR	   region	   of	  TRPM2,	  thought	  to	  be	  responsible	  for	  unknown	  protein-­‐protein	  interaction	  and	  the	  formation	  of	  the	  TRPM2	  tetramer	  through	  subunit	  formation	  (Perraud	  et	  al.,	  2003).	  Flag-­‐mTRPM2-­‐CaMMut(CTIQ)	   was	   transfected	   into	   HEK293	   cells,	   reduced	   protein	  expression	   (n=3)	  was	   found	   in	   cell	   lysates	   versus	  wild	   type	  TRPM2	  on	  a	  Western	  blot	   tested	   with	   anti-­‐flag	   (Figure	   3.12B).	   CaM	   binding	   analysis	   was	   assessed	   for	  truncated	  fragment	  CT5	  containing	  the	  normal	  CTIQ	  site	  versus	  MutCT5	  (Figure	  3.9).	  Substitution	  mutations	   at	   the	  CTIQ	   site	   resulted	   in	  no	   significant	   change	   (p=0.158,	  CT5=1.0,	   MutCT5=1.48±0.48,	   n=3)	   to	   CaM-­‐Sepharose	   binding	   to	   the	   truncated	  mTRPM2	  fragment	  versus	  wild	  type	  (Figure	  3.12C).	  Finally,	  TRPM2	  transfected	  into	  HEK293	   cells	   was	   assessed	   (n=6)	   using	   a	   whole-­‐cell	   patch-­‐clamp	   recording	   with	  0.3mM	  ADPR	  in	  the	  patch	  pipette	  and	  0.5mM	  or	  2mM	  Ca2+	  ECS	  applications	  (Figure	  3.12E).	   Flag-­‐mTRPM2-­‐CaMMut(CTIQ)	   resulted	   in	   a	   greatly	   reduced	   TRPM2	   current	  response	   (n=6)	   to	   either	   Ca2+	   ECS	   applications	   versus	   wild	   type	   TRPM2	   (3.12F).	  Furthermore,	  when	  ADPR	  was	  increased	  to	  5mM	  (n=6)	  to	  test	  for	  a	  potential	  shift	  in	  ADPR	  responsiveness,	  TRPM2	  currents	  were	  still	  reduced	  (Figure	  3.12G).	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3.9	  Assessment	  of	  CaM	  site	  NT1-­‐14	  flag-­‐mTRPM2-­‐CaMMut(NT1-­‐14)	  
	   The	  flag-­‐mTRPM2-­‐CaMMut(NT1-­‐14)	  mutant	   is	   found	  in	  a	  highly	  conserved	  NT	  region	  thought	  to	  be	  responsible	  for	  protein	  trafficking	  and	  expression	  (Perraud	  et	  al.,	  2003).	  Flag-­‐mTRPM2-­‐CaMMut(NT1-­‐14)	  was	  transfected	  into	  HEK293	  cells,	  reduced	  protein	   expression	   (n=3)	  was	   found	   in	   cell	   lysates	   versus	  wild	   type	   TRPM2	   on	   a	  Western	   blot	   tested	   with	   anti-­‐flag	   (Figure	   3.13B).	   CaM	   binding	   analysis	   was	  assessed	   for	   truncated	   fragment	   NT5	   containing	   the	   normal	   NT1-­‐14	   site	   versus	   –
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Figure	   3.13	   –	   Analysis	   of	   flag-­‐mTRPM2-­‐CaMMut(NT1-­‐14)	   A.	   TRPM2	   schematic	  highlighting	   the	   mutation’s	   location	   on	   the	   C-­‐terminal.	  B.	   Protein	   lysates	   of	   flag-­‐mTRPM2-­‐CaMMut(NT1-­‐14)	   from	   transfected	  HEK293	   cells	   show	   reduced	   expression	  when	   probed	   for	   anti-­‐flag	   on	   a	  Western	   blot	   (n=3).	  C.	   A	   truncated	   CT5	   fragment	  generated	   from	   a	   flag-­‐mTRPM2-­‐CaMMut(NTI1-­‐14)	   template	   (MutNT5)	   resulted	   in	   no	  significant	   change	   (p>0.05)	   in	   CaM-­‐Sepharose	   binding	   (p=0.161,	   NT5=1.0,	  
MutNT5=1.17±0.175,	   n=3).	   D.	   Sample	   trace	   whole-­‐cell	   patch-­‐clamp	   recording	   of	  Hek293	   transfected	   with	   mTRPM2	   exposed	   to	   ECF	   with	   0.5mM	   or	   2mM	   Ca2+	  treatments.	  E.	  Sample	  trace	  whole-­‐cell	  patch-­‐clamp	  recording	  of	  Hek293	  transfected	  with	   flag-­‐mTRPM2-­‐CaMMut(NT1-­‐14)	   exposed	   to	   ECS	   with	   0.5mM	   or	   2mM	   Ca2+	  treatments	  (n=6).	  F.	  Sample	  trace	  using	  5mM	  ADPR	  failed	  to	  produce	  a	  TRPM2-­‐like	  current.	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3.10	  Analysis	  of	  the	  hTRPM2	  P1018L	  substitution	  










Figure	  3.14	  –	  Analysis	  of	  CDI	  for	  the	  hTRPM2	  P1018L	  mutant.	  	  A/C.	  Sample	  whole-­‐cell	   patch-­‐clamp	   trace	   recording	   of	   hTRPM2	   transfected	   into	   HEK293	   cells	   with	  0.3mM	   ADPR	   and	   2mM	   or	   0.5mM	   Ca2+	   ECS	   applications.	   B/D.	   Sample	   trace	  recording	  of	  hTRPM2	  P1018L.	  E.	  No	  significant	  difference	  in	  CDI	  was	  observed	  for	  hTRPM2	  versus	  hTRPM2	  P1018L	  with	  2mM	  Ca2+	  ECS	  applications	  (p>0.05,	  n=6).	  F.	  No	  significant	  difference	  in	  CDI	  was	  observed	  for	  hTRPM2	  versus	  hTRPM2	  P1018L	  with	  0.5mM	  Ca2+	  ECS	  applications	  (p>0.05,	  n=6).	  G.	  A	  significant	  difference	  between	  the	   ratio	  of	  0.5mM	  and	  2mM	  Ca2+	  ECS	  applications	  was	   found	   for	  hTRPM2	  versus	  hTRPM2	  P1018L	  (p<0.05,	  n=6).	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3.11	  –	  TRPM2	  CDI	  in	  hTRPM2	  versus	  mTRPM2	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Figure	   3.15	   –	  Analysis	  of	  CDI	   for	  mTRPM2	  versus	  hTRPM2.	  A.	   Sample	  whole-­‐cell	  patch-­‐clamp	  trace	  recording	  of	  hTRPM2	  transfected	  into	  HEK293	  cells	  with	  0.3mM	  ADPR	  and	  2mM	  or	  0.5mM	  Ca2+	  ECS	  applications.	  B.	  Sample	  whole-­‐cell	  patch-­‐clamp	  trace	   recording	  of	  mTRPM2	   transfected	   into	  HEK293	   cells	  with	  0.3mM	  ADPR	  and	  2mM	  or	   0.5mM	  Ca2+	   ECS	   applications.	  C.	  A	   significant	   difference	   between	  TRPM2	  CDI	   was	   observed	   between	   hTRPM2	   and	   mTRPM2	   under	   2mM	   Ca2+	   applications	  (p<0.001,	   hTRPM2=0.594±0.0585,	   mTRPM2=0.284±0.0169,	   n=6).	  D.	   A	   significant	  difference	   between	   TRPM2	   CDI	   was	   observed	   between	   hTRPM2	   and	   mTRPM2	  under	   0.5mM	   Ca2+	   applications	   (p=0.0291,	   hTRPM2=0.933±0.0459,	  mTRPM2=0.760±0.0503,	  n=6).	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4.1	  Summary	  of	  Key	  Findings	  
	   	  	   The	  primary	  goal	  of	  this	  thesis	  was	  to	  uncover	  the	  mechanism	  through	  which	  CDI	  of	  TRPM2	  occurs.	  We	  based	  our	  approach	  on	  a	  previous	   study	  by	  Tong	  et	   al.,	  2006	  that	  hinted	  at	  unknown	  CaM	  binding	  sites	  on	  TRPM2.	  We	  choose	  a	  strategy	  of	  creating	   truncation	  mutations	   to	  produce	  minimum	  CaM	  binding	  domains	   (Zhulke	  and	  Reuter,	  1998)	  and	  a	  substitution	  mutation	  strategy	  at	  those	  minimum-­‐binding	  domains	  (Zuhlke	  et	  al.,	  1999;	  Tong	  et	  al.,	  2006).	  The	  novel	  findings	  from	  this	  project	  are	  summarized	  below:	  	  1)	   TRPM2	   undergoes	   CDI	   that	   is	   increased	   with	   larger	   applications	   of	  extracellular	  Ca2+.	  CDI	  of	  TRPM2	  has	  a	  linear	  voltage	  relationship	  that	  mimics	  the	  Ca2+	  ionic	  reversal	  potential	  (Figure	  3.1).	  2)	   In	   silico	   screening	   of	   TRPM2	   terminals	   reveals	   3	   novel	   candidate	   CaM	  consensus	   site	   sites.	   Additionally	   a	   truncated	   C-­‐terminal	   of	   TRPM2	   stably	  expressed	  in	  HEK293	  cells	  binds	  with	  CaM-­‐Sepharose	  in	  the	  presence	  of	  Ca2+.	  3)	   A	   systematic	   analysis	   of	   truncated	   TRPM2	   domains	   confirms	   3	   new	  binding	  sites	   (CTIQ,	  CT1-­‐14	  and	  NTIQ).	  Binding	   is	  not	  completely	  abolished	   in	  absence	  of	  Ca2+.	  4)	  An	  assessment	  of	  substitution	  mutations	  to	  four	  different	  CaM	  sites	  were	  preformed:	  	   -­‐NTIQ:	  confirmed	  expression,	  reduced	  CaM	  binding,	  abolished	  current.	  	   -­‐CT1-­‐14:	  confirmed	  expression,	  reduced	  CaM	  binding,	  no	  CDI	  change.	  	   -­‐CTIQ:	  reduced	  expression,	  regular	  CaM	  binding,	  reduced	  current.	  	   -­‐NT1-­‐14:	  reduced	  expression,	  regular	  CaM	  binding,	  abolished	  current.	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5)	   The	   Guam	   mutant	   hTRPM2	   P1018L	   shows	   normal	   CDI	   but	   increased	  current	  amplitude	  under	  0.5mM	  Ca2+	  applications.	  6)	  There	  is	  a	  significantly	  higher	  CDI	  for	  mTRPM2	  versus	  hTRPM2.	  
	  
	  
4.2	  TRPM2	  CDI	  is	  mediated	  by	  extracellular	  Ca2+	  	  	   Our	   laboratory	   having	   previously	   identified	   TRPM2	  CDI	  were	   interested	   in	  defining	  the	  mechanism.	  Previous	  unpublished	  work	  has	  established	  TRPM2	  CDI	  is	  dependent	  on	  intracellular	  [Ca2+]	  and	  can	  be	  fully	  recovered	  from	  after	  a	  period	  of	  0	  Ca2+	   exposure.	   I	   next	   wanted	   to	   establish	   how	   the	   extracellular	   [Ca2+]	   mediates	  TRPM2	   CDI	   and	   whether	   this	   process	   is	   affected	   by	   membrane	   voltage.	   TRPM2	  conductance	   is	   not	   directly	   influenced	   by	  membrane	   voltage.	   However,	   current	   is	  still	   indirectly	   affected	   by	   the	   electrical	   gradient	   of	   cations.	   By	   raising	  membrane	  holding	   voltage	   the	   peak	   amplitude	   of	   TRPM2	   current	   is	   decreased	   and	   therefore	  our	  measurement	  of	  CDI	  (Iss/Ip).	  	   An	  experimental	  protocol	  was	  designed	  with	  3	  min	  exposures	  of	  either	  2mM	  or	   0.5mM	   Ca2+.	   Between	   Ca2+	   sweeps	   a	   5	   minute	   0mM	   Ca2+	   exposure	   allowed	  complete	   recovery	   from	   CDI	   and	   furthermore	   voltage	   was	   raised	   in	   20mV	   steps.	  Figure	  3.1	  outlines	  the	  finding	  from	  this	  experiment.	  TRPM2	  CDI	  was	  highly	  evident	  with	  2mM	  Ca2+;	  however,	  CDI	  was	  only	  apparent	   for	  0.5mM	  Ca2+	  treatments	  when	  holding	  voltage	  was	  below	  -­‐60mV.	  The	  reason	  for	  this	  is	  likely	  twofold:	  under	  higher	  concentrations	   of	   Ca2+	   influx	   is	   larger	   and	   this	   translates	   to	   higher	   intracellular	  [Ca2+]	  and	  therefore	  greater	  TRPM2	  CDI.	  Secondly	  as	  voltage	  is	  hyperpolarized	  the	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electrical	  force	  driving	  Ca2+	  entry	  is	  greater	  thus	  increasing	  intracellular	  [Ca2+]	  and	  thereby	  TRPM2	  CDI.	  	   Also	   of	   note	   TRPM2	   CDI	   at	   the	   2mM	   Ca2+	   treatment	   decreased	   in	   a	   linear	  fashion	  as	  membrane	  voltage	  was	  depolarized.	  The	  most	   likely	  explanation	   is	   that	  voltage	  is	  not	  directly	  mediating	  TRPM2	  CDI.	  Instead	  the	  Ca2+	  electrical	  gradient	  is	  altered,	   lowering	  influx	  into	  the	  intracellular	  environment	  and	  slowing	  CDI.	  This	  is	  further	   evidenced	   by	   the	   extrapolation	   of	   the	   2mM	   Ca2+	   CDI	   trend,	   which	  approximates	  the	  reversal	  potential	  of	  Ca2+	  cations	  under	  this	  conditions.	  	  
	  
4.3	  Ca2+-­‐CaM	  binding,	  Ca2+	  specificity	  and	  ApoCaM	  	  With	  a	  basic	  understanding	  of	   the	  mechanisms	   that	   regulate	  TRPM2,	   I	  next	  wanted	   to	   establish	   if	   the	   CaM	   complex	   is	   interacting	   with	   TRPM2	   to	   evoke	   CDI.	  Evidence	  from	  Tong	  et	  al.,	  2006	  implicated	  additional	  uncharacterized	  CaM	  binding	  sites	  with	  unknown	  function.	  Previous	  studies	  have	  been	  conducted	  where	  proteins	  have	  been	  modulated	  by	  Ca2+-­‐CaM	  at	  more	  than	  one	  binding	  site	  (Scott	  et	  al.,	  1997;	  Wang	  et	  al.,	  1989;	  Buschmeier	  et	  al.,	  1987).	  Success	  has	  been	  achieved	  by	  generating	  a	   series	   of	   protein	   truncations	   and	   carrying	   out	   substitution	   mutagenesis	   at	   this	  target	  site	  to	  resolve	  the	  physiological	  function	  (Zhulke	  and	  Reuter,	  1998;	  Zuhlke	  et	  al.,	  1999).	  Using	  a	  similar	  strategy	  I	  first	  performed	  an	  in	  silico	  screening	  of	  TRPM2	  which	  successfully	  identified	  three	  additional	  CaM	  sites	  on	  the	  intracellular	  N-­‐	  and	  C-­‐terminal	   not	   discussed	   in	   the	   literature	   (Figure	   3.3).	   A	   truncation	   strategy	  was	  initially	  developed	  with	  stable	  expression	  of	   flag-­‐tagged	   truncated	   fragments.	  A	  C-­‐term	  TRPM2	  truncation	  incubated	  with	  CaM-­‐Sepharose	  was	  initially	  resolved	  with	  a	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Western	   blot	   (Figure	   3.3),	   further	   confirming	   my	   suspicion	   that	   previously	  undiscovered	  CaM	  binding	  sites	  exist	  in	  the	  terminal	  ends	  of	  TRPM2.	  	   A	  new	  protocol	  was	  adopted	  that	  allows	  for	  a	  much	  more	  rapid	  screening	  of	  truncated	  fragments	  and	  determination	  of	  the	  minimum	  binding	  domain.	  The	  TNT	  quick-­‐coupled	   reticulocyte	   system	   allows	   for	   transcription	   and	   translation	   of	   a	  plasmid	  into	  a	  fluorescent	  protein.	  The	  second	  feature	  of	  this	  system	  is	  direct	  in-­‐gel	  imaging	   of	   a	   protein,	   greatly	   reducing	   the	   time	   required	   to	   perform	   the	   binding	  experiments	  of	  this	  thesis	  and	  a	  more	  rapid	  confirmation	  of	  minimum	  binding	  sites.	  All	   truncated	   fragments	   were	   tagged	   with	   GST	   in	   both	   an	   effort	   to	   increase	  molecular	   weight	   for	   small-­‐truncated	   fragments	   and	   to	   ensure	   sufficient	   lysine	  incorporation	  into	  every	  fragment.	  GST	  also	  acted	  as	  a	  negative	  binding	  control	  for	  which	   truncated	   fragments	   binding	   to	   CaM-­‐Sepharose	   could	   be	   compared.	   Great	  success	   was	   achieved	   with	   this	   approach,	   I	   experimentally	   confirmed	   three	   new	  candidate	  sites	  which	  were	  able	  to	  interact	  with	  CaM-­‐Sepharose	  in	  consensus	  with	  the	   in	   silico	   screening.	   Figure	   3.5	   confirmed	   a	   CTIQ	   site	   located	   at	   1084-­‐1105AA,	  Figure	  3.6	  a	  CT1-­‐14	  located	  at	  1344-­‐1373AA	  and	  finally	  Figure	  3.8	  a	  NTIQ	  site	  at	  161-­‐197AA.	  	  	   We	   developed	   our	   truncation	   strategy	   around	   the	   TNT	   Quick-­‐Coupled	  Transcription/Translation	  kit,	  which	  allowed	   for	  more	  rapid	  CaM-­‐binding	  analysis	  versus	   traditional	   use	   of	   cell	   lysates.	   This	   method	   has	   been	   used	   previously	   to	  identify	   CaM	   interaction	   with	   channels,	   particularly	   using	   radiolabeled	   serine	  (Fanger	   et	   al.,	   1999).	   For	   my	   purposes	   fluorescent	   lysine	   reduced	   many	   of	   the	  hurdles	   when	   dealing	   with	   radiolabeled	   amino	   acids.	   A	   limitation	   with	   the	   kit	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however	   prevented	   complete	   analysis	   of	   truncated	   fragments.	   The	   protein	  concentration	  of	   the	   truncated	   fragments	   cannot	  be	  determined	   from	   the	  protein-­‐rich	  reaction	  solution.	  Due	   to	   this	   fact	   inputs	  were	  only	  controlled	  by	  volume,	  but	  protein	  concentration	  of	  each	  sample	  was	  variable.	  Signal	  strength	   is	  also	  variable	  from	   fragment	   to	   fragment	   depending	   on	   the	   number	   of	   fluorescent	   lysine.	   This	  limited	   experimental	   analysis	   to	   semi-­‐quantitative	   only	   and	   was	   achieved	   by	  standardizing	   volume	   between	   the	   fragment	   input	   and	   pull-­‐down.	   While	   it	   was	  efficient	   for	   quick	   confirmation	   of	   binding	   domains,	   the	   true	   strength	   of	   the	  interaction	  needs	  to	  be	  determined	  using	  cellular	  lysates	  of	  truncated	  fragments	  and	  standardized	   using	   a	   BSA	   assay	   and	  Western	   blotting.	   It	  was	   our	   hope	   to	   rapidly	  identify	   and	   characterize	   sites	   and	   return	   to	   further	   analyze	   candidate	   sites	   that	  demonstrated	  a	  physiological	  function.	  The	  protocol	  rapidly	  achieved	  this	  goal	  and	  worked	  successfully	  for	  our	  purposes.	  	   A	   Ca2+-­‐free	   5mM	   EGTA	   solution	   reduced,	   but	   did	   not	   completely	   abolish,	  CaM-­‐Sepharose	   binding	   to	   any	   of	   the	   truncated	   TRPM2	   fragments.	   A	   secondary	  explanation	   may	   account	   for	   some	   ApoCaM	   interaction	   at	   these	   sites,	   especially	  prominent	  amongst	   IQ-­‐like	   sites	   (Jurado	  et	  al.,	  1999).	  Future	  analysis	  will	  need	   to	  elucidate	   the	   true	   Ca2+-­‐specificity	   at	   these	   binding	   sites.	   This	   would	   be	   achieved	  through	   repeating	   experiments	   with	   lysates	   of	   HEK293	   cells	   transfected	   with	  truncated	   TRPM2	   fragments.	   We	   decided	   to	   then	   pursue	   electrophysiological	  recordings	   from	   mutated	   TRPM2	   at	   candidate	   sites.	   This	   would	   provide	   a	   more	  accurate	   analysis	   of	   the	   physiological	   relevance	   of	   these	   sites	   for	   mediation	   of	  TRPM2	  CDI.	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4.4	  NTIQ	  and	  TRPM2	  activation	  	  	   Tong	  et	  al.,	  2006	  originally	  characterized	  a	  NTIQ	  site	  responsible	  for	  TRPM2	  Ca2+-­‐CaM	   activation.	   I	   replicated	   the	   substitution	   mutations	   performed	   by	   their	  group	   and	   first	   examined	   the	   effects	   of	   those	   substitution	   mutations	   within	   our	  unique	   experimental	   recording	  protocol.	   Similar	   to	   findings	  by	  Tong	   et	   al.,	   2006	   I	  discovered	  a	  reduction	  in	  CaM-­‐Sepharose	  binding	  (Figure	  3.10C),	  but	  not	  a	  complete	  abolishment	  as	  a	  result	  of	  the	  substitution	  mutation.	  CaM-­‐Sepharose	  pulldown	  was	  still	   greater	   than	   GST	   alone;	   therefore	   the	   residual	   binding	   cannot	   be	   completely	  attributed	   to	  GST.	  As	  predicted,	  TRPM2	  current	   could	  not	  be	   recorded	   in	  HEK293	  cells	   transfected	   with	   flag-­‐mTRPM2-­‐CaMMut(NTIQ).	   When	   intracellular	   ADPR	   was	  increased	  to	  5mM	  no	  Ca2+	  mediated	  current	  was	  observed,	  which	  is	  expected	  from	  a	  site	   that	   is	   necessary	   for	   TRPM2	   activation.	   The	   analysis	   of	   the	   Tong	   et	   al.,	   2006	  mutant	  acts	  as	  a	  validation	  for	  the	  experimental	  design	  carried	  out	  in	  this	  thesis.	  	  
	  
4.5	  CT1-­‐14	  and	  the	  TRPM2	  NUDIX	  domain	  
	  
	   The	   second	  mutant	   I	   examined	  was	   at	   the	   CT1-­‐14	   site	   overlapping	  with	   the	  NUDIX	  domain,	  responsible	  for	  ADPR	  binding	  and	  activation	  of	  TRPM2	  	  (Perraud	  et	  al.,	   2003).	   It	   is	   possible	   that	   high	   intracellular	   [Ca2+]	   create	   an	   active	   CaM	   that	  indirectly	   competes	   with	   ADPR	   and	   prevents	   activation	   of	   TRPM2.	   Substitution	  mutations	  to	  the	  CT1=14	  site	  successfully	  reduced,	  but	  did	  not	  completely	  eliminate,	  CaM	   binding	   (Figure	   3.11C)	   similar	   to	   what	   I	   observed	   with	   the	   NTIQ	   mutant.	  Furthermore	  the	   full	   length	   flag-­‐mTRPM2-­‐CaMMut(CT1-­‐14)	  successfully	  expressed	   in	  HEK293	   cells	   (Figure	   3.11B).	   Despite	   these	   findings	   flag-­‐mTRPM2-­‐CaMMut(CT1-­‐14)	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current	   and	   CDI	   appear	   to	   be	   completely	   normal	   (Figure	   3.11)	   compared	   to	  WT	  mTRPM2	  recordings.	  	  	   The	  findings	  from	  this	  mutant	  are	  important	  for	  two	  reasons.	  First	  it	  acts	  as	  a	  strong	  validation	   that	   the	  process	  of	   substitution	  mutagenesis	   itself	  does	  not	  alter	  channel	  gating	  properties.	  Secondly	  it	  would	  appear	  that	  Ca2+-­‐CaM	  does	  not	  appear	  to	   be	   competing	   with	   ADPR	   binding	   in	   order	   to	   evoke	   CDI,	   at	   least	   at	   this	   CaM	  candidate	  site.	  Based	  on	  these	  findings	  it	  would	  appear	  the	  CT1-­‐14	  candidate	  site	  has	  no	  critical	  physiological	  role	  in	  TRPM2	  function	  or	  regulation.	  	  
	  
4.6	  CTIQ	  and	  the	  TRPM2	  CCR	  
	  	   A	   substitution	   mutation	   to	   the	   CTIQ	   candidate	   CaM	   binding	   site	   produced	  some	  unexpected	  but	  exciting	  results.	  The	  CTIQ	  site	  overlaps	  with	  the	  CCR,	  originally	  predicted	  to	  play	  some	  unknown	  role	  in	  the	  TRPM2	  channel	  structure,	  expression	  or	  gating	   (Perraud	   et	   al.,	   2003).	   In	   fact	   a	   CCR	   is	   often	   involved	   in	   protein-­‐protein	  interactions,	  a	  Ca2+-­‐CaM	  complex	  may	  play	  a	  functional	  role	  by	  changing	  the	  channel	  gating	  very	  close	  to	  the	  pore	  region.	  Substitution	  mutations	  to	  site	  CTIQ	  resulted	  in	  no	  significant	  change	  to	  CaM-­‐Sepharose	  binding	  in	  a	  truncated	  fragment	  compared	  to	  WT	   (Figure	   3.12C).	   Despite	   this,	   a	   significant	   reduction	   in	   TRPM2	   current	  was	  apparent	   from	   HEK293	   cells	   transfected	   with	   flag-­‐mTRPM2-­‐CaMMut(CTIQ)	   (Figure	  3.12).	  The	  mutant	  TRPM2	  still	  displayed	  some	  Ca2+	  responsiveness,	  but	  the	  reduced	  current	   could	  not	   be	   recovered	  with	   increased	  5mM	  ADPR.	  The	   current	   observed	  from	  flag-­‐mTRPM2-­‐CaMMut(CTIQ)	  is	  different	  than	  that	  obtained	  from	  flag-­‐mTRPM2-­‐
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CaMMut(NTIQ),	  the	  site	  responsible	  for	  TRPM2	  activation,	  as	  that	  mutant	  completely	  abolished	  all	  current	  regardless	  of	  Ca2+	  application.	  	   Several	  reasons	  for	  the	  reduced	  current	  may	  be	  likely:	  a	  reduced	  expression	  was	   found	   in	  Western	  blotting	   from	  cell	   lysates	   compared	   to	   the	  previous	  mutant	  examined	   (Figure	   3.12B).	   Secondly	   surface	   expression	   remains	   to	   be	   determined,	  reduced	   flag-­‐mTRPM2-­‐CaMMut(CTIQ)	   at	   the	   membrane	   may	   result	   in	   a	   reduced	  current.	  The	  CCR	  has	  also	  been	  implicated	  in	  formation	  of	  the	  tetrameric	  structure	  of	  TRPM2,	  if	  the	  substrate	  formation	  is	  altered	  by	  the	  mutations	  near	  the	  CCR	  region	  a	   malformed	   tetramer	   may	   result	   in	   reduced	   TRPM2	   current	   seen	   from	   flag-­‐mTRPM2-­‐CaMMut(CTIQ).	   Finally	   the	   Ca2+-­‐CaM	   site	   may	   be	   altering	   activation	   or	  inactivation	   kinetics,	   once	   again	   facing	   a	   common	   problem	   with	   separating	  overlapping	   kinetics	   both	   driven	   by	   the	   Ca2+-­‐CaM	   complex.	   While	   the	   CTIQ	   sites	  specific	   role	   in	   TRPM2	   CDI	   is	   still	   unknown,	   evidence	   from	   flag-­‐mTRPM2-­‐CaMMut(CTIQ)	   recordings	   suggests	   a	   novel	   site	   critical	   for	   proper	   TRPM2	   function	  that	  has	  not	  been	  thoroughly	  discussed	  in	  the	  literature.	  	  
	  
4.7	  NT1-­‐14	  and	  conserved	  NT	  regions	  
	  	   The	  final	  CaM	  candidate	  site	  to	  be	  discussed	  is	  a	  second	  NT	  site	  with	  a	  1-­‐14	  CaM	   consensus	  map.	   Similar	   to	   site	   CTIQ	   some	   unexpected	   but	   interesting	   results	  were	   produced	   by	   a	   substitution	   mutation	   to	   this	   region.	   Comparing	   the	   NTIQ	  mutated	   site	   and	  wild	   type,	   no	   significant	   change	   to	   CaM-­‐Sepharose	   binding	   was	  found	   (Figure	  3.13C).	  Despite	   this	   finding,	   a	   complete	   abolishment	  of	   current	  was	  found	   from	   HEK293	   cells	   transfected	   with	   flag-­‐mTRPM2-­‐CaMMut(NT1-­‐14)	   (Figure	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3.13).	  The	  response	   to	  Ca2+	   treatments,	  which	  completely	  mimics	   the	  mutant	  NTIQ	  site	  responsible	   for	  Ca2+-­‐CaM	  activation	  of	   the	  TRPM2	  channel	   (Tong	  et	  al.,	  2006).	  Despite	   an	   increase	   to	   5mM	  ADPR,	   currents	  were	   still	   unable	   to	   be	   elicited	   from	  flag-­‐mTRPM2-­‐CaMMut(NT1-­‐14).	  	  	   Future	  work	  remains	   to	  determine	   if	   this	  substitution	  mutant	   is	  preventing	  proper	  trafficking	  and	  expression	  at	  the	  membrane.	  Relatively	  little	  is	  known	  about	  the	   role	   of	   the	   highly	   conserved	   NT	   region,	   but	   it	   is	   believed	   to	   be	   primarily	  responsible	  for	  channel	  expression	  (Perraud	  et	  al.,	  2003).	  Similar	  to	  the	  CTIQ	  mutant	  reduced	   expression	   was	   observed	   from	   lysates	   of	   transfected	   HEK293	   with	   flag-­‐mTRPM2-­‐CaMMut(CTIQ)	   (Figure	   3.13B).	   Several	   explanations	   may	   exist	   for	   the	  abolished	   TRPM2	   current,	   but	   only	   abolished	   expression	   at	   the	  membrane	  would	  account	  for	  the	  complete	  absence	  of	  current.	  Alternatively	  multiple	  sites	  responsible	  to	   Ca2+-­‐CaM	   activation	  may	   exist.	   The	   precise	   reason	   the	  mutations	   performed	   to	  NT1-­‐14	  alter	  TRPM2	  current	  remain	  to	  be	  established,	  but	  this	  second	  CaM	  site	  holds	  a	   strong	   potential	   for	   playing	   an	   important	   physiological	   role	   in	   proper	   TRPM2	  protein	  function.	  
	  
	  
4.8	  hTRPM2	  P1018L	  CDI	  and	  peak	  amplitude	  
	  
	   Very	  little	  has	  been	  discussed	  in	  the	  literature	  concerning	  TRPM2	  CDI,	  in	  fact	  our	  novel	  recording	  protocol	  seems	  to	  have	  revealed	  a	  major	  physiological	  feature	  of	  the	  channel	  that	  has	  been	  largely	  overlooked.	  A	  study	  by	  Hermosura	  et	  al.,	  2008	  examined	   a	   genetic	  mutant	   hTRPM2	  with	   a	   proline	   to	   leucine	   substitution	   at	   site	  1018	  occurring	  near	  the	  pore-­‐forming	  region	  of	  TRPM2.	  Their	  results	  implicate	  the	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substitution	   creating	   an	   increase	   in	   inactivation	   over	   time	   not	   observed	   for	  wild-­‐type	  TRPM2.	  We	  believed	  this	   increased	   inactivation	  may	  be	  the	  same	  as	  our	  own	  CDI	  observed	  from	  TRPM2	  transfected	  HEK293	  cells.	  The	  P1018L	  hTRPM2	  mutant	  it	   was	   transfected	   into	   HEK293	   cells	   and	   whole-­‐cell	   patch-­‐clamp	   recordings	  performed	  with	  2mM	  Ca2+	  or	  0.5mM	  Ca2+	  applications.	  	  	   Several	  key	  differences	  exist	  between	  the	  recording	  protocols	   I	  utilized	  and	  the	  Hermosura	  et	  al.,	  2008	  paper.	  Primarily	  cells	  were	  held	  at	  -­‐80mV	  compared	  to	  -­‐60mV	   for	  my	  recordings.	  Additionally	   I	  prime	  cells	  with	  2mM	  Ca2+	   to	  both	  ensure	  sufficient	   activation	   and	   diffusion	   of	   ADPR	   and	   EGTA	   into	   the	   intracellular	  environment.	   The	   Hermosura	   group	   maintains	   cells	   in	   1.5mM	   Ca2+	   solution	  throughout	  compared	  to	  my	  use	  of	  Ca2+-­‐free	  solution	  to	  prevent	  current	  while	   the	  intracellular	   solution	   diffuses.	   These	   differences	  may	   result	   in	   different	   activation	  and	   inactivation	   kinetics,	   which	   may	   not	   reveal	   strong	   TRPM2	   CDI	   I	   normally	  observe	   from	  WT	  TRPM2	  channels.	  I	   discovered	   that	   the	  P1018L	  hTRPM2	  mutant	  did	  not	  have	  a	  significant	  change	  to	  CDI	  for	  either	  2mM	  or	  0.5mM	  Ca2+	  applications	  (Figure	  3.14).	  The	  suggestion	  by	  Hermosura	  et	  al.,	  2008	  that	  hTRPM2	  P1018L	  has	  an	   increased	   form	  of	   inactivation	  was	  not	  apparent	  within	  our	  recording	  protocol.	  However	   an	   interesting	   result	   was	   found	   by	   comparing	   peak	   amplitude	   between	  0.5mM	   and	   2mM	   Ca2+	   applications,	   where	   an	   increased	   TRPM2	   current	   was	  observed	   under	   low	   Ca2+	   for	   the	  mutant	   form	   versus	  wild	   type.	   The	   results	   from	  Hermosura	   et	   al.,	   2007	   suggested	   loss	   of	   TRPM2	   P1018L	   function	   causes	  neurodegeneration,	   which	   is	   counterintuitive	   to	   what	   we	   know	   about	   TRPM2	  function.	   In	   contract	   my	   findings	   of	   increased	   Ca2+	   influx	   is	   more	   intuitive.	   	   The	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implications	   of	   this	   finding	   are	   intriguing	   and	   should	   be	   followed	   up	  with	   future	  studies	  with	   the	   P1018L	   hTRPM2	  mutant.	   In	   addition	   to	   a	   substitution	  mutation,	  low	   environmental	   concentration	   of	  Mg2+	   and	  Ca2+	   have	   been	   implicated	   in	  Guam	  ALS	   and	   PD	   (Hermosura	   et	   al.,	   2007).	   Whether	   these	   environmental	   factors	   act	  synergistically	   with	   an	   increased	   TRPM2	   current	   under	   low	   Ca2+	   remains	   to	   be	  determined.	   Furthermore	   whether	   these	   findings	   translate	   to	   a	   physiological	  outcome	  of	  these	  diseases	  cannot	  yet	  be	  claimed,	  but	  nevertheless	  offer	  an	  exciting	  avenue	  to	  explore.	  	  
	  
4.9	  Implications	  of	  increased	  mTRPM2	  CDI	  
	   	  	   One	   additional	   finding	   has	   lead	   to	   more	   questions	   about	   the	   process	   of	  TRPM2	   CDI	   and	   the	   site(s)	   through	  which	   this	   CaM	   regulated	   process	   occurs.	   All	  experiments	  apart	  from	  hTRPM2	  P1018L	  used	  mTRPM2	  as	  a	  control	  and	  template	  for	  mutations.	  As	   such	   I	  noticed	  a	   significant	  difference	  between	   the	   two	   forms	  of	  TRPM2	   (Figure	   3.15)	   whereby	   mTRPM2	   had	   significant	   higher	   CDI	   under	   both	  0.5mM	  and	  2mM	  Ca2+	  applications	  versus	  hTRPM2.	  I	  will	  postulate	  on	  the	  reasoning	  behind	  these	  differences,	  but	  until	  further	  experimentation	  occurs	  the	  mechanism	  is	  unknown.	  	   I	   performed	   blast	   sequencing	   between	   mTRPM2	   and	   hTRPM2,	   which	  revealed	   an	   85%	   sequence	   homology	   between	  mTRPM2	   and	   hTRPM2.	   Structures	  implicated	   in	   TRPM2	   function	   are	   highly	   conserved	   between	   both	   mTRPM2	   and	  hTRPM2.	   Intriguingly	   only	   one	   of	   the	   candidate	   CaM	   sites	   CTIQ	   has	   three	  substitutions	  in	  the	  IQ	  region	  to	  non-­‐critical	  binding	  residues;	  the	  effect	  this	  has	  on	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CaM	  binding	  to	  this	  site	  may	  be	  further	  pursued.	  Targeted	  substitution	  mutations	  to	  the	  CTIQ	  site	  could	  replicate	  the	  differences	  in	  sequence	  homology	  from	  either	  form	  of	   TRPM2	   and	   electrophysiological	   recordings	   performed.	   Further	   work	   still	   is	  required	   to	  determine	   the	  exact	  means	  NT1-­‐14	   or	  CTIQ	   regulate	  TRPM2,	  but	   if	   CTIQ	  alters	   CDI	   the	   differences	   between	   mouse	   and	   human	   may	   result	   from	   these	   AA	  substitutions.	  	  	  
	  
4.10	  Significance	  of	  Work	  	  
	   Many	   diseases	   involve	   aberrant	   cellular	   behavior	   or	   cell	   death.	   The	  involvement	  of	  TRPM2	  with	  Ca2+	   influx	  and	  oxidative	  mediated	  stress	  has	   led	   to	  a	  focus	  on	  the	  channels	  role	  in	  disease	  throughout	  the	  body.	  TRPM2	  has	  been	  linked	  to	  genetic	  diseases,	   is	  activated	  by	  reactive	  oxygen	  species	  and	  is	  a	  mechanism	  for	  delayed	   cell	   death	   (Perraud	   et	   al.,	   2005).	   TRPM2	   is	   a	   self-­‐regulating	   channel	  controlled	   by	   the	   Ca2+-­‐CaM	   complex.	   Inactivation	   may	   prevent	   Ca2+	   intracellular	  overload	   during	   high	   Ca2+	   influx	   and	   subsequent	   damage	   to	   cells.	   A	   specific	  antagonist	   for	   the	   TRPM2	   channel	   has	   also	   yet	   to	   be	   identified.	   For	   this	   reason	   a	  more	   thorough	   understanding	   of	   the	   CDI	   of	   the	   channel	   may	   lead	   to	   further	  breakthroughs	  leading	  to	  therapeutic	  treatments.	  	  Many	   diseases	   have	   been	   implicated	   to	   be	   a	   result	   of	   TRPM2	   dysfunction;	  here	   I	   will	   highlight	   the	   current	   literature	   and	   the	   ways	   through	   which	   a	   more	  thorough	   understanding	   of	   TRPM2	   regulation	  may	   be	   beneficial.	   Recent	   evidence	  suggests	   TRPM2	   KO	   mice	   have	   higher	   insulin	   secretion	   and	   blood	   glucose	   levels	  (Uchida	  et	   al.,	   2011).	   Interestingly	  knockouts	  may	  be	  protected	   from	  diet-­‐induced	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obesity	   and	   insulin	   resistance	   (Zhang	   et	   al.,	   2012).	   KO	   mice	   had	   higher	   energy	  expenditure,	   even	   though	   insulin	   secretion	   was	   inhibited.	   TRPM2	   KO	  mice	   avoid	  hyper	   insulinemia,	   which	   prevents	   obesity	   through	   development	   of	   insulin	  resistance	   (Zhang	   et	   al.,	   2012;	   Uchida	   et	   al.,	   2011).	   Overall,	   the	   lowered	   insulin	  secretion	  under	  high	  fat	  diets	  creates	  a	  better	  metabolic	  state	  (Zhang	  et	  al.,	  2012).	  A	  case-­‐control	   study	   to	   assess	   TRPM2	   correlation	   with	   type-­‐2	   diabetes	   found	   no	  evidence	   for	   SNP’s	   or	   TRPM2	   mutations	   (Romero	   et	   al.,	   2010).	   TRPM2	   may	   be	  targeted	   to	   promote	   insulin	   release	   or	   therapeutically	   treat	   pre-­‐diabetic	   patients	  albeit	  with	   the	   risk	   of	  malignancy	   from	  damaged	  Beta	   cells	   (Uchinda	   et	   al.,	   2011;	  Scharenberg,	  2009).	  	  The	   role	   of	   melastatin	   in	   tumor	   proliferation	   in	   aberrant	   melanoma	   cells	   has	  generated	  interest	  for	  other	  TRP	  family	  members.	  Hypomethylation	  of	  the	  genome	  often	   leads	   to	   transcriptional	   noise	   and	   antisense	   transcripts	   generated	   in	  cancerous	  cells	  (Orfanelli	  et	  al.,	  2008).	  Two	  TRPM2	  antisense	  transcripts	  caused	  by	  a	  promoter	  in	  intron	  24	  were	  identified	  named	  TRPM2-­‐AS	  and	  TRPM2-­‐TE	  (Orfanelli	  et	  al.,	  2008).	  Quantitative	  RT-­‐PCR	  has	  discovered	  TRPM2-­‐AS	   in	  80%	  of	  melanoma	  cell	   lines	   and	   TRPM2-­‐TE	   expression	   was	   also	   correlated.	   These	   transcripts	   may	  reduce	  TRPM2	  current	  by	  interrupting	  the	  tetrameric	  structure	  as	  subunit	  members	  (Orfanelli	   et	   al.,	  2008).	  Knocking	  down	   the	  aberrant	   transcripts	  or	  overexpressing	  TRPM2	   increased	   melanoma	   cell	   apoptosis	   and	   necrosis	   (Orfanelli	   et	   al.,	   2008).	  Additionally	  TRPM2	  knockdown	   in	  prostate	   cancer	   cells	   inhibits	   cell	  proliferation,	  but	   knocking	   down	   in	   non-­‐cancerous	   cells	   had	   no	   effect	   (Zeng	   et	   al.,	   2010).	   The	  knockdown	  was	  independent	  of	  the	  PARP	  pathway	  (Zeng	  et	  al.,	  2010).	  Interestingly	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TRPM2	   was	   also	   highly	   expressed	   and	   clustered	   around	   the	   cell	   nuclei	   in	   the	  cancerous	  cells	  (Zeng	  et	  al.,	  2010).	  	   A	   correlation	   between	   SNP	   in	   exon	   11	   of	   TRPM2	   and	   early	   onset	   bi-­‐polar	  disorder	  (BD)	  was	  identified	  (Xu	  et	  al.,	  2009).	  Also	  a	  linkage	  analysis	  was	  performed	  with	  600	  bipolar	  research	  subjects	  and	  control	  subjects	  (McQuilliin	  et	  al.,	  2006).	  A	  base	   pair	   change	   from	   aspartic	   acid	   to	   glutamic	   acid	   at	   amino	   acid	   543	   was	  significantly	   associated	   with	   the	   disorder	   (McQuillin	   et	   al.,	   2006).	   Another	   study	  compared	   oxidative	   stress	   induced	   TRPM2	   currents	   from	   lymphoblast	   cells	   of	  bipolar	   and	   non-­‐afflicted	   control	   individuals	   (Roedding	   et	   al.,	   2012).	   Interestingly	  rotenone	   an	   oxidative	   stressor	   increased	   Ca2+	   in	   BD	   patient	   B	   lymphoblast	   cells,	  whereas	   TRPM2	   currents	   were	   decreased	   from	   normal	   patients	   (Roedding	   et	   al.,	  2012).	  A	  mutation	  to	  EFCH1	  has	  been	  associated	  with	  Juvenile	  myoclonic	  epilepsy	  and	  inhibits	   Ca2+	   currents	   (Kanata	   et	   al.,	   2012).	   EFCH1	   enhances	   TRPM2	   currents	  contributing	  to	  cell	  death	  (Kanata	  et	  al.,	  2012).	  EFCH1	  is	  believed	  to	  associate	  with	  TRPM2	  to	  mediate	  processes	  other	  than	  cell	  death	  such	  function	  and	  development	  of	  the	  central	  nervous	  system	  in	  normal	  physiology	  (Kanata	  et	  al.,	  2012).	  	   TRPM2	  has	   been	   implicated	   directly	   in	   several	   neurodegenerative	   diseases	  resulting	   from	   Ca2+	   neuronal	   cell	   death	   and	   apoptosis.	   Several	   groups	   have	  examined	   experimental	   stroke	   models	   and	   their	   subsequent	   effect	   on	   TRPM2	  regulation	   (Jia	   et	   al.,	   2011;	   Fonfria	   et	   al.,	   2006).	   TRPM2	   mRNA	   expression	   was	  increased	   at	   1	   and	   4	   weeks	   following	   a	   middle	   cerebral	   artery	   occlusion	   in	   rats	  (Fonfria	   et	   al.,	   2006).	   High	   TRPM2	   expression	  was	   seen	   in	   human	   C13	  microglia,	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which	   are	   activated	   and	   involved	   in	   neuroprotection	   during	   phagocytosis	   and	  mediate	  neurotoxic	  damage	   (Fonfria	  et	  al.,	  2006).	  Knockdowns	  of	  TRPM	   indicated	  ADPR	  mediated	  activation	  and	  Ca2+	  influx	  may	  promote	  neural	  cell	  death	  around	  the	  area	  of	  injury	  following	  ischemia	  (Fonfria	  et	  al.,	  2006).	  Sex	  specific	  effects	  of	  oxygen-­‐glucose	   deprivation	   were	   observed	   in	   mice	   with	   knocked-­‐down	   TRPM2	   using	  shRNA	  and	  pharmacological	  inhibitor	  clotrimazole	  (Jia	  et	  al.,	  2011).	  Infarct	  volume	  was	   significantly	   reduced	   with	   both	   treatments	   in	   males,	   but	   no	   reduction	   was	  observed	  for	  female	  mice	  (Jia	  et	  al.,	  2011).	  	   The	   same	   group	   examined	   TRPM2’s	   role	   in	   Alzheimer’s’	   Disease	   (AD)	   by	  examining	  Aβ1-­‐42	   toxicity	  on	   striatal	   rat	   cultures	  at	  2-­‐7	  days	   (Fonfria	   et	   al.,	   2005).	  Three	   methods	   of	   reducing	   functional	   TRPM2	   were	   utilized:	   PARP	   blocker	   (SB-­‐750139),	  siRNA	  and	  TRPM2-­‐S	  splice	  variant	  transfections	  (Fonfria	  et	  al.,	  2005).	  All	  three	  strategies	  significantly	  reduced	  cell	  death	  from	  oxidative	  stress	  (Fonfria	  et	  al.,	  2005).	  The	  study	  was	  inherently	  limited	  in	  its	  use	  of	  non-­‐physiological	  levels	  of	  non-­‐oligomeric	   forms	   of	   Aβ1-­‐42,	   striatal	   cultures	   where	   AD	   does	   not	   occur	   and	   poor	  TRPM2	   antibodies.	   TRPM2	   currents	   have	   since	   been	   isolated	   in	   hippocampal	  cultures	   (Olah	   et	   al.,	   2009)	   and	   additional	   work	   from	   our	   own	   laboratory	   is	  following	  up	  on	  the	  association	  between	  AD	  and	  TRPM2	  (unpublished).	  	  Finally	  dysfunction	  of	  TRPM2	  has	  been	  linked	  to	  an	  hTRPM2	  P1018L	  variant.	  I	  have	  developed	  a	  more	  thorough	  understanding	  through	  which	  the	  P1018L	  variant	  alters	  TRPM2	  function	  and	  the	  possible	  implications	  it	  has	  for	  normal	  physiological	  function.	   The	   increased	   hTRPM2	   currents	   for	   the	   P1018L	   Guam	   variant	   under	  0.5mM	   Ca2+	   provide	   new	   evidence	   towards	   the	   neurodegeneration	   seen	   in	   Guam	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patients.	   Previous	   studies	   by	   Hermosura	   et	   al.,	   2009	   only	   identified	   increased	  TRPM2	   inactivation	   within	   their	   recording	   protocol.	   This	   finding	   seemingly	  disagrees	  with	  a	  correlation	  of	  increased	  neurodegeneration;	  a	  reduction	  in	  TRPM2	  current	   and	   therefore	   Ca2+-­‐influx	   would	   more	   likely	   cause	   neuroprotection.	   It	  remains	  to	  be	  determined	  whether	  the	  association	  between	  low	  environmental	  Ca2+,	  increased	   hTRPM2	   P1018L	   current	   with	   low	   extracellular	   [Ca2+]	   and	  neurodegenerative	  disorders	  amongst	  the	  Guam	  population	  is	  significant.	  However,	  these	  preliminary	  findings	  are	  exciting	  and	  should	  be	  pursued	  in	  the	  future.	  While	  the	  exact	  mechanism	  behind	  CDI	  has	  yet	  to	  be	  conclusively	  identified,	  two	   strong	   candidate	   sites	   at	   NT1-­‐14	   and	   CTIQ	   exist	   that	   appear	   to	   play	   critical	  physiological	   functions	   in	   TRPM2	   regulation.	   Whether	   CaM	   has	   a	   regulatory	  function	   in	   TRPM2	   CDI	   remains	   to	   be	   determined.	   However,	   the	   evidence	   of	  multiple	  CaM	  sites	  required	  for	  proper	  TRPM2	  function	  hint	  at	  a	  tight	  regulation	  of	  TRPM2	  CDI	  by	  CaM.	  Whether	  one	  or	  more	  of	  these	  sites	  is	  directly	  responsible	  for	  CDI	  should	  be	  followed	  by	  future	  studies.	  The	  mutants	  tell	  us	  that	  TRPM2	  regulation	  by	  Ca2+-­‐CaM	  may	  be	  more	   complicated	   than	  previously	  envisioned,	  with	   two	  sites	  (NT1-­‐14	  and	  CTIQ)	  being	  required	  for	  proper	  TRPM2	  function.	  	  
	  
4.11	  Future	  Directions	  
	  	   Many	   interesting	   findings	   about	   TRPM2	   have	   been	   discovered	   throughout	  this	  thesis,	  but	  the	  story	  behind	  TRPM2	  CDI	  remains	  illusive.	  Two	  strong	  candidate	  sites	  CTIQ	  and	  NT1-­‐14	  cannot	  conclusively	  be	  implicated	  for	  TRPM2	  CDI,	  but	  appear	  to	  have	  a	  critical	  role	   in	  channel	   function	  or	  regulation.	  Future	  work	  with	  these	  sites	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needs	  to	  confirm	  proper	  expression	  of	  the	  protein	  before	  the	  alterations	  in	  current	  can	   be	   completely	   attributed	   to	   substitution	   mutations	   at	   these	   target	   sites.	  Furthermore,	   an	   interesting	   observation	   between	   mTRPM2	   and	   hTRPM2	   has	  revealed	  a	  significant	  difference	  between	  CDI	  at	  both	  0.5mM	  and	  2mM	  Ca2+.	  The	  AA	  sequence	  of	  the	  CTIQ	  site	  may	  provide	  a	  novel	  mutation	  strategy	  for	  which	  CDI	  may	  be	  altered	  without	   interrupting	   the	  protein	  expression	  or	   trafficking.	  Mutations	  at	  the	  CTIQ	  site	  may	  be	  negatively	  impacting	  substrate	  interaction	  of	  the	  tetramer,	  but	  a	  less	   aggressive	   mutation	   using	   hTRPM2	   as	   a	   guideline	   may	   provide	   a	   functional	  mTRPM2	  channel	  with	  altered	  CDI.	  	   Future	   experiments	   with	   truncated	   fragments	   should	   be	   pursued	   using	  transfected	  HEK293	   cells	   and	   cellular	   lysates.	   Fragments	   generated	   using	   cellular	  machinery	  will	  be	  more	   representative	  of	  physiological	   folding,	   a	   limitation	  of	   the	  protocol	   I	   used	   for	   the	   binding	   experiments.	   Ca2+-­‐dependence	   of	   CaM-­‐Sepharose	  binding	   with	   truncated	   fragments	   from	   cell	   lysates	   may	   reveal	   a	   more	  representative	  understanding	  of	  how	  the	  CaM	  candidate	  sites	  interact	  with	  CaM.	  	  	  
4.12	  Overall	  Conclusions	  
	  
	   Several	   important	   conclusions	   have	   been	   drawn	   from	   the	   course	   of	   this	  thesis.	   Very	   little	   was	   known	   about	   TRPM2	   CDI,	   I	   successfully	   defined	   the	  inactivation	  as	  being	  tightly	  regulated	  by	  extracellular	  [Ca2+].	  The	  literature	  behind	  CaM	   interaction	   at	   the	   TRPM2	   N-­‐	   and	   C-­‐terminal	   was	   incomplete.	   A	   systematic	  analysis	  of	   the	  TRPM2	  terminals	  revealed	  three	  novel	  sites	  named	  CTIQ,	  CT1-­‐14	  and	  NT1-­‐14.	  While	  we	  cannot	  conclude	   the	  exact	   regulatory	  nature	  behind	   two	  of	   these	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Figure	  A1	  –	  (Oies	  Hussein,	  Unpublished)	  TRPM2	  recovery	  from	  inactivation	  over	  time.	  4	  time	  intervals	  of	  0mM	  Ca2+	  treatments	  were	  utilized	  and	  peak	  amplitudes	  measures.	  Illustrating	  the	  recovery	  full	  recovery	  of	  TRPM2	  from	  an	  inactivated	  steady	  state	  following	  a	  period	  of	  3	  minutes	  0	  Ca2+.
	  	   111	  
	  
Figure	  A2	  –	  (Oies	  Hussein,	  Unpublished).	  The	  role	  of	  ADPR	  on	  inactivation	  recovery.	  (A/B)	  Representative	  traces	  for	  HEK293	  cells	  stably	  expressing	  doxycycline	  inducible	  TRPM2	  channels.	  0.3mM	  or	  1mM	  ADPR	  was	  used	  in	  the	  patch	  pipette	  to	  activate	  TRPM2,	  and	  currents	  were	  elicited	  with	  2mM	  treatments	  of	  Ca2+	  ECF.	  Higher	  concentrations	  of	  ADPR	  slowed	  the	  recovery	  from	  inactivation	  in	  both	  10sec	  and	  30sec	  0mM	  Ca2+	  treatments.	  (C)	  Time	  course	  of	  recovery	  from	  inactivation	  was	  determined	  from	  the	  ratio	  of	  Peak	  2/Peak	  1.	  (n=4-­‐9	  and	  n=4-­‐7)	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Figure	  A3	  –	  (Oies	  Hussein,	  Unpublished).	  TRPM2	  inactivation	  is	  dependent	  on	  intracellular	  CaM.	  	  (A/B)	  Trace	  recordings	  from	  HEK293	  cells	  stably	  expressing	  doxycycline	  induced	  TRPM2	  currents.	  (A)	  Characterization	  of	  TRPM2	  current	  with	  100uM	  Calmodulin	  in	  ICS	  (n=5)	  (B)	  Control	  recording,	  (C)	  Iss/Ip	  (%	  Inactivation)	  for	  control	  and	  100uM	  CaM	  recordings,	  CaM	  significantly	  increased	  the	  inactivation	  of	  TRPM2	  (p<0.05).	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